Selegiline	B-Chemical
-	O
induced	O
postural	B-Disease
hypotension	I-Disease
in	O
Parkinson	B-Disease
'	I-Disease
s	I-Disease
disease	I-Disease
:	O
a	O
longitudinal	O
study	O
on	O
the	O
effects	O
of	O
drug	O
withdrawal	O
.	O

OBJECTIVES	O
:	O
The	O
United	O
Kingdom	O
Parkinson	B-Disease
'	I-Disease
s	I-Disease
Disease	I-Disease
Research	O
Group	O
(	O
UKPDRG	O
)	O
trial	O
found	O
an	O
increased	O
mortality	O
in	O
patients	O
with	O
Parkinson	B-Disease
'	I-Disease
s	I-Disease
disease	I-Disease
(	O
PD	B-Disease
)	O
randomized	O
to	O
receive	O
10	O
mg	O
selegiline	B-Chemical
per	O
day	O
and	O
L	B-Chemical
-	I-Chemical
dopa	I-Chemical
compared	O
with	O
those	O
taking	O
L	B-Chemical
-	I-Chemical
dopa	I-Chemical
alone	O
.	O

Recently	O
,	O
we	O
found	O
that	O
therapy	O
with	O
selegiline	B-Chemical
and	O
L	B-Chemical
-	I-Chemical
dopa	I-Chemical
was	O
associated	O
with	O
selective	O
systolic	B-Disease
orthostatic	I-Disease
hypotension	I-Disease
which	O
was	O
abolished	O
by	O
withdrawal	O
of	O
selegiline	B-Chemical
.	O

The	O
aims	O
of	O
this	O
study	O
were	O
to	O
confirm	O
our	O
previous	O
findings	O
in	O
a	O
separate	O
cohort	O
of	O
patients	O
and	O
to	O
determine	O
the	O
time	O
course	O
of	O
the	O
cardiovascular	O
consequences	O
of	O
stopping	O
selegiline	B-Chemical
in	O
the	O
expectation	O
that	O
this	O
might	O
shed	O
light	O
on	O
the	O
mechanisms	O
by	O
which	O
the	O
drug	O
causes	O
orthostatic	B-Disease
hypotension	I-Disease
.	O

METHODS	O
:	O
The	O
cardiovascular	O
responses	O
to	O
standing	O
and	O
head	O
-	O
up	O
tilt	O
were	O
studied	O
repeatedly	O
in	O
PD	B-Disease
patients	O
receiving	O
selegiline	B-Chemical
and	O
as	O
the	O
drug	O
was	O
withdrawn	O
.	O

RESULTS	O
:	O
Head	O
-	O
up	O
tilt	O
caused	O
systolic	B-Disease
orthostatic	I-Disease
hypotension	I-Disease
which	O
was	O
marked	O
in	O
six	O
of	O
20	O
PD	B-Disease
patients	O
on	O
selegiline	B-Chemical
,	O
one	O
of	O
whom	O
lost	O
consciousness	O
with	O
unrecordable	O
blood	O
pressures	O
.	O

A	O
lesser	O
degree	O
of	O
orthostatic	B-Disease
hypotension	I-Disease
occurred	O
with	O
standing	O
.	O

Orthostatic	B-Disease
hypotension	I-Disease
was	O
ameliorated	O
4	O
days	O
after	O
withdrawal	O
of	O
selegiline	B-Chemical
and	O
totally	O
abolished	O
7	O
days	O
after	O
discontinuation	O
of	O
the	O
drug	O
.	O

Stopping	O
selegiline	B-Chemical
also	O
significantly	O
reduced	B-Disease
the	I-Disease
supine	I-Disease
systolic	I-Disease
and	I-Disease
diastolic	I-Disease
blood	I-Disease
pressures	I-Disease
consistent	O
with	O
a	O
previously	O
undescribed	O
supine	O
pressor	O
action	O
.	O

CONCLUSION	O
:	O
This	O
study	O
confirms	O
our	O
previous	O
finding	O
that	O
selegiline	B-Chemical
in	O
combination	O
with	O
L	B-Chemical
-	I-Chemical
dopa	I-Chemical
is	O
associated	O
with	O
selective	O
orthostatic	B-Disease
hypotension	I-Disease
.	O

The	O
possibilities	O
that	O
these	O
cardiovascular	O
findings	O
might	O
be	O
the	O
result	O
of	O
non	O
-	O
selective	O
inhibition	O
of	O
monoamine	O
oxidase	O
or	O
of	O
amphetamine	B-Chemical
and	O
metamphetamine	B-Chemical
are	O
discussed	O
.	O

The	O
results	O
have	O
shown	O
that	O
the	O
degradation	O
product	O
p	B-Chemical
-	I-Chemical
choloroaniline	I-Chemical
is	O
not	O
a	O
significant	O
factor	O
in	O
chlorhexidine	B-Chemical
-	I-Chemical
digluconate	I-Chemical
associated	O
erosive	O
cystitis	B-Disease
.	O

A	O
high	O
percentage	O
of	O
kanamycin	B-Chemical
-	O
colistin	B-Chemical
and	O
povidone	B-Chemical
-	I-Chemical
iodine	I-Chemical
irrigations	O
were	O
associated	O
with	O
erosive	O
cystitis	B-Disease
and	O
suggested	O
a	O
possible	O
complication	O
with	O
human	O
usage	O
.	O

Picloxydine	B-Chemical
irrigations	O
appeared	O
to	O
have	O
a	O
lower	O
incidence	O
of	O
erosive	O
cystitis	B-Disease
but	O
further	O
studies	O
would	O
have	O
to	O
be	O
performed	O
before	O
it	O
could	O
be	O
recommended	O
for	O
use	O
in	O
urological	O
procedures	O
.	O

Effects	O
of	O
tetrandrine	B-Chemical
and	O
fangchinoline	B-Chemical
on	O
experimental	O
thrombosis	B-Disease
in	O
mice	O
and	O
human	O
platelet	B-Disease
aggregation	I-Disease
.	O

Tetrandrine	O
(	O
TET	B-Chemical
)	O
and	O
fangchinoline	B-Chemical
(	O
FAN	B-Chemical
)	O
are	O
two	O
naturally	O
occurring	O
analogues	O
with	O
a	O
bisbenzylisoquinoline	B-Chemical
structure	O
.	O

The	O
present	O
study	O
was	O
undertaken	O
to	O
investigate	O
the	O
effects	O
of	O
TET	B-Chemical
and	O
FAN	B-Chemical
on	O
the	O
experimental	O
thrombosis	B-Disease
induced	O
by	O
collagen	O
plus	O
epinephrine	B-Chemical
(	O
EP	B-Chemical
)	O
in	O
mice	O
,	O
and	O
platelet	B-Disease
aggregation	I-Disease
and	O
blood	B-Disease
coagulation	I-Disease
in	O
vitro	O
.	O

In	O
the	O
in	O
vivo	O
study	O
,	O
the	O
administration	O
(	O
50	O
mg	O
/	O
kg	O
,	O
i	O
.	O
p	O
.	O
)	O
of	O
TET	B-Chemical
and	O
FAN	B-Chemical
in	O
mice	O
showed	O
the	O
inhibition	O
of	O
thrombosis	B-Disease
by	O
55	O
%	O
and	O
35	O
%	O
,	O
respectively	O
,	O
while	O
acetylsalicylic	B-Chemical
acid	I-Chemical
(	O
ASA	B-Chemical
,	O
50	O
mg	O
/	O
kg	O
,	O
i	O
.	O
p	O
.	O
)	O
,	O
a	O
positive	O
control	O
,	O
showed	O
only	O
30	O
%	O
inhibition	O
.	O

In	O
the	O
vitro	O
human	O
platelet	B-Disease
aggregations	I-Disease
induced	O
by	O
the	O
agonists	O
used	O
in	O
tests	O
,	O
TET	B-Chemical
and	O
FAN	B-Chemical
showed	O
the	O
inhibitions	O
dose	O
dependently	O
.	O

In	O
addition	O
,	O
neither	O
TET	B-Chemical
nor	O
FAN	B-Chemical
showed	O
any	O
anticoagulation	O
activities	O
in	O
the	O
measurement	O
of	O
the	O
activated	O
partial	O
thromboplastin	O
time	O
(	O
APTT	O
)	O
,	O
prothrombin	O
time	O
(	O
PT	O
)	O
and	O
thrombin	O
time	O
(	O
TT	O
)	O
using	O
human	O
-	O
citrated	O
plasma	O
.	O

These	O
results	O
suggest	O
that	O
antithrombosis	O
of	O
TET	B-Chemical
and	O
FAN	B-Chemical
in	O
mice	O
may	O
be	O
mainly	O
related	O
to	O
the	O
antiplatelet	O
aggregation	O
activities	O
.	O

Angioedema	B-Disease
due	O
to	O
ACE	B-Chemical
inhibitors	I-Chemical
:	O
common	O
and	O
inadequately	O
diagnosed	O
.	O

The	O
estimated	O
incidence	O
of	O
angioedema	B-Disease
during	O
angiotensin	B-Chemical
-	I-Chemical
converting	I-Chemical
enzyme	I-Chemical
(	I-Chemical
ACE	I-Chemical
)	I-Chemical
inhibitor	I-Chemical
treatment	O
is	O
between	O
1	O
and	O
7	O
per	O
thousand	O
patients	O
.	O

Cocaine	B-Chemical
-	O
induced	O
mood	B-Disease
disorder	I-Disease
:	O
prevalence	O
rates	O
and	O
psychiatric	B-Disease
symptoms	O
in	O
an	O
outpatient	O
cocaine	B-Chemical
-	O
dependent	O
sample	O
.	O

This	O
paper	O
attempts	O
to	O
examine	O
and	O
compare	O
prevalence	O
rates	O
and	O
symptom	O
patterns	O
of	O
DSM	O
substance	O
-	O
induced	O
and	O
other	O
mood	B-Disease
disorders	I-Disease
.	O

243	O
cocaine	B-Chemical
-	O
dependent	O
outpatients	O
with	O
cocaine	B-Chemical
-	O
induced	O
mood	B-Disease
disorder	I-Disease
(	O
CIMD	B-Disease
)	O
,	O
other	O
mood	B-Disease
disorders	I-Disease
,	O
or	O
no	O
mood	B-Disease
disorder	I-Disease
were	O
compared	O
on	O
measures	O
of	O
psychiatric	B-Disease
symptoms	O
.	O

The	O
prevalence	O
rate	O
for	O
CIMD	B-Disease
was	O
12	O
%	O
at	O
baseline	O
.	O

Introduction	O
of	O
the	O
DSM	O
-	O
IV	O
diagnosis	O
of	O
CIMD	B-Disease
did	O
not	O
substantially	O
affect	O
rates	O
of	O
the	O
other	O
depressive	B-Disease
disorders	I-Disease
.	O

Patients	O
with	O
CIMD	B-Disease
had	O
symptom	O
severity	O
levels	O
between	O
those	O
of	O
patients	O
with	O
and	O
without	O
a	O
mood	O
disorder	O
.	O

These	O
findings	O
suggest	O
some	O
validity	O
for	O
the	O
new	O
DSM	O
-	O
IV	O
diagnosis	O
of	O
CIMD	B-Disease
,	O
but	O
also	O
suggest	O
that	O
it	O
requires	O
further	O
specification	O
and	O
replication	O
.	O

Effect	O
of	O
fucoidan	B-Chemical
treatment	O
on	O
collagenase	O
-	O
induced	O
intracerebral	B-Disease
hemorrhage	I-Disease
in	O
rats	O
.	O

Inflammatory	O
cells	O
are	O
postulated	O
to	O
mediate	O
some	O
of	O
the	O
brain	B-Disease
damage	I-Disease
following	O
ischemic	B-Disease
stroke	I-Disease
.	O

Intracerebral	B-Disease
hemorrhage	I-Disease
is	O
associated	O
with	O
more	O
inflammation	B-Disease
than	O
ischemic	B-Disease
stroke	I-Disease
.	O

We	O
tested	O
the	O
sulfated	O
polysaccharide	O
fucoidan	B-Chemical
,	O
which	O
has	O
been	O
reported	O
to	O
reduce	O
inflammatory	O
brain	B-Disease
damage	I-Disease
,	O
in	O
a	O
rat	O
model	O
of	O
intracerebral	B-Disease
hemorrhage	I-Disease
induced	O
by	O
injection	O
of	O
bacterial	O
collagenase	O
into	O
the	O
caudate	O
nucleus	O
.	O

Rats	O
were	O
treated	O
with	O
seven	O
day	O
intravenous	O
infusion	O
of	O
fucoidan	B-Chemical
(	O
30	O
micrograms	O
h	O
-	O
1	O
)	O
or	O
vehicle	O
.	O

The	O
hematoma	B-Disease
was	O
assessed	O
in	O
vivo	O
by	O
magnetic	O
resonance	O
imaging	O
.	O

Fucoidan	B-Chemical
-	O
treated	O
rats	O
exhibited	O
evidence	O
of	O
impaired	B-Disease
blood	I-Disease
clotting	I-Disease
and	O
hemodilution	B-Disease
,	O
had	O
larger	O
hematomas	B-Disease
,	O
and	O
tended	O
to	O
have	O
less	O
inflammation	B-Disease
in	O
the	O
vicinity	O
of	O
the	O
hematoma	O
after	O
three	O
days	O
.	O

They	O
showed	O
significantly	O
more	O
rapid	O
improvement	O
of	O
motor	O
function	O
in	O
the	O
first	O
week	O
following	O
hemorrhage	B-Disease
and	O
better	O
memory	O
retention	O
in	O
the	O
passive	O
avoidance	O
test	O
.	O

Acute	O
white	B-Disease
matter	I-Disease
edema	I-Disease
and	O
eventual	O
neuronal	O
loss	O
in	O
the	O
striatum	O
adjacent	O
to	O
the	O
hematoma	B-Disease
did	O
not	O
differ	O
between	O
the	O
two	O
groups	O
.	O

Investigation	O
of	O
more	O
specific	O
anti	O
-	O
inflammatory	O
agents	O
and	O
hemodiluting	O
agents	O
are	O
warranted	O
in	O
intracerebral	B-Disease
hemorrhage	I-Disease
.	O

Accumulation	O
of	O
atracurium	B-Chemical
in	O
the	O
intravenous	O
line	O
led	O
to	O
recurarization	O
after	O
flushing	O
the	O
line	O
in	O
the	O
recovery	O
room	O
.	O

A	O
respiratory	B-Disease
arrest	I-Disease
with	O
severe	O
desaturation	B-Disease
and	O
bradycardia	B-Disease
occurred	O
.	O

Circumstances	O
leading	O
to	O
this	O
event	O
and	O
the	O
mechanisms	O
enabling	O
a	O
neuromuscular	B-Disease
blockade	I-Disease
to	O
occur	O
,	O
following	O
the	O
administration	O
of	O
a	O
small	O
dose	O
of	O
relaxant	O
,	O
are	O
discussed	O
.	O

The	O
haemodynamic	O
effects	O
of	O
propofol	B-Chemical
in	O
combination	O
with	O
ephedrine	B-Chemical
in	O
elderly	O
patients	O
(	O
ASA	O
groups	O
3	O
and	O
4	O
)	O
.	O

The	O
marked	O
vasodilator	O
and	O
negative	O
inotropic	O
effects	O
of	O
propofol	B-Chemical
are	O
disadvantages	O
in	O
frail	O
elderly	O
patients	O
.	O

We	O
investigated	O
the	O
safety	O
and	O
efficacy	O
of	O
adding	O
different	O
doses	O
of	O
ephedrine	B-Chemical
to	O
propofol	B-Chemical
in	O
order	O
to	O
obtund	O
the	O
hypotensive	B-Disease
response	O
.	O

The	O
haemodynamic	O
effects	O
of	O
adding	O
15	O
,	O
20	O
or	O
25	O
mg	O
of	O
ephedrine	B-Chemical
to	O
200	O
mg	O
of	O
propofol	B-Chemical
were	O
compared	O
to	O
control	O
in	O
40	O
ASA	O
3	O
/	O
4	O
patients	O
over	O
60	O
years	O
presenting	O
for	O
genito	O
-	O
urinary	O
surgery	O
.	O

The	O
addition	O
of	O
ephedrine	B-Chemical
to	O
propofol	B-Chemical
appears	O
to	O
be	O
an	O
effective	O
method	O
of	O
obtunding	O
the	O
hypotensive	B-Disease
response	O
to	O
propofol	B-Chemical
at	O
all	O
doses	O
used	O
in	O
this	O
study	O
.	O

However	O
,	O
marked	O
tachycardia	B-Disease
associated	O
with	O
the	O
use	O
of	O
ephedrine	B-Chemical
in	O
combination	O
with	O
propofol	B-Chemical
occurred	O
in	O
the	O
majority	O
of	O
patients	O
,	O
occasionally	O
reaching	O
high	O
levels	O
in	O
individual	O
patients	O
.	O

Due	O
to	O
the	O
risk	O
of	O
this	O
tachycardia	B-Disease
inducing	O
myocardial	B-Disease
ischemia	I-Disease
,	O
we	O
would	O
not	O
recommend	O
the	O
use	O
in	O
elderly	O
patients	O
of	O
any	O
of	O
the	O
ephedrine	B-Chemical
/	O
propofol	B-Chemical
/	O
mixtures	O
studied	O
.	O

Gemcitabine	B-Chemical
plus	O
vinorelbine	O
in	O
nonsmall	B-Disease
cell	I-Disease
lung	I-Disease
carcinoma	I-Disease
patients	O
age	O
70	O
years	O
or	O
older	O
or	O
patients	O
who	O
cannot	O
receive	O
cisplatin	B-Chemical
.	O

BACKGROUND	O
:	O
Although	O
the	O
prevalence	O
of	O
nonsmall	B-Disease
cell	I-Disease
lung	I-Disease
carcinoma	I-Disease
(	O
NSCLC	B-Disease
)	O
is	O
high	O
among	O
elderly	O
patients	O
,	O
few	O
data	O
are	O
available	O
regarding	O
the	O
efficacy	O
and	O
toxicity	B-Disease
of	O
chemotherapy	O
in	O
this	O
group	O
of	O
patients	O
.	O

Recent	O
reports	O
indicate	O
that	O
single	O
agent	O
therapy	O
with	O
vinorelbine	B-Chemical
(	O
VNB	O
)	O
or	O
gemcitabine	B-Chemical
(	O
GEM	B-Chemical
)	O
may	O
obtain	O
a	O
response	O
rate	O
of	O
20	O
-	O
30	O
%	O
in	O
elderly	O
patients	O
,	O
with	O
acceptable	O
toxicity	B-Disease
and	O
improvement	O
in	O
symptoms	O
and	O
quality	O
of	O
life	O
.	O

In	O
the	O
current	O
study	O
the	O
efficacy	O
and	O
toxicity	B-Disease
of	O
the	O
combination	O
of	O
GEM	B-Chemical
and	O
VNB	B-Chemical
in	O
elderly	O
patients	O
with	O
advanced	O
NSCLC	B-Disease
or	O
those	O
with	O
some	O
contraindication	O
to	O
receiving	O
cisplatin	B-Chemical
were	O
assessed	O
.	O

METHODS	O
:	O
Forty	O
-	O
nine	O
patients	O
with	O
advanced	O
NSCLC	B-Disease
were	O
included	O
,	O
38	O
of	O
whom	O
were	O
age	O
>	O
/	O
=	O
70	O
years	O
and	O
11	O
were	O
age	O
<	O
70	O
years	O
but	O
who	O
had	O
some	O
contraindication	O
to	O
receiving	O
cisplatin	B-Chemical
.	O

Treatment	O
was	O
comprised	O
of	O
VNB	B-Chemical
,	O
25	O
mg	O
/	O
m	O
(	O
2	O
)	O
,	O
plus	O
GEM	B-Chemical
,	O
1000	O
mg	O
/	O
m	O
(	O
2	O
)	O
,	O
both	O
on	O
Days	O
1	O
,	O
8	O
,	O
and	O
15	O
every	O
28	O
days	O
.	O

Toxicity	B-Disease
was	O
mild	O
.	O

Six	O
patients	O
(	O
12	O
%	O
)	O
had	O
World	O
Health	O
Organization	O
Grade	O
3	O
-	O
4	O
neutropenia	O
,	O
2	O
patients	O
(	O
4	O
%	O
)	O
had	O
Grade	O
3	O
-	O
4	O
thrombocytopenia	B-Disease
,	O
and	O
2	O
patients	O
(	O
4	O
%	O
)	O
had	O
Grade	O
3	O
neurotoxicity	B-Disease
.	O

Three	O
patients	O
with	O
severe	O
neutropenia	B-Disease
(	O
6	O
%	O
)	O
died	O
of	O
sepsis	B-Disease
.	O

The	O
median	O
age	O
of	O
those	O
patients	O
developing	O
Grade	O
3	O
-	O
4	O
neutropenia	B-Disease
was	O
significantly	O
higher	O
than	O
that	O
of	O
the	O
remaining	O
patients	O
(	O
75	O
years	O
vs	O
.	O
72	O
years	O
;	O
P	O
=	O
0	O
.	O
047	O
)	O
.	O

CONCLUSIONS	O
:	O
The	O
combination	O
of	O
GEM	B-Chemical
and	O
VNB	B-Chemical
is	O
moderately	O
active	O
and	O
well	O
tolerated	O
except	O
in	O
patients	O
age	O
>	O
/	O
=	O
75	O
years	O
.	O

This	O
age	O
group	O
had	O
an	O
increased	O
risk	O
of	O
myelosuppression	B-Disease
.	O

New	O
chemotherapy	O
combinations	O
with	O
higher	O
activity	O
and	O
lower	O
toxicity	B-Disease
are	O
needed	O
for	O
elderly	O
patients	O
with	O
advanced	O
NSCLC	B-Disease
.	O

A	O
selective	O
dopamine	B-Chemical
D4	O
receptor	O
antagonist	O
,	O
NRA0160	B-Chemical
:	O
a	O
preclinical	O
neuropharmacological	O
profile	O
.	O

NRA0160	O
,	O
5	B-Chemical
-	I-Chemical
[	I-Chemical
2	I-Chemical
-	I-Chemical
(	I-Chemical
4	I-Chemical
-	I-Chemical
(	I-Chemical
3	I-Chemical
-	I-Chemical
fluorobenzylidene	I-Chemical
)	I-Chemical
piperidin	I-Chemical
-	I-Chemical
1	I-Chemical
-	I-Chemical
yl	I-Chemical
)	I-Chemical
ethyl	I-Chemical
]	I-Chemical
-	I-Chemical
4	I-Chemical
-	I-Chemical
(	I-Chemical
4	I-Chemical
-	I-Chemical
fluorophenyl	I-Chemical
)	I-Chemical
thiazole	I-Chemical
-	I-Chemical
2	I-Chemical
-	I-Chemical
carboxamide	I-Chemical
,	O
has	O
a	O
high	O
affinity	O
for	O
human	O
cloned	O
dopamine	O
D4	O
.	O
2	O
,	O
D4	O
.	O
4	O
and	O
D4	O
.	O
7	O
receptors	O
,	O
with	O
Ki	O
values	O
of	O
0	O
.	O
5	O
,	O
0	O
.	O
9	O
and	O
2	O
.	O
7	O
nM	O
,	O
respectively	O
.	O

NRA0160	B-Chemical
is	O
over	O
20	O
,	O
000fold	O
more	O
potent	O
at	O
the	O
dopamine	B-Chemical
D4	O
.	O
2	O
receptor	O
compared	O
with	O
the	O
human	O
cloned	O
dopamine	B-Chemical
D2L	O
receptor	O
.	O

NRA0160	B-Chemical
has	O
negligible	O
affinity	O
for	O
the	O
human	O
cloned	O
dopamine	B-Chemical
D3	O
receptor	O
(	O
Ki	O
=	O
39	O
nM	O
)	O
,	O
rat	O
serotonin	B-Chemical
(	O
5	B-Chemical
-	I-Chemical
HT	I-Chemical
)	O
2A	O
receptors	O
(	O
Ki	O
=	O
180	O
nM	O
)	O
and	O
rat	O
alpha1	O
adrenoceptor	O
(	O
Ki	O
=	O
237	O
nM	O
)	O
.	O

NRA0160	B-Chemical
and	O
clozapine	B-Chemical
antagonized	O
locomotor	O
hyperactivity	B-Disease
induced	O
by	O
methamphetamine	B-Chemical
(	O
MAP	B-Chemical
)	O
in	O
mice	O
.	O

NRA0160	B-Chemical
and	O
clozapine	B-Chemical
antagonized	O
MAP	B-Chemical
-	O
induced	O
stereotyped	O
behavior	O
in	O
mice	O
,	O
although	O
their	O
effects	O
did	O
not	O
exceed	O
50	O
%	O
inhibition	O
,	O
even	O
at	O
the	O
highest	O
dose	O
given	O
.	O

NRA0160	B-Chemical
and	O
clozapine	B-Chemical
significantly	O
induced	O
catalepsy	B-Disease
in	O
rats	O
,	O
although	O
their	O
effects	O
did	O
not	O
exceed	O
50	O
%	O
induction	O
even	O
at	O
the	O
highest	O
dose	O
given	O
.	O

NRA0160	B-Chemical
and	O
clozapine	B-Chemical
significantly	O
reversed	O
the	O
disruption	O
of	O
prepulse	O
inhibition	O
(	O
PPI	O
)	O
in	O
rats	O
produced	O
by	O
apomorphine	B-Chemical
.	O

NRA0160	B-Chemical
and	O
clozapine	B-Chemical
significantly	O
shortened	O
the	O
phencyclidine	B-Chemical
(	O
PCP	B-Chemical
)	O
-	O
induced	O
prolonged	O
swimming	O
latency	O
in	O
rats	O
in	O
a	O
water	O
maze	O
task	O
.	O

These	O
findings	O
suggest	O
that	O
NRA0160	B-Chemical
may	O
have	O
unique	O
antipsychotic	O
activities	O
without	O
the	O
liability	O
of	O
motor	O
side	O
effects	O
typical	O
of	O
classical	O
antipsychotics	O
.	O

Warfarin	B-Chemical
-	O
induced	O
artery	B-Disease
calcification	I-Disease
is	O
accelerated	O
by	O
growth	O
and	O
vitamin	B-Chemical
D	I-Chemical
.	O

The	O
present	O
studies	O
demonstrate	O
that	O
growth	O
and	O
vitamin	B-Chemical
D	I-Chemical
treatment	O
enhance	O
the	O
extent	O
of	O
artery	B-Disease
calcification	I-Disease
in	O
rats	O
given	O
sufficient	O
doses	O
of	O
Warfarin	B-Chemical
to	O
inhibit	O
gamma	O
-	O
carboxylation	O
of	O
matrix	O
Gla	O
protein	O
,	O
a	O
calcification	B-Disease
inhibitor	O
known	O
to	O
be	O
expressed	O
by	O
smooth	O
muscle	O
cells	O
and	O
macrophages	O
in	O
the	O
artery	O
wall	O
.	O

The	O
first	O
series	O
of	O
experiments	O
examined	O
the	O
influence	O
of	O
age	O
and	O
growth	O
status	O
on	O
artery	B-Disease
calcification	I-Disease
in	O
Warfarin	B-Chemical
-	O
treated	O
rats	O
.	O

Treatment	O
for	O
2	O
weeks	O
with	O
Warfarin	B-Chemical
caused	O
massive	O
focal	O
calcification	B-Disease
of	I-Disease
the	I-Disease
artery	I-Disease
media	O
in	O
20	O
-	O
day	O
-	O
old	O
rats	O
and	O
less	O
extensive	O
focal	O
calcification	B-Disease
in	O
42	O
-	O
day	O
-	O
old	O
rats	O
.	O

In	O
contrast	O
,	O
no	O
artery	B-Disease
calcification	I-Disease
could	O
be	O
detected	O
in	O
10	O
-	O
month	O
-	O
old	O
adult	O
rats	O
even	O
after	O
4	O
weeks	O
of	O
Warfarin	B-Chemical
treatment	O
.	O

To	O
directly	O
examine	O
the	O
importance	O
of	O
growth	O
to	O
Warfarin	B-Chemical
-	O
induced	O
artery	B-Disease
calcification	I-Disease
in	O
animals	O
of	O
the	O
same	O
age	O
,	O
20	O
-	O
day	O
-	O
old	O
rats	O
were	O
fed	O
for	O
2	O
weeks	O
either	O
an	O
ad	O
libitum	O
diet	O
or	O
a	O
6	O
-	O
g	O
/	O
d	O
restricted	O
diet	O
that	O
maintains	O
weight	O
but	O
prevents	O
growth	O
.	O

Concurrent	O
treatment	O
of	O
both	O
dietary	O
groups	O
with	O
Warfarin	B-Chemical
produced	O
massive	O
focal	O
calcification	B-Disease
of	I-Disease
the	I-Disease
artery	I-Disease
media	O
in	O
the	O
ad	O
libitum	O
-	O
fed	O
rats	O
but	O
no	O
detectable	O
artery	B-Disease
calcification	I-Disease
in	O
the	O
restricted	O
-	O
diet	O
,	O
growth	O
-	O
inhibited	O
group	O
.	O

Although	O
the	O
explanation	O
for	O
the	O
association	O
between	O
artery	B-Disease
calcification	I-Disease
and	O
growth	O
status	O
cannot	O
be	O
determined	O
from	O
the	O
present	O
study	O
,	O
there	O
was	O
a	O
relationship	O
between	O
higher	O
serum	O
phosphate	B-Chemical
and	O
susceptibility	O
to	O
artery	B-Disease
calcification	I-Disease
,	O
with	O
30	O
%	O
higher	O
levels	O
of	O
serum	O
phosphate	B-Chemical
in	O
young	O
,	O
ad	O
libitum	O
-	O
fed	O
rats	O
compared	O
with	O
either	O
of	O
the	O
groups	O
that	O
was	O
resistant	O
to	O
Warfarin	B-Chemical
-	O
induced	O
artery	B-Disease
calcification	I-Disease
,	O
ie	O
,	O
the	O
10	O
-	O
month	O
-	O
old	O
rats	O
and	O
the	O
restricted	O
-	O
diet	O
,	O
growth	O
-	O
inhibited	O
young	O
rats	O
.	O

This	O
observation	O
suggests	O
that	O
increased	O
susceptibility	O
to	O
Warfarin	B-Chemical
-	O
induced	O
artery	B-Disease
calcification	I-Disease
could	O
be	O
related	O
to	O
higher	O
serum	O
phosphate	B-Chemical
levels	O
.	O

The	O
second	O
set	O
of	O
experiments	O
examined	O
the	O
possible	O
synergy	O
between	O
vitamin	B-Chemical
D	I-Chemical
and	O
Warfarin	B-Chemical
in	O
artery	B-Disease
calcification	I-Disease
.	O

High	O
doses	O
of	O
vitamin	B-Chemical
D	I-Chemical
are	O
known	O
to	O
cause	O
calcification	B-Disease
of	I-Disease
the	I-Disease
artery	I-Disease
media	O
in	O
as	O
little	O
as	O
3	O
to	O
4	O
days	O
.	O

High	O
doses	O
of	O
the	O
vitamin	B-Chemical
K	I-Chemical
antagonist	O
Warfarin	B-Chemical
are	O
also	O
known	O
to	O
cause	O
calcification	B-Disease
of	I-Disease
the	I-Disease
artery	I-Disease
media	O
,	O
but	O
at	O
treatment	O
times	O
of	O
2	O
weeks	O
or	O
longer	O
yet	O
not	O
at	O
1	O
week	O
.	O

In	O
the	O
current	O
study	O
,	O
we	O
investigated	O
the	O
synergy	O
between	O
these	O
2	O
treatments	O
and	O
found	O
that	O
concurrent	O
Warfarin	B-Chemical
administration	O
dramatically	O
increased	O
the	O
extent	O
of	O
calcification	B-Disease
in	O
the	O
media	O
of	O
vitamin	B-Chemical
D	I-Chemical
-	O
treated	O
rats	O
at	O
3	O
and	O
4	O
days	O
.	O

There	O
was	O
a	O
close	O
parallel	O
between	O
the	O
effect	O
of	O
vitamin	B-Chemical
D	I-Chemical
dose	O
on	O
artery	B-Disease
calcification	I-Disease
and	O
the	O
effect	O
of	O
vitamin	B-Chemical
D	I-Chemical
dose	O
on	O
the	O
elevation	O
of	O
serum	O
calcium	B-Chemical
,	O
which	O
suggests	O
that	O
vitamin	B-Chemical
D	I-Chemical
may	O
induce	O
artery	B-Disease
calcification	I-Disease
through	O
its	O
effect	O
on	O
serum	O
calcium	B-Chemical
.	O

Because	O
Warfarin	B-Chemical
treatment	O
had	O
no	O
effect	O
on	O
the	O
elevation	O
in	O
serum	O
calcium	B-Chemical
produced	O
by	O
vitamin	B-Chemical
D	I-Chemical
,	O
the	O
synergy	O
between	O
Warfarin	B-Chemical
and	O
vitamin	B-Chemical
D	I-Chemical
is	O
probably	O
best	O
explained	O
by	O
the	O
hypothesis	O
that	O
Warfarin	B-Chemical
inhibits	O
the	O
activity	O
of	O
matrix	O
Gla	O
protein	O
as	O
a	O
calcification	B-Disease
inhibitor	O
.	O

High	O
levels	O
of	O
matrix	O
Gla	O
protein	O
are	O
found	O
at	O
sites	O
of	O
artery	B-Disease
calcification	I-Disease
in	O
rats	O
treated	O
with	O
vitamin	B-Chemical
D	I-Chemical
plus	O
Warfarin	B-Chemical
,	O
and	O
chemical	O
analysis	O
showed	O
that	O
the	O
protein	O
that	O
accumulated	O
was	O
indeed	O
not	O
gamma	B-Chemical
-	I-Chemical
carboxylated	I-Chemical
.	O

These	O
observations	O
indicate	O
that	O
although	O
the	O
gamma	B-Chemical
-	I-Chemical
carboxyglutamate	I-Chemical
residues	O
of	O
matrix	O
Gla	O
protein	O
are	O
apparently	O
required	O
for	O
its	O
function	O
as	O
a	O
calcification	B-Disease
inhibitor	O
,	O
they	O
are	O
not	O
required	O
for	O
its	O
accumulation	O
at	O
calcification	B-Disease
sites	O
.	O

Apomorphine	B-Chemical
,	O
a	O
nonselective	O
dopamine	B-Chemical
agonist	I-Chemical
,	O
was	O
selected	O
due	O
to	O
its	O
biphasic	O
behavioral	O
effects	O
,	O
its	O
ability	O
to	O
induce	O
hypothermia	B-Disease
,	O
and	O
to	O
produce	O
distinct	O
changes	O
to	O
dopamine	B-Chemical
turnover	O
in	O
the	O
rodent	O
brain	O
.	O

From	O
such	O
experiments	O
there	O
is	O
evidence	O
that	O
characterization	O
and	O
detection	O
of	O
apomorphine	B-Chemical
-	O
induced	O
activity	O
in	O
rodents	O
critically	O
depends	O
upon	O
the	O
test	O
conditions	O
employed	O
.	O

In	O
rats	O
,	O
detection	O
of	O
apomorphine	B-Chemical
-	O
induced	O
hyperactivity	B-Disease
was	O
facilitated	O
by	O
a	O
period	O
of	O
acclimatization	O
to	O
the	O
test	O
conditions	O
.	O

Moreover	O
,	O
test	O
conditions	O
can	O
impact	O
upon	O
other	O
physiological	O
responses	O
to	O
apomorphine	B-Chemical
such	O
as	O
drug	O
-	O
induced	O
hypothermia	B-Disease
.	O

In	O
mice	O
,	O
apomorphine	B-Chemical
produced	O
qualitatively	O
different	O
responses	O
under	O
novel	O
conditions	O
when	O
compared	O
to	O
those	O
behaviors	O
elicited	O
in	O
the	O
home	O
test	O
cage	O
.	O

By	O
contrast	O
,	O
apomorphine	B-Chemical
-	O
induced	O
locomotion	O
was	O
more	O
prominent	O
in	O
the	O
novel	O
exploratory	O
box	O
.	O

Dopamine	B-Chemical
turnover	O
ratios	O
(	O
DOPAC	B-Chemical
:	O
DA	O
and	O
HVA	B-Chemical
:	O
DA	B-Chemical
)	O
were	O
found	O
to	O
be	O
lower	O
in	O
those	O
animals	O
exposed	O
to	O
the	O
exploratory	O
box	O
when	O
compared	O
to	O
their	O
home	O
cage	O
counterparts	O
.	O

However	O
,	O
apomorphine	B-Chemical
-	O
induced	O
reductions	O
in	O
striatal	O
dopamine	B-Chemical
turnover	O
were	O
detected	O
in	O
both	O
novel	O
and	O
home	O
cage	O
environments	O
.	O

Hemolysis	B-Disease
of	O
human	O
erythrocytes	O
induced	O
by	O
tamoxifen	B-Chemical
is	O
related	O
to	O
disruption	O
of	O
membrane	O
structure	O
.	O

Tamoxifen	B-Chemical
(	O
TAM	B-Chemical
)	O
,	O
the	O
antiestrogenic	O
drug	O
most	O
widely	O
prescribed	O
in	O
the	O
chemotherapy	O
of	O
breast	B-Disease
cancer	I-Disease
,	O
induces	O
changes	O
in	O
normal	O
discoid	O
shape	O
of	O
erythrocytes	O
and	O
hemolytic	B-Disease
anemia	I-Disease
.	O

This	O
work	O
evaluates	O
the	O
effects	O
of	O
TAM	B-Chemical
on	O
isolated	O
human	O
erythrocytes	O
,	O
attempting	O
to	O
identify	O
the	O
underlying	O
mechanisms	O
on	O
TAM	B-Chemical
-	O
induced	O
hemolytic	B-Disease
anemia	I-Disease
and	O
the	O
involvement	O
of	O
biomembranes	O
in	O
its	O
cytostatic	O
action	O
mechanisms	O
.	O

TAM	B-Chemical
induces	O
hemolysis	B-Disease
of	O
erythrocytes	O
as	O
a	O
function	O
of	O
concentration	O
.	O

The	O
extension	O
of	O
hemolysis	B-Disease
is	O
variable	O
with	O
erythrocyte	O
samples	O
,	O
but	O
12	O
.	O
5	O
microM	O
TAM	B-Chemical
induces	O
total	O
hemolysis	B-Disease
of	O
all	O
tested	O
suspensions	O
.	O

Despite	O
inducing	O
extensive	O
erythrocyte	O
lysis	O
,	O
TAM	B-Chemical
does	O
not	O
shift	O
the	O
osmotic	O
fragility	O
curves	O
of	O
erythrocytes	O
.	O

The	O
hemolytic	B-Disease
effect	O
of	O
TAM	B-Chemical
is	O
prevented	O
by	O
low	O
concentrations	O
of	O
alpha	B-Chemical
-	I-Chemical
tocopherol	I-Chemical
(	O
alpha	B-Chemical
-	I-Chemical
T	I-Chemical
)	O
and	O
alpha	B-Chemical
-	I-Chemical
tocopherol	I-Chemical
acetate	I-Chemical
(	O
alpha	B-Chemical
-	I-Chemical
TAc	I-Chemical
)	O
(	O
inactivated	O
functional	O
hydroxyl	B-Chemical
)	O
indicating	O
that	O
TAM	B-Chemical
-	O
induced	O
hemolysis	B-Disease
is	O
not	O
related	O
to	O
oxidative	O
membrane	O
damage	O
.	O

This	O
was	O
further	O
evidenced	O
by	O
absence	O
of	O
oxygen	B-Chemical
consumption	O
and	O
hemoglobin	O
oxidation	O
both	O
determined	O
in	O
parallel	O
with	O
TAM	B-Chemical
-	O
induced	O
hemolysis	B-Disease
.	O

Furthermore	O
,	O
it	O
was	O
observed	O
that	O
TAM	B-Chemical
inhibits	O
the	O
peroxidation	O
of	O
human	O
erythrocytes	O
induced	O
by	O
AAPH	B-Chemical
,	O
thus	O
ruling	O
out	O
TAM	B-Chemical
-	O
induced	O
cell	O
oxidative	O
stress	O
.	O

Hemolysis	B-Disease
caused	O
by	O
TAM	B-Chemical
was	O
not	O
preceded	O
by	O
the	O
leakage	O
of	O
K	B-Chemical
(	O
+	O
)	O
from	O
the	O
cells	O
,	O
also	O
excluding	O
a	O
colloid	O
-	O
osmotic	O
type	O
mechanism	O
of	O
hemolysis	B-Disease
,	O
according	O
to	O
the	O
effects	O
on	O
osmotic	O
fragility	O
curves	O
.	O

However	O
,	O
TAM	B-Chemical
induces	O
release	O
of	O
peripheral	O
proteins	O
of	O
membrane	O
-	O
cytoskeleton	O
and	O
cytosol	O
proteins	O
essentially	O
bound	O
to	O
band	O
3	O
.	O

Either	O
alpha	B-Chemical
-	I-Chemical
T	I-Chemical
or	O
alpha	B-Chemical
-	I-Chemical
TAc	I-Chemical
increases	O
membrane	O
packing	O
and	O
prevents	O
TAM	B-Chemical
partition	O
into	O
model	O
membranes	O
.	O

These	O
effects	O
suggest	O
that	O
the	O
protection	O
from	O
hemolysis	B-Disease
by	O
tocopherols	B-Chemical
is	O
related	O
to	O
a	O
decreased	O
TAM	B-Chemical
incorporation	O
in	O
condensed	O
membranes	O
and	O
the	O
structural	O
damage	O
of	O
the	O
erythrocyte	O
membrane	O
is	O
consequently	O
avoided	O
.	O

Therefore	O
,	O
TAM	B-Chemical
-	O
induced	O
hemolysis	B-Disease
results	O
from	O
a	O
structural	O
perturbation	O
of	O
red	O
cell	O
membrane	O
,	O
leading	O
to	O
changes	O
in	O
the	O
framework	O
of	O
the	O
erythrocyte	O
membrane	O
and	O
its	O
cytoskeleton	O
caused	O
by	O
its	O
high	O
partition	O
in	O
the	O
membrane	O
.	O

These	O
defects	O
explain	O
the	O
abnormal	O
erythrocyte	O
shape	O
and	O
decreased	O
mechanical	O
stability	O
promoted	O
by	O
TAM	B-Chemical
,	O
resulting	O
in	O
hemolytic	B-Disease
anemia	I-Disease
.	O

Additionally	O
,	O
since	O
membrane	O
leakage	O
is	O
a	O
final	O
stage	O
of	O
cytotoxicity	O
,	O
the	O
disruption	O
of	O
the	O
structural	O
characteristics	O
of	O
biomembranes	O
by	O
TAM	B-Chemical
may	O
contribute	O
to	O
the	O
multiple	O
mechanisms	O
of	O
its	O
anticancer	O
action	O
.	O

Changes	O
of	O
sodium	B-Chemical
and	O
ATP	B-Chemical
affinities	O
of	O
the	O
cardiac	O
(	O
Na	B-Chemical
,	O
K	B-Chemical
)	O
-	O
ATPase	O
during	O
and	O
after	O
nitric	B-Chemical
oxide	I-Chemical
deficient	O
hypertension	B-Disease
.	O

In	O
the	O
cardiovascular	O
system	O
,	O
NO	B-Chemical
is	O
involved	O
in	O
the	O
regulation	O
of	O
a	O
variety	O
of	O
functions	O
.	O

Inhibition	O
of	O
NO	B-Chemical
synthesis	O
induces	O
sustained	O
hypertension	B-Disease
.	O

In	O
several	O
models	O
of	O
hypertension	B-Disease
,	O
elevation	O
of	O
intracellular	O
sodium	B-Chemical
level	O
was	O
documented	O
in	O
cardiac	O
tissue	O
.	O

To	O
assess	O
the	O
molecular	O
basis	O
of	O
disturbances	O
in	O
transmembraneous	O
transport	O
of	O
Na	B-Chemical
+	O
,	O
we	O
studied	O
the	O
response	O
of	O
cardiac	O
(	O
Na	B-Chemical
,	O
K	B-Chemical
)	O
-	O
ATPase	O
to	O
NO	B-Chemical
-	O
deficient	O
hypertension	B-Disease
induced	O
in	O
rats	O
by	O
NO	B-Chemical
-	O
synthase	O
inhibition	O
with	O
40	O
mg	O
/	O
kg	O
/	O
day	O
N	B-Chemical
(	I-Chemical
G	I-Chemical
)	I-Chemical
-	I-Chemical
nitro	I-Chemical
-	I-Chemical
L	I-Chemical
-	I-Chemical
arginine	I-Chemical
methyl	I-Chemical
ester	I-Chemical
(	O
L	B-Chemical
-	I-Chemical
NAME	I-Chemical
)	O
for	O
4	O
four	O
weeks	O
.	O

After	O
4	O
-	O
week	O
administration	O
of	O
L	B-Chemical
-	I-Chemical
NAME	I-Chemical
,	O
the	O
systolic	O
blood	O
pressure	O
(	O
SBP	O
)	O
increased	O
by	O
36	O
%	O
.	O

When	O
activating	O
the	O
(	O
Na	B-Chemical
,	O
K	B-Chemical
)	O
-	O
ATPase	O
with	O
its	O
substrate	O
ATP	B-Chemical
,	O
no	O
changes	O
in	O
Km	O
and	O
Vmax	O
values	O
were	O
observed	O
in	O
NO	B-Chemical
-	O
deficient	O
rats	O
.	O

During	O
activation	O
with	O
Na	B-Chemical
+	O
,	O
the	O
Vmax	O
remained	O
unchanged	O
,	O
however	O
the	O
K	B-Chemical
(	O
Na	B-Chemical
)	O
increased	O
by	O
50	O
%	O
,	O
indicating	O
a	O
profound	O
decrease	O
in	O
the	O
affinity	O
of	O
the	O
Na	B-Chemical
+	O
-	O
binding	O
site	O
in	O
NO	B-Chemical
-	O
deficient	O
rats	O
.	O

After	O
recovery	O
from	O
hypertension	B-Disease
,	O
the	O
activity	O
of	O
(	O
Na	B-Chemical
,	O
K	B-Chemical
)	O
-	O
ATPase	O
increased	O
,	O
due	O
to	O
higher	O
affinity	O
of	O
the	O
ATP	B-Chemical
-	O
binding	O
site	O
,	O
as	O
revealed	O
from	O
the	O
lowered	O
Km	O
value	O
for	O
ATP	B-Chemical
.	O

The	O
K	B-Chemical
(	O
Na	O
)	O
value	O
for	O
Na	B-Chemical
+	O
returned	O
to	O
control	O
value	O
.	O

Inhibition	O
of	O
NO	B-Chemical
-	O
synthase	O
induced	O
a	O
reversible	O
hypertension	B-Disease
accompanied	O
by	O
depressed	B-Disease
Na	B-Chemical
+	O
-	O
extrusion	O
from	O
cardiac	O
cells	O
as	O
a	O
consequence	O
of	O
deteriorated	O
Na	B-Chemical
+	O
-	O
binding	O
properties	O
of	O
the	O
(	O
Na	B-Chemical
,	O
K	B-Chemical
)	O
-	O
ATPase	O
.	O

After	O
recovery	O
of	O
blood	O
pressure	O
to	O
control	O
values	O
,	O
the	O
extrusion	O
of	O
Na	B-Chemical
+	O
from	O
cardiac	O
cells	O
was	O
normalized	O
,	O
as	O
revealed	O
by	O
restoration	O
of	O
the	O
(	O
Na	B-Chemical
,	O
K	B-Chemical
)	O
-	O
ATPase	O
activity	O
.	O

Effects	O
of	O
long	O
-	O
term	O
pretreatment	O
with	O
isoproterenol	B-Chemical
on	O
bromocriptine	B-Chemical
-	O
induced	O
tachycardia	B-Disease
in	O
conscious	O
rats	O
.	O

It	O
has	O
been	O
shown	O
that	O
bromocriptine	B-Chemical
-	O
induced	O
tachycardia	B-Disease
,	O
which	O
persisted	O
after	O
adrenalectomy	O
,	O
is	O
(	O
i	O
)	O
mediated	O
by	O
central	O
dopamine	B-Chemical
D2	O
receptor	O
activation	O
and	O
(	O
ii	O
)	O
reduced	O
by	O
5	O
-	O
day	O
isoproterenol	B-Chemical
pretreatment	O
,	O
supporting	O
therefore	O
the	O
hypothesis	O
that	O
this	O
effect	O
is	O
dependent	O
on	O
sympathetic	O
outflow	O
to	O
the	O
heart	O
.	O

This	O
study	O
was	O
conducted	O
to	O
examine	O
whether	O
prolonged	O
pretreatment	O
with	O
isoproterenol	B-Chemical
could	O
abolish	O
bromocriptine	B-Chemical
-	O
induced	O
tachycardia	B-Disease
in	O
conscious	O
rats	O
.	O

Isoproterenol	B-Chemical
pretreatment	O
for	O
15	O
days	O
caused	O
cardiac	B-Disease
hypertrophy	I-Disease
without	O
affecting	O
baseline	O
blood	O
pressure	O
and	O
heart	O
rate	O
.	O

In	O
control	O
rats	O
,	O
intravenous	O
bromocriptine	B-Chemical
(	O
150	O
microg	O
/	O
kg	O
)	O
induced	O
significant	O
hypotension	B-Disease
and	O
tachycardia	B-Disease
.	O

Bromocriptine	B-Chemical
-	O
induced	O
hypotension	B-Disease
was	O
unaffected	O
by	O
isoproterenol	B-Chemical
pretreatment	O
,	O
while	O
tachycardia	B-Disease
was	O
reversed	O
to	O
significant	O
bradycardia	B-Disease
,	O
an	O
effect	O
that	O
was	O
partly	O
reduced	O
by	O
i	O
.	O
v	O
.	O
domperidone	B-Chemical
(	O
0	O
.	O
5	O
mg	O
/	O
kg	O
)	O
.	O

Neither	O
cardiac	O
vagal	O
nor	O
sympathetic	O
tone	O
was	O
altered	O
by	O
isoproterenol	B-Chemical
pretreatment	O
.	O

In	O
isolated	O
perfused	O
heart	O
preparations	O
from	O
isoproterenol	B-Chemical
-	O
pretreated	O
rats	O
,	O
the	O
isoproterenol	B-Chemical
-	O
induced	O
maximal	O
increase	O
in	O
left	O
ventricular	O
systolic	O
pressure	O
was	O
significantly	O
reduced	O
,	O
compared	O
with	O
saline	O
-	O
pretreated	O
rats	O
(	O
the	O
EC50	O
of	O
the	O
isoproterenol	B-Chemical
-	O
induced	O
increase	O
in	O
left	O
ventricular	O
systolic	O
pressure	O
was	O
enhanced	O
approximately	O
22	O
-	O
fold	O
)	O
.	O

These	O
results	O
show	O
that	O
15	O
-	O
day	O
isoproterenol	B-Chemical
pretreatment	O
not	O
only	O
abolished	O
but	O
reversed	O
bromocriptine	B-Chemical
-	O
induced	O
tachycardia	B-Disease
to	O
bradycardia	B-Disease
,	O
an	O
effect	O
that	O
is	O
mainly	O
related	O
to	O
further	O
cardiac	O
beta	O
-	O
adrenoceptor	O
desensitization	O
rather	O
than	O
to	O
impairment	O
of	O
autonomic	O
regulation	O
of	O
the	O
heart	O
.	O

They	O
suggest	O
that	O
,	O
in	O
normal	O
conscious	O
rats	O
,	O
the	O
central	O
tachycardia	B-Disease
of	O
bromocriptine	B-Chemical
appears	O
to	O
predominate	O
and	O
to	O
mask	O
the	O
bradycardia	B-Disease
of	O
this	O
agonist	O
at	O
peripheral	O
dopamine	B-Chemical
D2	O
receptors	O
.	O

A	O
developmental	O
analysis	O
of	O
clonidine	B-Chemical
'	O
s	O
effects	O
on	O
cardiac	O
rate	O
and	O
ultrasound	O
production	O
in	O
infant	O
rats	O
.	O

Under	O
controlled	O
conditions	O
,	O
infant	O
rats	O
emit	O
ultrasonic	O
vocalizations	O
during	O
extreme	O
cold	O
exposure	O
and	O
after	O
administration	O
of	O
the	O
alpha	O
(	O
2	O
)	O
adrenoceptor	O
agonist	O
,	O
clonidine	B-Chemical
.	O

Previous	O
investigations	O
have	O
determined	O
that	O
,	O
in	O
response	O
to	O
clonidine	B-Chemical
,	O
ultrasound	O
production	O
increases	O
through	O
the	O
2nd	O
-	O
week	O
postpartum	O
and	O
decreases	O
thereafter	O
.	O

Given	O
that	O
sympathetic	O
neural	O
dominance	O
exhibits	O
a	O
similar	O
developmental	O
pattern	O
,	O
and	O
given	O
that	O
clonidine	B-Chemical
induces	O
sympathetic	O
withdrawal	O
and	O
bradycardia	B-Disease
,	O
we	O
hypothesized	O
that	O
clonidine	B-Chemical
'	O
s	O
developmental	O
effects	O
on	O
cardiac	O
rate	O
and	O
ultrasound	O
production	O
would	O
mirror	O
each	O
other	O
.	O

Therefore	O
,	O
in	O
the	O
present	O
experiment	O
,	O
the	O
effects	O
of	O
clonidine	B-Chemical
administration	O
(	O
0	O
.	O
5	O
mg	O
/	O
kg	O
)	O
on	O
cardiac	O
rate	O
and	O
ultrasound	O
production	O
were	O
examined	O
in	O
2	O
-	O
,	O
8	O
-	O
,	O
15	O
-	O
,	O
and	O
20	O
-	O
day	O
-	O
old	O
rats	O
.	O

Age	O
-	O
related	O
changes	O
in	O
ultrasound	O
production	O
corresponded	O
with	O
changes	O
in	O
cardiovascular	O
variables	O
,	O
including	O
baseline	O
cardiac	O
rate	O
and	O
clonidine	B-Chemical
-	O
induced	O
bradycardia	B-Disease
.	O

This	O
experiment	O
is	O
discussed	O
with	O
regard	O
to	O
the	O
hypothesis	O
that	O
ultrasound	O
production	O
is	O
the	O
acoustic	O
by	O
-	O
product	O
of	O
a	O
physiological	O
maneuver	O
that	O
compensates	O
for	O
clonidine	B-Chemical
'	O
s	O
detrimental	O
effects	O
on	O
cardiovascular	O
function	O
.	O

Recurrent	O
use	O
of	O
newer	O
oral	B-Chemical
contraceptives	I-Chemical
and	O
the	O
risk	O
of	O
venous	B-Disease
thromboembolism	I-Disease
.	O

The	O
epidemiological	O
studies	O
that	O
assessed	O
the	O
risk	O
of	O
venous	B-Disease
thromboembolism	I-Disease
(	O
VTE	B-Disease
)	O
associated	O
with	O
newer	O
oral	B-Chemical
contraceptives	I-Chemical
(	O
OC	B-Chemical
)	O
did	O
not	O
distinguish	O
between	O
patterns	O
of	O
OC	B-Chemical
use	O
,	O
namely	O
first	O
-	O
time	O
users	O
,	O
repeaters	O
and	O
switchers	O
.	O

Data	O
from	O
a	O
Transnational	O
case	O
-	O
control	O
study	O
were	O
used	O
to	O
assess	O
the	O
risk	O
of	O
VTE	B-Disease
for	O
the	O
latter	O
patterns	O
of	O
use	O
,	O
while	O
accounting	O
for	O
duration	O
of	O
use	O
.	O

Over	O
the	O
period	O
1993	O
-	O
1996	O
,	O
551	O
cases	O
of	O
VTE	B-Disease
were	O
identified	O
in	O
Germany	O
and	O
the	O
UK	O
along	O
with	O
2066	O
controls	O
.	O

The	O
adjusted	O
rate	O
ratio	O
of	O
VTE	B-Disease
for	O
repeat	O
users	O
of	O
third	O
generation	O
OC	B-Chemical
was	O
0	O
.	O
6	O
(	O
95	O
%	O
CI	O
:	O
0	O
.	O
3	O
-	O
1	O
.	O
2	O
)	O
relative	O
to	O
repeat	O
users	O
of	O
second	O
generation	O
pills	O
,	O
whereas	O
it	O
was	O
1	O
.	O
3	O
(	O
95	O
%	O
CI	O
:	O
0	O
.	O
7	O
-	O
2	O
.	O
4	O
)	O
for	O
switchers	O
from	O
second	O
to	O
third	O
generation	O
pills	O
relative	O
to	O
switchers	O
from	O
third	O
to	O
second	O
generation	O
pills	O
.	O

We	O
conclude	O
that	O
second	O
and	O
third	O
generation	O
agents	O
are	O
associated	O
with	O
equivalent	O
risks	O
of	O
VTE	B-Disease
when	O
the	O
same	O
agent	O
is	O
used	O
repeatedly	O
after	O
interruption	O
periods	O
or	O
when	O
users	O
are	O
switched	O
between	O
the	O
two	O
generations	O
of	O
pills	O
.	O

These	O
analyses	O
suggest	O
that	O
the	O
higher	O
risk	O
observed	O
for	O
the	O
newer	O
OC	B-Chemical
in	O
other	O
studies	O
may	O
be	O
the	O
result	O
of	O
inadequate	O
comparisons	O
of	O
pill	O
users	O
with	O
different	O
patterns	O
of	O
pill	O
use	O
.	O

Differential	O
effects	O
of	O
systemically	O
administered	O
ketamine	B-Chemical
and	O
lidocaine	B-Chemical
on	O
dynamic	O
and	O
static	O
hyperalgesia	B-Disease
induced	O
by	O
intradermal	O
capsaicin	B-Chemical
in	O
humans	O
.	O

We	O
have	O
examined	O
the	O
effect	O
of	O
systemic	O
administration	O
of	O
ketamine	B-Chemical
and	O
lidocaine	B-Chemical
on	O
brush	O
-	O
evoked	O
(	O
dynamic	O
)	O
pain	B-Disease
and	O
punctate	O
-	O
evoked	O
(	O
static	O
)	O
hyperalgesia	B-Disease
induced	O
by	O
capsaicin	B-Chemical
.	O

Capsaicin	B-Chemical
100	O
micrograms	O
was	O
injected	O
intradermally	O
on	O
the	O
volar	O
forearm	O
followed	O
by	O
an	O
i	O
.	O
v	O
.	O
infusion	O
of	O
ketamine	B-Chemical
(	O
bolus	O
0	O
.	O
1	O
mg	O
kg	O
-	O
1	O
over	O
10	O
min	O
followed	O
by	O
infusion	O
of	O
7	O
micrograms	O
kg	O
-	O
1	O
min	O
-	O
1	O
)	O
,	O
lidocaine	B-Chemical
5	O
mg	O
kg	O
-	O
1	O
or	O
saline	O
for	O
50	O
min	O
.	O

Infusion	O
started	O
15	O
min	O
after	O
injection	O
of	O
capsaicin	B-Chemical
.	O

The	O
following	O
were	O
measured	O
:	O
spontaneous	O
pain	B-Disease
,	O
pain	B-Disease
evoked	O
by	O
punctate	O
and	O
brush	O
stimuli	O
(	O
VAS	O
)	O
,	O
and	O
areas	O
of	O
brush	O
-	O
evoked	O
and	O
punctate	O
-	O
evoked	O
hyperalgesia	B-Disease
.	O

Ketamine	B-Chemical
reduced	O
both	O
the	O
area	O
of	O
brush	O
-	O
evoked	O
and	O
punctate	O
-	O
evoked	O
hyperalgesia	B-Disease
significantly	O
and	O
it	O
tended	O
to	O
reduce	O
brush	O
-	O
evoked	O
pain	O
.	O

Lidocaine	B-Chemical
reduced	O
the	O
area	O
of	O
punctate	O
-	O
evoked	O
hyperalgesia	B-Disease
significantly	O
.	O

It	O
tended	O
to	O
reduce	O
VAS	O
scores	O
of	O
spontaneous	O
pain	B-Disease
but	O
had	O
no	O
effect	O
on	O
evoked	O
pain	B-Disease
.	O

The	O
differential	O
effects	O
of	O
ketamine	B-Chemical
and	O
lidocaine	B-Chemical
on	O
static	O
and	O
dynamic	O
hyperalgesia	B-Disease
suggest	O
that	O
the	O
two	O
types	O
of	O
hyperalgesia	B-Disease
are	O
mediated	O
by	O
separate	O
mechanisms	O
and	O
have	O
a	O
distinct	O
pharmacology	O
.	O

Development	O
of	O
apomorphine	B-Chemical
-	O
induced	O
aggressive	B-Disease
behavior	I-Disease
:	O
comparison	O
of	O
adult	O
male	O
and	O
female	O
Wistar	O
rats	O
.	O

The	O
development	O
of	O
apomorphine	B-Chemical
-	O
induced	O
(	O
1	O
.	O
0	O
mg	O
/	O
kg	O
s	O
.	O
c	O
.	O
once	O
daily	O
)	O
aggressive	B-Disease
behavior	I-Disease
of	O
adult	O
male	O
and	O
female	O
Wistar	O
rats	O
obtained	O
from	O
the	O
same	O
breeder	O
was	O
studied	O
in	O
two	O
consecutive	O
sets	O
.	O

In	O
male	O
animals	O
,	O
repeated	O
apomorphine	B-Chemical
treatment	O
induced	O
a	O
gradual	O
development	O
of	O
aggressive	B-Disease
behavior	I-Disease
as	O
evidenced	O
by	O
the	O
increased	O
intensity	O
of	O
aggressiveness	B-Disease
and	O
shortened	O
latency	O
before	O
the	O
first	O
attack	O
toward	O
the	O
opponent	O
.	O

In	O
female	O
rats	O
,	O
only	O
a	O
weak	O
tendency	O
toward	O
aggressiveness	B-Disease
was	O
found	O
.	O

In	O
conclusion	O
,	O
the	O
present	O
study	O
demonstrates	O
gender	O
differences	O
in	O
the	O
development	O
of	O
the	O
apomorphine	B-Chemical
-	O
induced	O
aggressive	B-Disease
behavior	I-Disease
and	O
indicates	O
that	O
the	O
female	O
rats	O
do	O
not	O
fill	O
the	O
validation	O
criteria	O
for	O
use	O
in	O
this	O
method	O
.	O

Intracranial	B-Disease
aneurysms	I-Disease
and	O
cocaine	B-Disease
abuse	I-Disease
:	O
analysis	O
of	O
prognostic	O
indicators	O
.	O

OBJECTIVE	O
:	O
The	O
outcome	O
of	O
subarachnoid	B-Disease
hemorrhage	I-Disease
associated	O
with	O
cocaine	B-Disease
abuse	I-Disease
is	O
reportedly	O
poor	O
.	O

METHODS	O
:	O
A	O
review	O
of	O
admissions	O
during	O
a	O
6	O
-	O
year	O
period	O
revealed	O
14	O
patients	O
with	O
cocaine	B-Chemical
-	O
related	O
aneurysms	B-Disease
.	O

This	O
group	O
was	O
compared	O
with	O
a	O
control	O
group	O
of	O
135	O
patients	O
with	O
ruptured	B-Disease
aneurysms	I-Disease
and	O
no	O
history	O
of	O
cocaine	B-Disease
abuse	I-Disease
.	O

Age	O
at	O
presentation	O
,	O
time	O
of	O
ictus	O
after	O
intoxication	O
,	O
Hunt	O
and	O
Hess	O
grade	O
of	O
subarachnoid	B-Disease
hemorrhage	I-Disease
,	O
size	O
of	O
the	O
aneurysm	B-Disease
,	O
location	O
of	O
the	O
aneurysm	B-Disease
,	O
and	O
the	O
Glasgow	O
Outcome	O
Scale	O
score	O
were	O
assessed	O
and	O
compared	O
.	O

In	O
patients	O
in	O
the	O
study	O
group	O
,	O
all	O
aneurysms	B-Disease
were	O
located	O
in	O
the	O
anterior	O
circulation	O
.	O

The	O
majority	O
of	O
these	O
aneurysms	B-Disease
were	O
smaller	O
than	O
those	O
of	O
the	O
control	O
group	O
(	O
8	O
+	O
/	O
-	O
6	O
.	O
08	O
mm	O
versus	O
11	O
+	O
/	O
-	O
5	O
.	O
4	O
mm	O
;	O
P	O
=	O
0	O
.	O
05	O
)	O
.	O

Hunt	O
and	O
Hess	O
grade	O
(	O
P	O
<	O
0	O
.	O
005	O
)	O
and	O
age	O
(	O
P	O
<	O
0	O
.	O
007	O
)	O
were	O
significant	O
predictors	O
of	O
outcome	O
for	O
the	O
patients	O
with	O
cocaine	B-Chemical
-	O
related	O
aneurysms	B-Disease
.	O

CONCLUSION	O
:	O
Cocaine	B-Chemical
use	O
predisposed	O
aneurysmal	B-Disease
rupture	I-Disease
at	O
a	O
significantly	O
earlier	O
age	O
and	O
in	O
much	O
smaller	O
aneurysms	B-Disease
.	O

Effect	O
of	O
intravenous	O
nimodipine	B-Chemical
on	O
blood	O
pressure	O
and	O
outcome	O
after	O
acute	B-Disease
stroke	I-Disease
.	O

BACKGROUND	O
AND	O
PURPOSE	O
:	O
The	O
Intravenous	O
Nimodipine	B-Chemical
West	O
European	O
Stroke	B-Disease
Trial	O
(	O
INWEST	O
)	O
found	O
a	O
correlation	O
between	O
nimodipine	B-Chemical
-	O
induced	O
reduction	B-Disease
in	I-Disease
blood	I-Disease
pressure	I-Disease
(	O
BP	O
)	O
and	O
an	O
unfavorable	O
outcome	O
in	O
acute	B-Disease
stroke	I-Disease
.	O

We	O
sought	O
to	O
confirm	O
this	O
correlation	O
with	O
and	O
without	O
adjustment	O
for	O
prognostic	O
variables	O
and	O
to	O
investigate	O
outcome	O
in	O
subgroups	O
with	O
increasing	O
levels	O
of	O
BP	B-Disease
reduction	I-Disease
.	O

METHODS	O
:	O
Patients	O
with	O
a	O
clinical	O
diagnosis	O
of	O
ischemic	B-Disease
stroke	I-Disease
(	O
within	O
24	O
hours	O
)	O
were	O
consecutively	O
allocated	O
to	O
receive	O
placebo	O
(	O
n	O
=	O
100	O
)	O
,	O
1	O
mg	O
/	O
h	O
(	O
low	O
-	O
dose	O
)	O
nimodipine	B-Chemical
(	O
n	O
=	O
101	O
)	O
,	O
or	O
2	O
mg	O
/	O
h	O
(	O
high	O
-	O
dose	O
)	O
nimodipine	B-Chemical
(	O
n	O
=	O
94	O
)	O
.	O

Nimodipine	B-Chemical
treatment	O
resulted	O
in	O
a	O
statistically	O
significant	O
reduction	B-Disease
in	I-Disease
systolic	I-Disease
BP	I-Disease
(	O
SBP	O
)	O
and	O
diastolic	O
BP	O
(	O
DBP	O
)	O
from	O
baseline	O
compared	O
with	O
placebo	O
during	O
the	O
first	O
few	O
days	O
.	O

In	O
multivariate	O
analysis	O
,	O
a	O
significant	O
correlation	O
between	O
DBP	B-Disease
reduction	I-Disease
and	O
worsening	O
of	O
the	O
neurological	O
score	O
was	O
found	O
for	O
the	O
high	O
-	O
dose	O
group	O
(	O
beta	O
=	O
0	O
.	O
49	O
,	O
P	O
=	O
0	O
.	O
048	O
)	O
.	O

Patients	O
with	O
a	O
DBP	B-Disease
reduction	I-Disease
of	O
>	O
or	O
=	O
20	O
%	O
in	O
the	O
high	O
-	O
dose	O
group	O
had	O
a	O
significantly	O
increased	O
adjusted	O
OR	O
for	O
the	O
compound	O
outcome	O
variable	O
death	B-Disease
or	O
dependency	O
(	O
Barthel	O
Index	O
<	O
60	O
)	O
(	O
n	O
/	O
N	O
=	O
25	O
/	O
26	O
,	O
OR	O
10	O
.	O
16	O
,	O
95	O
%	O
CI	O
1	O
.	O
02	O
to	O
101	O
.	O
74	O
)	O
and	O
death	B-Disease
alone	O
(	O
n	O
/	O
N	O
=	O
9	O
/	O
26	O
,	O
OR	O
4	O
.	O
336	O
,	O
95	O
%	O
CI	O
1	O
.	O
131	O
16	O
.	O
619	O
)	O
compared	O
with	O
all	O
placebo	O
patients	O
(	O
n	O
/	O
N	O
=	O
62	O
/	O
92	O
and	O
14	O
/	O
92	O
,	O
respectively	O
)	O
.	O

CONCLUSIONS	O
:	O
DBP	O
,	O
but	O
not	O
SBP	O
,	O
reduction	O
was	O
associated	O
with	O
neurological	O
worsening	O
after	O
the	O
intravenous	O
administration	O
of	O
high	O
-	O
dose	O
nimodipine	B-Chemical
after	O
acute	B-Disease
stroke	I-Disease
.	O

For	O
low	O
-	O
dose	O
nimodipine	B-Chemical
,	O
the	O
results	O
were	O
not	O
conclusive	O
.	O

These	O
results	O
do	O
not	O
confirm	O
or	O
exclude	O
a	O
neuroprotective	O
property	O
of	O
nimodipine	B-Chemical
.	O

Neonatal	O
pyridoxine	B-Chemical
responsive	O
convulsions	B-Disease
due	O
to	O
isoniazid	B-Chemical
therapy	O
.	O

A	O
17	O
-	O
day	O
-	O
old	O
infant	O
on	O
isoniazid	B-Chemical
therapy	O
13	O
mg	O
/	O
kg	O
daily	O
from	O
birth	O
because	O
of	O
maternal	O
tuberculosis	B-Disease
was	O
admitted	O
after	O
4	O
days	O
of	O
clonic	B-Disease
fits	I-Disease
.	O

The	O
fits	B-Disease
ceased	O
within	O
4	O
hours	O
of	O
administering	O
intramuscular	O
pyridoxine	B-Chemical
,	O
suggesting	O
an	O
aetiology	O
of	O
pyridoxine	B-Chemical
deficiency	O
secondary	O
to	O
isoniazid	B-Chemical
medication	O
.	O

Ketamine	B-Chemical
sedation	O
for	O
the	O
reduction	O
of	O
children	O
'	O
s	O
fractures	B-Disease
in	O
the	O
emergency	O
department	O
.	O

BACKGROUND	O
:	O
There	O
recently	O
has	O
been	O
a	O
resurgence	O
in	O
the	O
utilization	O
of	O
ketamine	B-Chemical
,	O
a	O
unique	O
anesthetic	O
,	O
for	O
emergency	O
-	O
department	O
procedures	O
requiring	O
sedation	O
.	O

The	O
purpose	O
of	O
the	O
present	O
study	O
was	O
to	O
examine	O
the	O
safety	O
and	O
efficacy	O
of	O
ketamine	B-Chemical
for	O
sedation	O
in	O
the	O
treatment	O
of	O
children	O
'	O
s	O
fractures	B-Disease
in	O
the	O
emergency	O
department	O
.	O

METHODS	O
:	O
One	O
hundred	O
and	O
fourteen	O
children	O
(	O
average	O
age	O
,	O
5	O
.	O
3	O
years	O
;	O
range	O
,	O
twelve	O
months	O
to	O
ten	O
years	O
and	O
ten	O
months	O
)	O
who	O
underwent	O
closed	O
reduction	O
of	O
an	O
isolated	O
fracture	B-Disease
or	O
dislocation	B-Disease
in	O
the	O
emergency	O
department	O
at	O
a	O
level	O
-	O
I	O
trauma	B-Disease
center	O
were	O
prospectively	O
evaluated	O
.	O

Ketamine	B-Chemical
hydrochloride	I-Chemical
was	O
administered	O
intravenously	O
(	O
at	O
a	O
dose	O
of	O
two	O
milligrams	O
per	O
kilogram	O
of	O
body	O
weight	O
)	O
in	O
ninety	O
-	O
nine	O
of	O
the	O
patients	O
and	O
intramuscularly	O
(	O
at	O
a	O
dose	O
of	O
four	O
milligrams	O
per	O
kilogram	O
of	O
body	O
weight	O
)	O
in	O
the	O
other	O
fifteen	O
.	O

Any	O
pain	B-Disease
during	O
the	O
reduction	O
was	O
rated	O
by	O
the	O
orthopaedic	O
surgeon	O
treating	O
the	O
patient	O
according	O
to	O
the	O
Children	O
'	O
s	O
Hospital	O
of	O
Eastern	O
Ontario	O
Pain	B-Disease
Scale	O
(	O
CHEOPS	O
)	O
.	O

RESULTS	O
:	O
The	O
average	O
time	O
from	O
intravenous	O
administration	O
of	O
ketamine	B-Chemical
to	O
manipulation	O
of	O
the	O
fracture	B-Disease
or	O
dislocation	B-Disease
was	O
one	O
minute	O
and	O
thirty	O
-	O
six	O
seconds	O
(	O
range	O
,	O
twenty	O
seconds	O
to	O
five	O
minutes	O
)	O
,	O
and	O
the	O
average	O
time	O
from	O
intramuscular	O
administration	O
to	O
manipulation	O
was	O
four	O
minutes	O
and	O
forty	O
-	O
two	O
seconds	O
(	O
range	O
,	O
sixty	O
seconds	O
to	O
fifteen	O
minutes	O
)	O
.	O

The	O
average	O
score	O
according	O
to	O
the	O
Children	O
'	O
s	O
Hospital	O
of	O
Eastern	O
Ontario	O
Pain	B-Disease
Scale	O
was	O
6	O
.	O
4	O
points	O
(	O
range	O
,	O
5	O
to	O
10	O
points	O
)	O
,	O
reflecting	O
minimal	O
or	O
no	O
pain	B-Disease
during	O
fracture	B-Disease
reduction	O
.	O

Adequate	O
fracture	B-Disease
reduction	O
was	O
obtained	O
in	O
111	O
of	O
the	O
children	O
.	O

Minor	O
side	O
effects	O
included	O
nausea	B-Disease
(	O
thirteen	O
patients	O
)	O
,	O
emesis	B-Disease
(	O
eight	O
of	O
the	O
thirteen	O
patients	O
with	O
nausea	B-Disease
)	O
,	O
clumsiness	B-Disease
(	O
evident	O
as	O
ataxic	B-Disease
movements	I-Disease
in	O
ten	O
patients	O
)	O
,	O
and	O
dysphoric	B-Disease
reaction	I-Disease
(	O
one	O
patient	O
)	O
.	O

No	O
long	O
-	O
term	O
sequelae	O
were	O
noted	O
,	O
and	O
no	O
patients	O
had	O
hallucinations	B-Disease
or	O
nightmares	O
.	O

CONCLUSIONS	O
:	O
Ketamine	B-Chemical
reliably	O
,	O
safely	O
,	O
and	O
quickly	O
provided	O
adequate	O
sedation	O
to	O
effectively	O
facilitate	O
the	O
reduction	O
of	O
children	O
'	O
s	O
fractures	B-Disease
in	O
the	O
emergency	O
department	O
at	O
our	O
institution	O
.	O

Ketamine	B-Chemical
should	O
only	O
be	O
used	O
in	O
an	O
environment	O
such	O
as	O
the	O
emergency	O
department	O
,	O
where	O
proper	O
one	O
-	O
on	O
-	O
one	O
monitoring	O
is	O
used	O
and	O
board	O
-	O
certified	O
physicians	O
skilled	O
in	O
airway	O
management	O
are	O
directly	O
involved	O
in	O
the	O
care	O
of	O
the	O
patient	O
.	O

Cyclosporine	B-Chemical
and	O
tacrolimus	B-Chemical
-	O
associated	O
thrombotic	B-Disease
microangiopathy	I-Disease
.	O

The	O
development	O
of	O
thrombotic	B-Disease
microangiopathy	I-Disease
(	O
TMA	B-Disease
)	O
associated	O
with	O
the	O
use	O
of	O
cyclosporine	B-Chemical
has	O
been	O
well	O
documented	O
.	O

Treatments	O
have	O
included	O
discontinuation	O
or	O
reduction	O
of	O
cyclosporine	B-Chemical
dose	O
with	O
or	O
without	O
concurrent	O
plasma	O
exchange	O
,	O
plasma	O
infusion	O
,	O
anticoagulation	O
,	O
and	O
intravenous	O
immunoglobulin	O
G	O
infusion	O
.	O

The	O
last	O
decade	O
has	O
seen	O
the	O
emergence	O
of	O
tacrolimus	B-Chemical
as	O
a	O
potent	O
immunosuppressive	O
agent	O
with	O
mechanisms	O
of	O
action	O
virtually	O
identical	O
to	O
those	O
of	O
cyclosporine	B-Chemical
.	O

As	O
a	O
result	O
,	O
switching	O
to	O
tacrolimus	B-Chemical
has	O
been	O
reported	O
to	O
be	O
a	O
viable	O
therapeutic	O
option	O
in	O
the	O
setting	O
of	O
cyclosporine	B-Chemical
-	O
induced	O
TMA	B-Disease
.	O

With	O
the	O
more	O
widespread	O
application	O
of	O
tacrolimus	B-Chemical
in	O
organ	O
transplantation	O
,	O
tacrolimus	B-Chemical
-	O
associated	O
TMA	B-Disease
has	O
also	O
been	O
recognized	O
.	O

However	O
,	O
literature	O
regarding	O
the	O
incidence	O
of	O
the	O
recurrence	O
of	O
TMA	B-Disease
in	O
patients	O
exposed	O
sequentially	O
to	O
cyclosporine	B-Chemical
and	O
tacrolimus	B-Chemical
is	O
limited	O
.	O

We	O
report	O
a	O
case	O
of	O
a	O
living	O
donor	O
renal	O
transplant	O
recipient	O
who	O
developed	O
cyclosporine	B-Chemical
-	O
induced	O
TMA	B-Disease
that	O
responded	O
to	O
the	O
withdrawal	O
of	O
cyclosporine	B-Chemical
in	O
conjunction	O
with	O
plasmapheresis	O
and	O
fresh	O
frozen	O
plasma	O
replacement	O
therapy	O
.	O

Introduction	O
of	O
tacrolimus	B-Chemical
as	O
an	O
alternative	O
immunosuppressive	O
agent	O
resulted	O
in	O
the	O
recurrence	O
of	O
TMA	B-Disease
and	O
the	O
subsequent	O
loss	O
of	O
the	O
renal	O
allograft	O
.	O

Patients	O
who	O
are	O
switched	O
from	O
cyclosporine	B-Chemical
to	O
tacrolimus	B-Chemical
or	O
vice	O
versa	O
should	O
be	O
closely	O
monitored	O
for	O
the	O
signs	O
and	O
symptoms	O
of	O
recurrent	O
TMA	B-Disease
.	O

Analgesic	O
effect	O
of	O
intravenous	O
ketamine	B-Chemical
in	O
cancer	B-Disease
patients	O
on	O
morphine	B-Chemical
therapy	O
:	O
a	O
randomized	O
,	O
controlled	O
,	O
double	O
-	O
blind	O
,	O
crossover	O
,	O
double	O
-	O
dose	O
study	O
.	O

Pain	B-Disease
not	O
responsive	O
to	O
morphine	B-Chemical
is	O
often	O
problematic	O
.	O

Animal	O
and	O
clinical	O
studies	O
have	O
suggested	O
that	O
N	B-Chemical
-	I-Chemical
methyl	I-Chemical
-	I-Chemical
D	I-Chemical
-	I-Chemical
aspartate	I-Chemical
(	O
NMDA	B-Chemical
)	O
antagonists	O
,	O
such	O
as	O
ketamine	B-Chemical
,	O
may	O
be	O
effective	O
in	O
improving	O
opioid	O
analgesia	O
in	O
difficult	O
pain	B-Disease
syndromes	O
,	O
such	O
as	O
neuropathic	B-Disease
pain	I-Disease
.	O

A	O
slow	O
bolus	O
of	O
subhypnotic	O
doses	O
of	O
ketamine	B-Chemical
(	O
0	O
.	O
25	O
mg	O
/	O
kg	O
or	O
0	O
.	O
50	O
mg	O
/	O
kg	O
)	O
was	O
given	O
to	O
10	O
cancer	B-Disease
patients	O
whose	O
pain	B-Disease
was	O
unrelieved	O
by	O
morphine	B-Chemical
in	O
a	O
randomized	O
,	O
double	O
-	O
blind	O
,	O
crossover	O
,	O
double	O
-	O
dose	O
study	O
.	O

Pain	B-Disease
intensity	O
on	O
a	O
0	O
to	O
10	O
numerical	O
scale	O
;	O
nausea	B-Disease
and	O
vomiting	B-Disease
,	O
drowsiness	O
,	O
confusion	B-Disease
,	O
and	O
dry	B-Disease
mouth	I-Disease
,	O
using	O
a	O
scale	O
from	O
0	O
to	O
3	O
(	O
not	O
at	O
all	O
,	O
slight	O
,	O
a	O
lot	O
,	O
awful	O
)	O
;	O
Mini	O
-	O
Mental	O
State	O
Examination	O
(	O
MMSE	O
)	O
(	O
0	O
-	O
30	O
)	O
;	O
and	O
arterial	O
pressure	O
were	O
recorded	O
before	O
administration	O
of	O
drugs	O
(	O
T0	O
)	O
and	O
after	O
30	O
minutes	O
(	O
T30	O
)	O
,	O
60	O
minutes	O
(	O
T60	O
)	O
,	O
120	O
minutes	O
(	O
T120	O
)	O
,	O
and	O
180	O
minutes	O
(	O
T180	O
)	O
.	O

Ketamine	B-Chemical
,	O
but	O
not	O
saline	O
solution	O
,	O
significantly	O
reduced	O
the	O
pain	B-Disease
intensity	O
in	O
almost	O
all	O
the	O
patients	O
at	O
both	O
doses	O
.	O

Hallucinations	B-Disease
occurred	O
in	O
4	O
patients	O
,	O
and	O
an	O
unpleasant	O
sensation	O
(	O
"	O
empty	O
head	O
"	O
)	O
was	O
also	O
reported	O
by	O
2	O
patients	O
.	O

These	O
episodes	O
reversed	O
after	O
the	O
administration	O
of	O
diazepam	B-Chemical
1	O
mg	O
intravenously	O
.	O

Significant	O
increases	O
in	O
drowsiness	O
were	O
reported	O
in	O
patients	O
treated	O
with	O
ketamine	B-Chemical
in	O
both	O
groups	O
and	O
were	O
more	O
marked	O
with	O
ketamine	B-Chemical
0	O
.	O
50	O
mg	O
/	O
kg	O
.	O

A	O
significant	O
difference	O
in	O
MMSE	O
was	O
observed	O
at	O
T30	O
in	O
patients	O
who	O
received	O
0	O
.	O
50	O
mg	O
/	O
kg	O
of	O
ketamine	B-Chemical
.	O

Ketamine	B-Chemical
can	O
improve	O
morphine	B-Chemical
analgesia	O
in	O
difficult	O
pain	B-Disease
syndromes	O
,	O
such	O
as	O
neuropathic	B-Disease
pain	I-Disease
.	O

This	O
observation	O
should	O
be	O
tested	O
in	O
studies	O
of	O
prolonged	O
ketamine	B-Chemical
administration	O
.	O

Paclitaxel	B-Chemical
,	O
cisplatin	B-Chemical
,	O
and	O
gemcitabine	B-Chemical
combination	O
chemotherapy	O
within	O
a	O
multidisciplinary	O
therapeutic	O
approach	O
in	O
metastatic	O
nonsmall	B-Disease
cell	I-Disease
lung	I-Disease
carcinoma	I-Disease
.	O

BACKGROUND	O
:	O
Cisplatin	B-Chemical
-	O
based	O
chemotherapy	O
combinations	O
improve	O
quality	O
of	O
life	O
and	O
survival	O
in	O
advanced	O
nonsmall	B-Disease
cell	I-Disease
lung	I-Disease
carcinoma	I-Disease
(	O
NSCLC	B-Disease
)	O
.	O

METHODS	O
:	O
The	O
objective	O
of	O
this	O
study	O
was	O
to	O
determine	O
the	O
feasibility	O
,	O
response	O
rate	O
,	O
and	O
toxicity	B-Disease
of	O
a	O
paclitaxel	B-Chemical
,	O
cisplatin	B-Chemical
,	O
and	O
gemcitabine	B-Chemical
combination	O
to	O
treat	O
metastatic	O
NSCLC	B-Disease
.	O

Thirty	O
-	O
five	O
consecutive	O
chemotherapy	O
-	O
naive	O
patients	O
with	O
Stage	O
IV	O
NSCLC	B-Disease
and	O
an	O
Eastern	O
Cooperative	O
Oncology	O
Group	O
performance	O
status	O
of	O
0	O
-	O
2	O
were	O
treated	O
with	O
a	O
combination	O
of	O
paclitaxel	B-Chemical
(	O
135	O
mg	O
/	O
m	O
(	O
2	O
)	O
given	O
intravenously	O
in	O
3	O
hours	O
)	O
on	O
Day	O
1	O
,	O
cisplatin	B-Chemical
(	O
120	O
mg	O
/	O
m	O
(	O
2	O
)	O
given	O
intravenously	O
in	O
6	O
hours	O
)	O
on	O
Day	O
1	O
,	O
and	O
gemcitabine	B-Chemical
(	O
800	O
mg	O
/	O
m	O
(	O
2	O
)	O
given	O
intravenously	O
in	O
30	O
minutes	O
)	O
on	O
Days	O
1	O
and	O
8	O
,	O
every	O
4	O
weeks	O
.	O

Although	O
responding	O
patients	O
were	O
scheduled	O
to	O
receive	O
consolidation	O
radiotherapy	O
and	O
24	O
patients	O
received	O
preplanned	O
second	O
-	O
line	O
chemotherapy	O
after	O
disease	O
progression	O
,	O
the	O
response	O
and	O
toxicity	B-Disease
rates	O
reported	O
refer	O
only	O
to	O
the	O
chemotherapy	O
regimen	O
given	O
.	O

RESULTS	O
:	O
All	O
the	O
patients	O
were	O
examined	O
for	O
toxicity	B-Disease
;	O
34	O
were	O
examinable	O
for	O
response	O
.	O

After	O
154	O
courses	O
of	O
therapy	O
,	O
the	O
median	O
dose	O
intensity	O
was	O
131	O
mg	O
/	O
m	O
(	O
2	O
)	O
for	O
paclitaxel	B-Chemical
(	O
97	O
.	O
3	O
%	O
)	O
,	O
117	O
mg	O
/	O
m	O
(	O
2	O
)	O
for	O
cisplatin	B-Chemical
(	O
97	O
.	O
3	O
%	O
)	O
,	O
and	O
1378	O
mg	O
/	O
m	O
(	O
2	O
)	O
for	O
gemcitabine	B-Chemical
(	O
86	O
.	O
2	O
%	O
)	O
.	O

World	O
Health	O
Organization	O
Grade	O
3	O
-	O
4	O
neutropenia	B-Disease
and	O
thrombocytopenia	B-Disease
occurred	O
in	O
39	O
.	O
9	O
%	O
and	O
11	O
.	O
4	O
%	O
of	O
patients	O
,	O
respectively	O
.	O

There	O
was	O
one	O
treatment	O
-	O
related	O
death	B-Disease
.	O

Nonhematologic	O
toxicities	B-Disease
were	O
mild	O
.	O

CONCLUSIONS	O
:	O
The	O
combination	O
of	O
paclitaxel	B-Chemical
,	O
cisplatin	B-Chemical
,	O
and	O
gemcitabine	B-Chemical
is	O
well	O
tolerated	O
and	O
shows	O
high	O
activity	O
in	O
metastatic	O
NSCLC	B-Disease
.	O

This	O
treatment	O
merits	O
further	O
comparison	O
with	O
other	O
cisplatin	B-Chemical
-	O
based	O
regimens	O
.	O

Serotonergic	O
antidepressants	O
and	O
urinary	B-Disease
incontinence	I-Disease
.	O

Many	O
new	O
serotonergic	B-Chemical
antidepressants	I-Chemical
have	O
been	O
introduced	O
over	O
the	O
past	O
decade	O
.	O

Although	O
urinary	B-Disease
incontinence	I-Disease
is	O
listed	O
as	O
one	O
side	O
effect	O
of	O
these	O
drugs	O
in	O
their	O
package	O
inserts	O
there	O
is	O
only	O
one	O
report	O
in	O
the	O
literature	O
.	O

This	O
concerns	O
2	O
male	O
patients	O
who	O
experienced	O
incontinence	B-Disease
while	O
taking	O
venlafaxine	B-Chemical
.	O

In	O
the	O
present	O
paper	O
the	O
authors	O
describe	O
2	O
female	O
patients	O
who	O
developed	O
incontinence	B-Disease
secondary	O
to	O
the	O
selective	O
serotonin	B-Chemical
reuptake	O
inhibitors	O
paroxetine	B-Chemical
and	O
sertraline	B-Chemical
,	O
as	O
well	O
as	O
a	O
third	O
who	O
developed	O
this	O
side	O
effect	O
on	O
venlafaxine	B-Chemical
.	O

In	O
2	O
of	O
the	O
3	O
cases	O
the	O
patients	O
were	O
also	O
taking	O
lithium	B-Chemical
carbonate	I-Chemical
and	O
beta	O
-	O
blockers	O
,	O
both	O
of	O
which	O
could	O
have	O
contributed	O
to	O
the	O
incontinence	B-Disease
.	O

Animal	O
studies	O
suggest	O
that	O
incontinence	O
secondary	O
to	O
serotonergic	B-Chemical
antidepressants	I-Chemical
could	O
be	O
mediated	O
by	O
the	O
5HT4	O
receptors	O
found	O
on	O
the	O
bladder	O
.	O

Acute	O
cocaine	B-Chemical
-	O
induced	O
seizures	B-Disease
:	O
differential	O
sensitivity	O
of	O
six	O
inbred	O
mouse	O
strains	O
.	O

Mature	O
male	O
and	O
female	O
mice	O
from	O
six	O
inbred	O
stains	O
were	O
tested	O
for	O
susceptibility	O
to	O
behavioral	O
seizures	B-Disease
induced	O
by	O
a	O
single	O
injection	O
of	O
cocaine	B-Chemical
.	O

Cocaine	B-Chemical
was	O
injected	O
ip	O
over	O
a	O
range	O
of	O
doses	O
(	O
50	O
-	O
100	O
mg	O
/	O
kg	O
)	O
and	O
behavior	O
was	O
monitored	O
for	O
20	O
minutes	O
.	O

Seizure	O
end	O
points	O
included	O
latency	O
to	O
forelimb	O
or	O
hindlimb	O
clonus	O
,	O
latency	O
to	O
clonic	O
running	O
seizure	B-Disease
and	O
latency	O
to	O
jumping	O
bouncing	O
seizure	B-Disease
.	O

Additionally	O
,	O
levels	O
of	O
cocaine	B-Chemical
determined	O
in	O
hippocampus	O
and	O
cortex	O
were	O
not	O
different	O
between	O
sensitive	O
and	O
resistant	O
strains	O
.	O

Additional	O
studies	O
of	O
these	O
murine	O
strains	O
may	O
be	O
useful	O
for	O
investigating	O
genetic	O
influences	O
on	O
cocaine	B-Chemical
-	O
induced	O
seizures	B-Disease
.	O

Hypotension	B-Disease
following	O
the	O
initiation	O
of	O
tizanidine	B-Chemical
in	O
a	O
patient	O
treated	O
with	O
an	O
angiotensin	B-Chemical
converting	O
enzyme	O
inhibitor	O
for	O
chronic	O
hypertension	B-Disease
.	O

Centrally	O
acting	O
alpha	O
-	O
2	O
adrenergic	O
agonists	O
are	O
one	O
of	O
several	O
pharmacologic	O
agents	O
used	O
in	O
the	O
treatment	O
of	O
spasticity	B-Disease
related	O
to	O
disorders	B-Disease
of	I-Disease
the	I-Disease
central	I-Disease
nervous	I-Disease
system	I-Disease
.	O

In	O
addition	O
to	O
their	O
effects	O
on	O
spasticity	B-Disease
,	O
certain	O
adverse	O
cardiorespiratory	O
effects	O
have	O
been	O
reported	O
.	O

Adults	O
chronically	O
treated	O
with	O
angiotensin	B-Chemical
converting	O
enzyme	O
inhibitors	O
may	O
have	O
a	O
limited	O
ability	O
to	O
respond	O
to	O
hypotension	B-Disease
when	O
the	O
sympathetic	O
response	O
is	O
simultaneously	O
blocked	O
.	O

The	O
authors	O
present	O
a	O
10	O
-	O
year	O
-	O
old	O
boy	O
chronically	O
treated	O
with	O
lisinopril	B-Chemical
,	O
an	O
angiotensin	B-Chemical
converting	O
enzyme	O
inhibitor	O
,	O
to	O
control	O
hypertension	B-Disease
who	O
developed	O
hypotension	B-Disease
following	O
the	O
addition	O
of	O
tizanidine	B-Chemical
,	O
an	O
alpha	O
-	O
2	O
agonist	O
,	O
for	O
the	O
treatment	O
of	O
spasticity	B-Disease
.	O

The	O
possible	O
interaction	O
of	O
tizanidine	B-Chemical
and	O
other	O
antihypertensive	O
agents	O
should	O
be	O
kept	O
in	O
mind	O
when	O
prescribing	O
therapy	O
to	O
treat	O
either	O
hypertension	B-Disease
or	O
spasticity	B-Disease
in	O
such	O
patients	O
.	O

Two	O
mouse	O
lines	O
selected	O
for	O
differential	O
sensitivities	O
to	O
beta	B-Chemical
-	I-Chemical
carboline	I-Chemical
-	O
induced	O
seizures	B-Disease
are	O
also	O
differentially	O
sensitive	O
to	O
various	O
pharmacological	O
effects	O
of	O
other	O
GABA	B-Chemical
(	O
A	O
)	O
receptor	O
ligands	O
.	O

Two	O
mouse	O
lines	O
were	O
selectively	O
bred	O
according	O
to	O
their	O
sensitivity	O
(	O
BS	O
line	O
)	O
or	O
resistance	O
(	O
BR	O
line	O
)	O
to	O
seizures	B-Disease
induced	O
by	O
a	O
single	O
i	O
.	O
p	O
.	O
injection	O
of	O
methyl	B-Chemical
beta	I-Chemical
-	I-Chemical
carboline	I-Chemical
-	I-Chemical
3	I-Chemical
-	I-Chemical
carboxylate	I-Chemical
(	O
beta	B-Chemical
-	I-Chemical
CCM	I-Chemical
)	O
,	O
an	O
inverse	O
agonist	O
of	O
the	O
GABA	B-Chemical
(	O
A	O
)	O
receptor	O
benzodiazepine	B-Chemical
site	O
.	O

Our	O
aim	O
was	O
to	O
characterize	O
both	O
lines	O
'	O
sensitivities	O
to	O
various	O
physiological	O
effects	O
of	O
other	O
ligands	O
of	O
the	O
GABA	B-Chemical
(	O
A	O
)	O
receptor	O
.	O

We	O
measured	O
diazepam	B-Chemical
-	O
induced	O
anxiolysis	O
with	O
the	O
elevated	O
plus	O
-	O
maze	O
test	O
,	O
diazepam	B-Chemical
-	O
induced	O
sedation	O
by	O
recording	O
the	O
vigilance	O
states	O
,	O
and	O
picrotoxin	B-Chemical
-	O
and	O
pentylenetetrazol	B-Chemical
-	O
induced	O
seizures	B-Disease
after	O
i	O
.	O
p	O
.	O
injections	O
.	O

Results	O
presented	O
here	O
show	O
that	O
the	O
differential	O
sensitivities	O
of	O
BS	O
and	O
BR	O
lines	O
to	O
beta	B-Chemical
-	I-Chemical
CCM	I-Chemical
can	O
be	O
extended	O
to	O
diazepam	B-Chemical
,	O
picrotoxin	B-Chemical
,	O
and	O
pentylenetetrazol	B-Chemical
,	O
suggesting	O
a	O
genetic	O
selection	O
of	O
a	O
general	O
sensitivity	O
and	O
resistance	O
to	O
several	O
ligands	O
of	O
the	O
GABA	B-Chemical
(	O
A	O
)	O
receptor	O
.	O

Propylthiouracil	B-Chemical
-	O
induced	O
perinuclear	O
-	O
staining	O
antineutrophil	O
cytoplasmic	O
autoantibody	O
-	O
positive	O
vasculitis	B-Disease
in	O
conjunction	O
with	O
pericarditis	B-Disease
.	O

OBJECTIVE	O
:	O
To	O
describe	O
a	O
case	O
of	O
propylthiouracil	B-Chemical
-	O
induced	O
vasculitis	B-Disease
manifesting	O
with	O
pericarditis	B-Disease
.	O

METHODS	O
:	O
We	O
present	O
the	O
first	O
case	O
report	O
of	O
a	O
woman	O
with	O
hyperthyroidism	B-Disease
treated	O
with	O
propylthiouracil	B-Chemical
in	O
whom	O
a	O
syndrome	O
of	O
pericarditis	B-Disease
,	O
fever	B-Disease
,	O
and	O
glomerulonephritis	B-Disease
developed	O
.	O

RESULTS	O
:	O
A	O
25	O
-	O
year	O
-	O
old	O
woman	O
with	O
Graves	B-Disease
'	I-Disease
disease	I-Disease
had	O
a	O
febrile	B-Disease
illness	I-Disease
and	O
evidence	O
of	O
pericarditis	B-Disease
,	O
which	O
was	O
confirmed	O
by	O
biopsy	O
.	O

Propylthiouracil	B-Chemical
therapy	O
was	O
withdrawn	O
,	O
and	O
she	O
was	O
treated	O
with	O
a	O
1	O
-	O
month	O
course	O
of	O
prednisone	B-Chemical
,	O
which	O
alleviated	O
her	O
symptoms	O
.	O

A	O
literature	O
review	O
revealed	O
no	O
prior	O
reports	O
of	O
pericarditis	B-Disease
in	O
anti	O
-	O
MPO	O
pANCA	O
-	O
positive	O
vasculitis	B-Disease
associated	O
with	O
propylthio	B-Chemical
-	I-Chemical
uracil	I-Chemical
therapy	O
.	O

CONCLUSION	O
:	O
Pericarditis	B-Disease
may	O
be	O
the	O
initial	O
manifestation	O
of	O
drug	O
-	O
induced	O
vasculitis	B-Disease
attributable	O
to	O
propylthio	B-Chemical
-	I-Chemical
uracil	I-Chemical
therapy	O
.	O

Repeated	O
transient	O
anuria	B-Disease
following	O
losartan	B-Chemical
administration	O
in	O
a	O
patient	O
with	O
a	O
solitary	O
kidney	O
.	O

We	O
report	O
the	O
case	O
of	O
a	O
70	O
-	O
year	O
-	O
old	O
hypertensive	O
man	O
with	O
a	O
solitary	O
kidney	O
and	O
chronic	B-Disease
renal	I-Disease
insufficiency	I-Disease
who	O
developed	O
two	O
episodes	O
of	O
transient	O
anuria	B-Disease
after	O
losartan	B-Chemical
administration	O
.	O

He	O
was	O
hospitalized	O
for	O
a	O
myocardial	B-Disease
infarction	I-Disease
with	O
pulmonary	B-Disease
edema	I-Disease
,	O
treated	O
with	O
high	O
-	O
dose	O
diuretics	O
.	O

Due	O
to	O
severe	O
systolic	B-Disease
dysfunction	I-Disease
losartan	B-Chemical
was	O
prescribed	O
.	O

Surprisingly	O
,	O
the	O
first	O
dose	O
of	O
50	O
mg	O
of	O
losartan	B-Chemical
resulted	O
in	O
a	O
sudden	O
anuria	B-Disease
,	O
which	O
lasted	O
eight	O
hours	O
despite	O
high	O
-	O
dose	O
furosemide	B-Chemical
and	O
amine	B-Chemical
infusion	O
.	O

One	O
week	O
later	O
,	O
by	O
mistake	O
,	O
losartan	B-Chemical
was	O
prescribed	O
again	O
and	O
after	O
the	O
second	O
dose	O
of	O
50	O
mg	O
,	O
the	O
patient	O
developed	O
a	O
second	O
episode	O
of	O
transient	O
anuria	B-Disease
lasting	O
10	O
hours	O
.	O

During	O
these	O
two	O
episodes	O
,	O
his	O
blood	O
pressure	O
diminished	O
but	O
no	O
severe	O
hypotension	B-Disease
was	O
noted	O
.	O

Ultimately	O
,	O
an	O
arteriography	O
showed	O
a	O
70	O
-	O
80	O
%	O
renal	B-Disease
artery	I-Disease
stenosis	I-Disease
.	O

In	O
this	O
patient	O
,	O
renal	B-Disease
artery	I-Disease
stenosis	I-Disease
combined	O
with	O
heart	B-Disease
failure	I-Disease
and	O
diuretic	O
therapy	O
certainly	O
resulted	O
in	O
a	O
strong	O
activation	O
of	O
the	O
renin	O
-	O
angiotensin	B-Chemical
system	O
(	O
RAS	O
)	O
.	O

Under	O
such	O
conditions	O
,	O
angiotensin	B-Chemical
II	I-Chemical
receptor	O
blockade	O
by	O
losartan	B-Chemical
probably	O
induced	O
a	O
critical	O
fall	O
in	O
glomerular	O
filtration	O
pressure	O
.	O

This	O
case	O
report	O
highlights	O
the	O
fact	O
that	O
the	O
angiotensin	B-Chemical
II	I-Chemical
receptor	O
antagonist	O
losartan	B-Chemical
can	O
cause	O
serious	O
unexpected	O
complications	O
in	O
patients	O
with	O
renovascular	B-Disease
disease	I-Disease
and	O
should	O
be	O
used	O
with	O
extreme	O
caution	O
in	O
this	O
setting	O
.	O

Calcineurin	O
-	O
inhibitor	O
induced	O
pain	B-Disease
syndrome	O
(	O
CIPS	B-Disease
)	O
:	O
a	O
severe	O
disabling	O
complication	O
after	O
organ	O
transplantation	O
.	O

Bone	O
pain	B-Disease
after	O
transplantation	O
is	O
a	O
frequent	O
complication	O
that	O
can	O
be	O
caused	O
by	O
several	O
diseases	O
.	O

Treatment	O
strategies	O
depend	O
on	O
the	O
correct	O
diagnosis	O
of	O
the	O
pain	B-Disease
.	O

Nine	O
patients	O
with	O
severe	O
pain	B-Disease
in	O
their	O
feet	O
,	O
which	O
was	O
registered	O
after	O
transplantation	O
,	O
were	O
investigated	O
.	O

Magnetic	O
resonance	O
imaging	O
demonstrated	O
bone	B-Disease
marrow	I-Disease
oedema	I-Disease
in	O
the	O
painful	O
bones	O
.	O

Pain	B-Disease
was	O
not	O
explained	O
by	O
other	O
diseases	O
causing	O
foot	O
pain	B-Disease
,	O
like	O
reflex	B-Disease
sympathetic	I-Disease
dystrophy	I-Disease
,	O
polyneuropathy	B-Disease
,	O
Morton	B-Disease
'	I-Disease
s	I-Disease
neuralgia	I-Disease
,	O
gout	B-Disease
,	O
osteoporosis	B-Disease
,	O
avascular	B-Disease
necrosis	I-Disease
,	O
intermittent	B-Disease
claudication	I-Disease
,	O
orthopaedic	O
foot	B-Disease
deformities	I-Disease
,	O
stress	B-Disease
fractures	I-Disease
,	O
and	O
hyperparathyroidism	B-Disease
.	O

The	O
reduction	O
of	O
cyclosporine	B-Chemical
-	O
or	O
tacrolimus	B-Chemical
trough	O
levels	O
and	O
the	O
administration	O
of	O
calcium	B-Chemical
channel	O
blockers	O
led	O
to	O
relief	O
of	O
pain	B-Disease
.	O

The	O
Calcineurin	O
-	O
inhibitor	O
Induced	O
Pain	B-Disease
Syndrome	O
(	O
CIPS	B-Disease
)	O
is	O
a	O
rare	O
but	O
severe	O
side	O
effect	O
of	O
cyclosporine	B-Chemical
or	O
tacrolimus	B-Chemical
and	O
is	O
accurately	O
diagnosed	O
by	O
its	O
typical	O
presentation	O
,	O
magnetic	O
resonance	O
imaging	O
and	O
bone	O
scans	O
.	O

Incorrect	O
diagnosis	O
of	O
the	O
syndrome	O
will	O
lead	O
to	O
a	O
significant	O
reduction	O
of	O
life	O
quality	O
in	O
patients	O
suffering	O
from	O
CIPS	B-Disease
.	O

Brain	O
natriuretic	O
peptide	O
is	O
a	O
predictor	O
of	O
anthracycline	B-Chemical
-	O
induced	O
cardiotoxicity	B-Disease
.	O

Anthracyclines	B-Chemical
are	O
effective	O
antineoplastic	O
drugs	O
,	O
but	O
they	O
frequently	O
cause	O
dose	O
-	O
related	O
cardiotoxicity	B-Disease
.	O

The	O
cardiotoxicity	B-Disease
of	O
conventional	O
anthracycline	B-Chemical
therapy	O
highlights	O
a	O
need	O
to	O
search	O
for	O
methods	O
that	O
are	O
highly	O
sensitive	O
and	O
capable	O
of	O
predicting	O
cardiac	B-Disease
dysfunction	I-Disease
.	O

We	O
measured	O
the	O
plasma	O
level	O
of	O
brain	O
natriuretic	O
peptide	O
(	O
BNP	O
)	O
to	O
determine	O
whether	O
BNP	O
might	O
serve	O
as	O
a	O
simple	O
diagnostic	O
indicator	O
of	O
anthracycline	B-Chemical
-	O
induced	O
cardiotoxicity	B-Disease
in	O
patients	O
with	O
acute	B-Disease
leukemia	I-Disease
treated	O
with	O
a	O
daunorubicin	B-Chemical
(	O
DNR	B-Chemical
)	O
-	O
containing	O
regimen	O
.	O

Thirteen	O
patients	O
with	O
acute	B-Disease
leukemia	I-Disease
were	O
treated	O
with	O
a	O
DNR	B-Chemical
-	O
containing	O
regimen	O
.	O

Three	O
patients	O
developed	O
congestive	B-Disease
heart	I-Disease
failure	I-Disease
after	O
the	O
completion	O
of	O
chemotherapy	O
.	O

Five	O
patients	O
were	O
diagnosed	O
as	O
having	O
subclinical	O
heart	B-Disease
failure	I-Disease
after	O
the	O
completion	O
of	O
chemotherapy	O
.	O

The	O
plasma	O
levels	O
of	O
BNP	O
in	O
all	O
the	O
patients	O
with	O
clinical	O
and	O
subclinical	O
heart	B-Disease
failure	I-Disease
increased	O
above	O
the	O
normal	O
limit	O
(	O
40	O
pg	O
/	O
ml	O
)	O
before	O
the	O
detection	O
of	O
clinical	O
or	O
subclinical	O
heart	B-Disease
failure	I-Disease
by	O
radionuclide	O
angiography	O
.	O

On	O
the	O
other	O
hand	O
,	O
BNP	O
did	O
not	O
increase	O
in	O
the	O
patients	O
without	O
heart	B-Disease
failure	I-Disease
given	O
DNR	B-Chemical
,	O
even	O
at	O
more	O
than	O
700	O
mg	O
/	O
m	O
(	O
2	O
)	O
.	O

The	O
plasma	O
level	O
of	O
ANP	O
did	O
not	O
always	O
increase	O
in	O
all	O
the	O
patients	O
with	O
clinical	O
and	O
subclinical	O
heart	B-Disease
failure	I-Disease
.	O

These	O
preliminary	O
results	O
suggest	O
that	O
BNP	O
may	O
be	O
useful	O
as	O
an	O
early	O
and	O
sensitive	O
indicator	O
of	O
anthracycline	B-Chemical
-	O
induced	O
cardiotoxicity	B-Disease
.	O

Nephrotoxicity	B-Disease
of	O
combined	O
cephalothin	B-Chemical
-	O
gentamicin	B-Chemical
regimen	O
.	O

Two	O
patients	O
developed	O
acute	B-Disease
tubular	I-Disease
necrosis	I-Disease
,	O
characterized	O
clinically	O
by	O
acute	O
oliguric	B-Disease
renal	I-Disease
failure	I-Disease
,	O
while	O
they	O
were	O
receiving	O
a	O
combination	O
of	O
cephalothin	B-Chemical
sodium	I-Chemical
and	O
gentamicin	B-Chemical
sulfate	I-Chemical
therapy	O
.	O

Patients	O
who	O
are	O
given	O
this	O
drug	O
regimen	O
should	O
be	O
observed	O
very	O
carefully	O
for	O
early	O
signs	O
of	O
nephrotoxicity	B-Disease
.	O

Patients	O
with	O
renal	B-Disease
insufficiency	I-Disease
should	O
not	O
be	O
given	O
this	O
regimen	O
.	O

In	O
vivo	O
protection	O
of	O
dna	O
damage	O
associated	O
apoptotic	O
and	O
necrotic	B-Disease
cell	O
deaths	O
during	O
acetaminophen	B-Chemical
-	O
induced	O
nephrotoxicity	B-Disease
,	O
amiodarone	B-Chemical
-	O
induced	O
lung	B-Disease
toxicity	I-Disease
and	O
doxorubicin	B-Chemical
-	O
induced	O
cardiotoxicity	B-Disease
by	O
a	O
novel	O
IH636	B-Chemical
grape	I-Chemical
seed	I-Chemical
proanthocyanidin	I-Chemical
extract	I-Chemical
.	O

Grape	B-Chemical
seed	I-Chemical
extract	I-Chemical
,	O
primarily	O
a	O
mixture	O
of	O
proanthocyanidins	B-Chemical
,	O
has	O
been	O
shown	O
to	O
modulate	O
a	O
wide	O
-	O
range	O
of	O
biological	O
,	O
pharmacological	O
and	O
toxicological	O
effects	O
which	O
are	O
mainly	O
cytoprotective	O
.	O

This	O
study	O
assessed	O
the	O
ability	O
of	O
IH636	B-Chemical
grape	I-Chemical
seed	I-Chemical
proanthocyanidin	I-Chemical
extract	I-Chemical
(	O
GSPE	B-Chemical
)	O
to	O
prevent	O
acetaminophen	B-Chemical
(	O
AAP	B-Chemical
)	O
-	O
induced	O
nephrotoxicity	B-Disease
,	O
amiodarone	B-Chemical
(	O
AMI	B-Chemical
)	O
-	O
induced	O
lung	B-Disease
toxicity	I-Disease
,	O
and	O
doxorubicin	B-Chemical
(	O
DOX	B-Chemical
)	O
-	O
induced	O
cardiotoxicity	B-Disease
in	O
mice	O
.	O

Experimental	O
design	O
consisted	O
of	O
four	O
groups	O
:	O
control	O
(	O
vehicle	O
alone	O
)	O
,	O
GSPE	B-Chemical
alone	O
,	O
drug	O
alone	O
and	O
GSPE	B-Chemical
+	O
drug	O
.	O

For	O
the	O
cytoprotection	O
study	O
,	O
animals	O
were	O
orally	O
gavaged	O
100	O
mg	O
/	O
Kg	O
GSPE	B-Chemical
for	O
7	O
-	O
10	O
days	O
followed	O
by	O
i	O
.	O
p	O
.	O
injections	O
of	O
organ	O
specific	O
three	O
drugs	O
(	O
AAP	B-Chemical
:	O
500	O
mg	O
/	O
Kg	O
for	O
24	O
h	O
;	O
AMI	B-Chemical
:	O
50	O
mg	O
/	O
Kg	O
/	O
day	O
for	O
four	O
days	O
;	O
DOX	B-Chemical
:	O
20	O
mg	O
/	O
Kg	O
for	O
48	O
h	O
)	O
.	O

Results	O
indicate	O
that	O
GSPE	B-Chemical
preexposure	O
prior	O
to	O
AAP	B-Chemical
,	O
AMI	B-Chemical
and	O
DOX	B-Chemical
,	O
provided	O
near	O
complete	O
protection	O
in	O
terms	O
of	O
serum	O
chemistry	O
changes	O
(	O
ALT	O
,	O
BUN	O
and	O
CPK	O
)	O
,	O
and	O
significantly	O
reduced	O
DNA	O
fragmentation	O
.	O

Histopathological	O
examination	O
of	O
kidney	O
,	O
heart	O
and	O
lung	O
sections	O
revealed	O
moderate	O
to	O
massive	O
tissue	O
damage	O
with	O
a	O
variety	O
of	O
morphological	O
aberrations	O
by	O
all	O
the	O
three	O
drugs	O
in	O
the	O
absence	O
of	O
GSPE	B-Chemical
preexposure	O
than	O
in	O
its	O
presence	O
.	O

GSPE	B-Chemical
+	O
drug	O
exposed	O
tissues	O
exhibited	O
minor	O
residual	O
damage	O
or	O
near	O
total	O
recovery	O
.	O

Interestingly	O
,	O
all	O
the	O
drugs	O
,	O
such	O
as	O
,	O
AAP	B-Chemical
,	O
AMI	B-Chemical
and	O
DOX	B-Chemical
induced	O
apoptotic	O
death	O
in	O
addition	O
to	O
necrosis	B-Disease
in	O
the	O
respective	O
organs	O
which	O
was	O
very	O
effectively	O
blocked	O
by	O
GSPE	B-Chemical
.	O

Since	O
AAP	B-Chemical
,	O
AMI	B-Chemical
and	O
DOX	B-Chemical
undergo	O
biotransformation	O
and	O
are	O
known	O
to	O
produce	O
damaging	O
radicals	O
in	O
vivo	O
,	O
the	O
protection	O
by	O
GSPE	B-Chemical
may	O
be	O
linked	O
to	O
both	O
inhibition	O
of	O
metabolism	O
and	O
/	O
or	O
detoxification	O
of	O
cytotoxic	O
radicals	O
.	O

Additionally	O
,	O
this	O
may	O
have	O
been	O
the	O
first	O
report	O
on	O
AMI	B-Chemical
-	O
induced	O
apoptotic	O
death	O
in	O
the	O
lung	O
tissue	O
.	O

Taken	O
together	O
,	O
these	O
events	O
undoubtedly	O
establish	O
GSPE	B-Chemical
'	O
s	O
abundant	O
bioavailability	O
,	O
and	O
the	O
power	O
to	O
defend	O
multiple	O
target	O
organs	O
from	O
toxic	O
assaults	O
induced	O
by	O
structurally	O
diverse	O
and	O
functionally	O
different	O
entities	O
in	O
vivo	O
.	O

Antidepressant	B-Chemical
-	O
induced	O
mania	B-Disease
in	O
bipolar	B-Disease
patients	O
:	O
identification	O
of	O
risk	O
factors	O
.	O

BACKGROUND	O
:	O
Concerns	O
about	O
possible	O
risks	O
of	O
switching	O
to	O
mania	B-Disease
associated	O
with	O
antidepressants	B-Chemical
continue	O
to	O
interfere	O
with	O
the	O
establishment	O
of	O
an	O
optimal	O
treatment	O
paradigm	O
for	O
bipolar	B-Disease
depression	I-Disease
.	O

METHOD	O
:	O
The	O
response	O
of	O
44	O
patients	O
meeting	O
DSM	O
-	O
IV	O
criteria	O
for	O
bipolar	B-Disease
disorder	I-Disease
to	O
naturalistic	O
treatment	O
was	O
assessed	O
for	O
at	O
least	O
6	O
weeks	O
using	O
the	O
Montgomery	O
-	O
Asberg	O
Depression	O
Rating	O
Scale	O
and	O
the	O
Bech	O
-	O
Rafaelson	O
Mania	O
Rating	O
Scale	O
.	O

Patients	O
who	O
experienced	O
a	O
manic	B-Disease
or	O
hypomanic	B-Disease
switch	O
were	O
compared	O
with	O
those	O
who	O
did	O
not	O
on	O
several	O
variables	O
including	O
age	O
,	O
sex	O
,	O
diagnosis	O
(	O
DSM	B-Disease
-	I-Disease
IV	I-Disease
bipolar	I-Disease
I	I-Disease
vs	O
.	O
bipolar	B-Disease
II	I-Disease
)	O
,	O
number	O
of	O
previous	O
manic	B-Disease
episodes	O
,	O
type	O
of	O
antidepressant	B-Chemical
therapy	O
used	O
(	O
electroconvulsive	O
therapy	O
vs	O
.	O
antidepressant	B-Chemical
drugs	O
and	O
,	O
more	O
particularly	O
,	O
selective	O
serotonin	O
reuptake	O
inhibitors	O
[	O
SSRIs	B-Chemical
]	O
)	O
,	O
use	O
and	O
type	O
of	O
mood	O
stabilizers	O
(	O
lithium	B-Chemical
vs	O
.	O
anticonvulsants	O
)	O
,	O
and	O
temperament	O
of	O
the	O
patient	O
,	O
assessed	O
during	O
a	O
normothymic	O
period	O
using	O
the	O
hyperthymia	O
component	O
of	O
the	O
Semi	O
-	O
structured	O
Affective	O
Temperament	O
Interview	O
.	O

RESULTS	O
:	O
Switches	O
to	O
hypomania	B-Disease
or	O
mania	B-Disease
occurred	O
in	O
27	O
%	O
of	O
all	O
patients	O
(	O
N	O
=	O
12	O
)	O
(	O
and	O
in	O
24	O
%	O
of	O
the	O
subgroup	O
of	O
patients	O
treated	O
with	O
SSRIs	B-Chemical
[	O
8	O
/	O
33	O
]	O
)	O
;	O
16	O
%	O
(	O
N	O
=	O
7	O
)	O
experienced	O
manic	B-Disease
episodes	O
,	O
and	O
11	O
%	O
(	O
N	O
=	O
5	O
)	O
experienced	O
hypomanic	B-Disease
episodes	O
.	O

Sex	O
,	O
age	O
,	O
diagnosis	O
(	O
bipolar	B-Disease
I	I-Disease
vs	O
.	O
bipolar	B-Disease
II	I-Disease
)	O
,	O
and	O
additional	O
treatment	O
did	O
not	O
affect	O
the	O
risk	O
of	O
switching	O
.	O

In	O
contrast	O
,	O
mood	O
switches	O
were	O
less	O
frequent	O
in	O
patients	O
receiving	O
lithium	B-Chemical
(	O
15	O
%	O
,	O
4	O
/	O
26	O
)	O
than	O
in	O
patients	O
not	O
treated	O
with	O
lithium	B-Chemical
(	O
44	O
%	O
,	O
8	O
/	O
18	O
;	O
p	O
=	O
.	O
04	O
)	O
.	O

The	O
number	O
of	O
previous	O
manic	B-Disease
episodes	O
did	O
not	O
affect	O
the	O
probability	O
of	O
switching	O
,	O
whereas	O
a	O
high	O
score	O
on	O
the	O
hyperthymia	O
component	O
of	O
the	O
Semistructured	O
Affective	O
Temperament	O
Interview	O
was	O
associated	O
with	O
a	O
greater	O
risk	O
of	O
switching	O
(	O
p	O
=	O
.	O
008	O
)	O
.	O

CONCLUSION	O
:	O
The	O
frequency	O
of	O
mood	O
switching	O
associated	O
with	O
acute	O
antidepressant	B-Chemical
therapy	O
may	O
be	O
reduced	O
by	O
lithium	B-Chemical
treatment	O
.	O

Peritubular	O
capillary	O
basement	O
membrane	O
reduplication	O
in	O
allografts	O
and	O
native	O
kidney	B-Disease
disease	I-Disease
:	O
a	O
clinicopathologic	O
study	O
of	O
278	O
consecutive	O
renal	O
specimens	O
.	O

BACKGROUND	O
:	O
An	O
association	O
has	O
been	O
found	O
between	O
transplant	B-Disease
glomerulopathy	I-Disease
(	O
TG	B-Disease
)	O
and	O
reduplication	O
of	O
peritubular	O
capillary	O
basement	O
membranes	O
(	O
PTCR	O
)	O
.	O

In	O
addition	O
to	O
renal	O
allografts	O
with	O
TG	B-Disease
,	O
we	O
also	O
examined	O
grafts	O
with	O
acute	O
rejection	O
,	O
recurrent	O
glomerulonephritis	B-Disease
,	O
chronic	B-Disease
allograft	I-Disease
nephropathy	I-Disease
and	O
stable	O
grafts	O
(	O
"	O
protocol	O
biopsies	O
"	O
)	O
.	O

Native	O
kidney	O
specimens	O
included	O
a	O
wide	O
range	O
of	O
glomerulopathies	B-Disease
as	O
well	O
as	O
cases	O
of	O
thrombotic	B-Disease
microangiopathy	I-Disease
,	O
malignant	B-Disease
hypertension	I-Disease
,	O
acute	O
interstitial	B-Disease
nephritis	I-Disease
,	O
and	O
acute	B-Disease
tubular	I-Disease
necrosis	I-Disease
.	O

RESULTS	O
:	O
We	O
found	O
PTCR	O
in	O
14	O
of	O
15	O
cases	O
of	O
TG	B-Disease
,	O
in	O
7	O
transplant	O
biopsy	O
specimens	O
without	O
TG	B-Disease
,	O
and	O
in	O
13	O
of	O
143	O
native	O
kidney	O
biopsy	O
specimens	O
.	O

These	O
13	O
included	O
cases	O
of	O
malignant	B-Disease
hypertension	I-Disease
,	O
thrombotic	B-Disease
microangiopathy	I-Disease
,	O
lupus	B-Disease
nephritis	I-Disease
,	O
Henoch	O
-	O
Schonlein	O
nephritis	O
,	O
crescentic	O
glomerulonephritis	B-Disease
,	O
and	O
cocaine	B-Chemical
-	O
related	O
acute	B-Disease
renal	I-Disease
failure	I-Disease
.	O

Mild	O
PTCR	O
in	O
allografts	O
without	O
TG	B-Disease
did	O
not	O
predict	O
renal	B-Disease
failure	I-Disease
or	O
significant	O
proteinuria	B-Disease
after	O
follow	O
-	O
up	O
periods	O
of	O
between	O
3	O
months	O
and	O
1	O
year	O
.	O

CONCLUSIONS	O
:	O
We	O
conclude	O
that	O
in	O
transplants	O
,	O
there	O
is	O
a	O
strong	O
association	O
between	O
well	O
-	O
developed	O
PTCR	O
and	O
TG	B-Disease
,	O
while	O
the	O
significance	O
of	O
mild	O
PTCR	O
and	O
its	O
predictive	O
value	O
in	O
the	O
absence	O
of	O
TG	B-Disease
is	O
unclear	O
.	O

PTCR	O
also	O
occurs	O
in	O
certain	O
native	O
kidney	B-Disease
diseases	I-Disease
,	O
though	O
the	O
association	O
is	O
not	O
as	O
strong	O
as	O
that	O
for	O
TG	B-Disease
.	O

We	O
suggest	O
that	O
repeated	O
endothelial	B-Disease
injury	I-Disease
,	O
including	O
immunologic	B-Disease
injury	I-Disease
,	O
may	O
be	O
the	O
cause	O
of	O
this	O
lesion	O
both	O
in	O
allografts	O
and	O
native	O
kidneys	O
.	O

Caffeine	B-Chemical
-	O
induced	O
cardiac	B-Disease
arrhythmia	I-Disease
:	O
an	O
unrecognised	O
danger	O
of	O
healthfood	O
products	O
.	O

We	O
describe	O
a	O
25	O
-	O
year	O
-	O
old	O
woman	O
with	O
pre	O
-	O
existing	O
mitral	B-Disease
valve	I-Disease
prolapse	I-Disease
who	O
developed	O
intractable	O
ventricular	B-Disease
fibrillation	I-Disease
after	O
consuming	O
a	O
"	O
natural	O
energy	O
"	O
guarana	O
health	O
drink	O
containing	O
a	O
high	O
concentration	O
of	O
caffeine	B-Chemical
.	O

Conformationally	O
restricted	O
analogs	O
of	O
BD1008	B-Chemical
and	O
an	O
antisense	O
oligodeoxynucleotide	B-Chemical
targeting	O
sigma1	O
receptors	O
produce	O
anti	O
-	O
cocaine	B-Chemical
effects	O
in	O
mice	O
.	O

Cocaine	B-Chemical
'	O
s	O
ability	O
to	O
interact	O
with	O
sigma	O
receptors	O
suggests	O
that	O
these	O
proteins	O
mediate	O
some	O
of	O
its	O
behavioral	O
effects	O
.	O

Therefore	O
,	O
three	O
novel	O
sigma	O
receptor	O
ligands	O
with	O
antagonist	O
activity	O
were	O
evaluated	O
in	O
Swiss	O
Webster	O
mice	O
:	O
BD1018	B-Chemical
(	O
3S	B-Chemical
-	I-Chemical
1	I-Chemical
-	I-Chemical
[	I-Chemical
2	I-Chemical
-	I-Chemical
(	I-Chemical
3	I-Chemical
,	I-Chemical
4	I-Chemical
-	I-Chemical
dichlorophenyl	I-Chemical
)	I-Chemical
ethyl	I-Chemical
]	I-Chemical
-	I-Chemical
1	I-Chemical
,	I-Chemical
4	I-Chemical
-	I-Chemical
diazabicyclo	I-Chemical
[	I-Chemical
4	I-Chemical
.	I-Chemical
3	I-Chemical
.	I-Chemical
0	I-Chemical
]	I-Chemical
nonane	I-Chemical
)	O
,	O
BD1063	B-Chemical
(	O
1	B-Chemical
-	I-Chemical
[	I-Chemical
2	I-Chemical
-	I-Chemical
(	I-Chemical
3	I-Chemical
,	I-Chemical
4	I-Chemical
-	I-Chemical
dichlorophenyl	I-Chemical
)	I-Chemical
ethyl	I-Chemical
]	I-Chemical
-	I-Chemical
4	I-Chemical
-	I-Chemical
methylpiperazine	I-Chemical
)	O
,	O
and	O
LR132	B-Chemical
(	O
1R	O
,	O
2S	O
-	O
(	O
+	O
)	O
-	O
cis	O
-	O
N	O
-	O
[	O
2	O
-	O
(	O
3	O
,	O
4	O
-	O
dichlorophenyl	O
)	O
ethyl	O
]	O
-	O
2	O
-	O
(	O
1	O
-	O
pyrrolidinyl	O
)	O
cyclohexylamine	O
)	O
.	O

The	O
three	O
compounds	O
vary	O
in	O
their	O
affinities	O
for	O
sigma2	O
receptors	O
and	O
exhibit	O
negligible	O
affinities	O
for	O
dopamine	B-Chemical
,	O
opioid	O
,	O
GABA	B-Chemical
(	O
A	O
)	O
and	O
NMDA	B-Chemical
receptors	O
.	O

In	O
behavioral	O
studies	O
,	O
pre	O
-	O
treatment	O
of	O
mice	O
with	O
BD1018	B-Chemical
,	O
BD1063	B-Chemical
,	O
or	O
LR132	B-Chemical
significantly	O
attenuated	O
cocaine	B-Chemical
-	O
induced	O
convulsions	B-Disease
and	O
lethality	O
.	O

Moreover	O
,	O
post	O
-	O
treatment	O
with	O
LR132	B-Chemical
prevented	O
cocaine	B-Chemical
-	O
induced	O
lethality	O
in	O
a	O
significant	O
proportion	O
of	O
animals	O
.	O

In	O
contrast	O
to	O
the	O
protection	O
provided	O
by	O
the	O
putative	O
antagonists	O
,	O
the	O
well	O
-	O
characterized	O
sigma	O
receptor	O
agonist	O
di	B-Chemical
-	I-Chemical
o	I-Chemical
-	I-Chemical
tolylguanidine	I-Chemical
(	O
DTG	B-Chemical
)	O
and	O
the	O
novel	O
sigma	O
receptor	O
agonist	O
BD1031	B-Chemical
(	O
3R	B-Chemical
-	I-Chemical
1	I-Chemical
-	I-Chemical
[	I-Chemical
2	I-Chemical
-	I-Chemical
(	I-Chemical
3	I-Chemical
,	I-Chemical
4	I-Chemical
-	I-Chemical
dichlorophenyl	I-Chemical
)	I-Chemical
ethyl	I-Chemical
]	I-Chemical
-	I-Chemical
1	I-Chemical
,	I-Chemical
4	I-Chemical
-	I-Chemical
diazabicyclo	I-Chemical
[	I-Chemical
4	I-Chemical
.	I-Chemical
3	I-Chemical
.	I-Chemical
0	I-Chemical
]	I-Chemical
nonane	I-Chemical
)	O
each	O
worsened	O
the	O
behavioral	O
toxicity	B-Disease
of	O
cocaine	B-Chemical
.	O

At	O
doses	O
where	O
alone	O
,	O
they	O
produced	O
no	O
significant	O
effects	O
on	O
locomotion	O
,	O
BD1018	B-Chemical
,	O
BD1063	B-Chemical
and	O
LR132	B-Chemical
significantly	O
attenuated	O
the	O
locomotor	O
stimulatory	O
effects	O
of	O
cocaine	B-Chemical
.	O

To	O
further	O
validate	O
the	O
hypothesis	O
that	O
the	O
anti	O
-	O
cocaine	B-Chemical
effects	O
of	O
the	O
novel	O
ligands	O
involved	O
antagonism	O
of	O
sigma	O
receptors	O
,	O
an	O
antisense	O
oligodeoxynucleotide	B-Chemical
against	O
sigma1	O
receptors	O
was	O
also	O
shown	O
to	O
significantly	O
attenuate	O
the	O
convulsive	B-Disease
and	O
locomotor	O
stimulatory	O
effects	O
of	O
cocaine	B-Chemical
.	O

Together	O
,	O
the	O
data	O
suggests	O
that	O
functional	O
antagonism	O
of	O
sigma	O
receptors	O
is	O
capable	O
of	O
attenuating	O
a	O
number	O
of	O
cocaine	B-Chemical
-	O
induced	O
behaviors	O
.	O

Ranitidine	B-Chemical
-	O
induced	O
acute	O
interstitial	B-Disease
nephritis	I-Disease
in	O
a	O
cadaveric	O
renal	O
allograft	O
.	O

Ranitidine	B-Chemical
frequently	O
is	O
used	O
for	O
preventing	O
peptic	O
ulceration	O
after	O
renal	O
transplantation	O
.	O

This	O
drug	O
occasionally	O
has	O
been	O
associated	O
with	O
acute	O
interstitial	B-Disease
nephritis	I-Disease
in	O
native	O
kidneys	O
.	O

We	O
report	O
a	O
case	O
of	O
ranitidine	B-Chemical
-	O
induced	O
acute	O
interstitial	B-Disease
nephritis	I-Disease
in	O
a	O
recipient	O
of	O
a	O
cadaveric	O
renal	O
allograft	O
presenting	O
with	O
acute	O
allograft	O
dysfunction	O
within	O
48	O
hours	O
of	O
exposure	O
to	O
the	O
drug	O
.	O

Liver	B-Disease
disease	I-Disease
caused	O
by	O
propylthiouracil	B-Chemical
.	O

This	O
report	O
presents	O
the	O
clinical	O
,	O
laboratory	O
,	O
and	O
light	O
and	O
electron	O
microscopic	O
observations	O
on	O
a	O
patient	O
with	O
chronic	B-Disease
active	I-Disease
(	I-Disease
aggressive	I-Disease
)	I-Disease
hepatitis	I-Disease
caused	O
by	O
the	O
administration	O
of	O
propylthiouracil	B-Chemical
.	O

This	O
is	O
an	O
addition	O
to	O
the	O
list	O
of	O
drugs	O
that	O
must	O
be	O
considered	O
in	O
the	O
evaluation	O
of	O
chronic	O
liver	B-Disease
disease	I-Disease
.	O

Withdrawal	B-Disease
-	I-Disease
emergent	I-Disease
rabbit	I-Disease
syndrome	I-Disease
during	O
dose	O
reduction	O
of	O
risperidone	B-Chemical
.	O

Rabbit	B-Disease
syndrome	I-Disease
(	O
RS	B-Disease
)	O
is	O
a	O
rare	O
extrapyramidal	O
side	O
effect	O
caused	O
by	O
prolonged	O
neuroleptic	O
medication	O
.	O

Here	O
we	O
present	O
a	O
case	O
of	O
withdrawal	B-Disease
-	I-Disease
emergent	I-Disease
RS	I-Disease
,	O
which	O
is	O
the	O
first	O
of	O
its	O
kind	O
to	O
be	O
reported	O
.	O

The	O
patient	O
developed	O
RS	B-Disease
during	O
dose	O
reduction	O
of	O
risperidone	B-Chemical
.	O

The	O
symptom	O
was	O
treated	O
successfully	O
with	O
trihexyphenidyl	B-Chemical
anticholinergic	O
therapy	O
.	O

The	O
underlying	O
mechanism	O
of	O
withdrawal	B-Disease
-	I-Disease
emergent	I-Disease
RS	I-Disease
in	O
the	O
present	O
case	O
may	O
have	O
been	O
related	O
to	O
the	O
pharmacological	O
profile	O
of	O
risperidone	B-Chemical
,	O
a	O
serotonin	O
-	O
dopamine	B-Chemical
antagonist	O
,	O
suggesting	O
the	O
pathophysiologic	O
influence	O
of	O
the	O
serotonin	B-Chemical
system	O
in	O
the	O
development	O
of	O
RS	B-Disease
.	O

Pharmacokinetic	O
/	O
pharmacodynamic	O
assessment	O
of	O
the	O
effects	O
of	O
E4031	B-Chemical
,	O
cisapride	B-Chemical
,	O
terfenadine	B-Chemical
and	O
terodiline	B-Chemical
on	O
monophasic	O
action	O
potential	O
duration	O
in	O
dog	O
.	O

Torsades	B-Disease
de	I-Disease
pointes	I-Disease
(	O
TDP	B-Disease
)	O
is	O
a	O
potentially	O
fatal	O
ventricular	O
tachycardia	O
associated	O
with	O
increases	O
in	O
QT	O
interval	O
and	O
monophasic	O
action	O
potential	O
duration	O
(	O
MAPD	O
)	O
.	O

TDP	B-Disease
is	O
a	O
side	O
-	O
effect	O
that	O
has	O
led	O
to	O
withdrawal	O
of	O
several	O
drugs	O
from	O
the	O
market	O
(	O
e	O
.	O
g	O
.	O
terfenadine	B-Chemical
and	O
terodiline	B-Chemical
)	O
.	O

The	O
potential	O
of	O
compounds	O
to	O
cause	O
TDP	B-Disease
was	O
evaluated	O
by	O
monitoring	O
their	O
effects	O
on	O
MAPD	O
in	O
dog	O
.	O

Four	O
compounds	O
known	O
to	O
increase	O
QT	O
interval	O
and	O
cause	O
TDP	B-Disease
were	O
investigated	O
:	O
terfenadine	B-Chemical
,	O
terodiline	B-Chemical
,	O
cisapride	B-Chemical
and	O
E4031	B-Chemical
.	O

These	O
data	O
indicate	O
that	O
the	O
free	O
ED50	O
in	O
plasma	O
for	O
terfenadine	B-Chemical
(	O
1	O
.	O
9	O
nM	O
)	O
,	O
terodiline	B-Chemical
(	O
76	O
nM	O
)	O
,	O
cisapride	B-Chemical
(	O
11	O
nM	O
)	O
and	O
E4031	B-Chemical
(	O
1	O
.	O
9	O
nM	O
)	O
closely	O
correlate	O
with	O
the	O
free	O
concentration	O
in	O
man	O
causing	O
QT	O
effects	O
.	O

For	O
compounds	O
that	O
have	O
shown	O
TDP	B-Disease
in	O
the	O
clinic	O
(	O
terfenadine	B-Chemical
,	O
terodiline	B-Chemical
,	O
cisapride	B-Chemical
)	O
there	O
is	O
little	O
differentiation	O
between	O
the	O
dog	O
ED50	O
and	O
the	O
efficacious	O
free	O
plasma	O
concentrations	O
in	O
man	O
(	O
<	O
10	O
-	O
fold	O
)	O
reflecting	O
their	O
limited	O
safety	O
margins	O
.	O

These	O
data	O
underline	O
the	O
need	O
to	O
maximize	O
the	O
therapeutic	O
ratio	O
with	O
respect	O
to	O
TDP	B-Disease
in	O
potential	O
development	O
candidates	O
and	O
the	O
importance	O
of	O
using	O
free	O
drug	O
concentrations	O
in	O
pharmacokinetic	O
/	O
pharmacodynamic	O
studies	O
.	O

Bladder	O
retention	B-Disease
of	I-Disease
urine	I-Disease
as	O
a	O
result	O
of	O
continuous	O
intravenous	O
infusion	O
of	O
fentanyl	B-Chemical
:	O
2	O
case	O
reports	O
.	O

Sedation	O
has	O
been	O
commonly	O
used	O
in	O
the	O
neonate	O
to	O
decrease	O
the	O
stress	O
and	O
pain	B-Disease
from	O
the	O
noxious	O
stimuli	O
and	O
invasive	O
procedures	O
in	O
the	O
neonatal	O
intensive	O
care	O
unit	O
,	O
as	O
well	O
as	O
to	O
facilitate	O
synchrony	O
between	O
ventilator	O
and	O
spontaneous	O
breaths	O
.	O

Fentanyl	B-Chemical
,	O
an	O
opioid	O
analgesic	O
,	O
is	O
frequently	O
used	O
in	O
the	O
neonatal	O
intensive	O
care	O
unit	O
setting	O
for	O
these	O
very	O
purposes	O
.	O

Various	O
reported	O
side	O
effects	O
of	O
fentanyl	B-Chemical
administration	O
include	O
chest	B-Disease
wall	I-Disease
rigidity	I-Disease
,	O
hypotension	B-Disease
,	O
respiratory	B-Disease
depression	I-Disease
,	O
and	O
bradycardia	B-Disease
.	O

Here	O
,	O
2	O
cases	O
of	O
urinary	B-Disease
bladder	I-Disease
retention	I-Disease
leading	O
to	O
renal	O
pelvocalyceal	O
dilatation	O
mimicking	O
hydronephrosis	B-Disease
as	O
a	O
result	O
of	O
continuous	O
infusion	O
of	O
fentanyl	B-Chemical
are	O
reported	O
.	O

Fatal	O
myeloencephalopathy	B-Disease
due	O
to	O
accidental	O
intrathecal	O
vincristin	B-Chemical
administration	O
:	O
a	O
report	O
of	O
two	O
cases	O
.	O

We	O
report	O
on	O
two	O
fatal	O
cases	O
of	O
accidental	O
intrathecal	O
vincristine	B-Chemical
instillation	O
in	O
a	O
5	O
-	O
year	O
old	O
girl	O
with	O
recurrent	O
acute	B-Disease
lymphoblastic	I-Disease
leucemia	I-Disease
and	O
a	O
57	O
-	O
year	O
old	O
man	O
with	O
lymphoblastic	B-Disease
lymphoma	I-Disease
.	O

The	O
girl	O
died	O
seven	O
days	O
,	O
the	O
man	O
four	O
weeks	O
after	O
intrathecal	O
injection	O
of	O
vincristine	B-Chemical
.	O

Clinically	O
,	O
the	O
onset	O
was	O
characterized	O
by	O
the	O
signs	O
of	O
opistothonus	B-Disease
,	I-Disease
sensory	I-Disease
and	I-Disease
motor	I-Disease
dysfunction	I-Disease
and	O
ascending	O
paralysis	B-Disease
.	O

Histological	O
and	O
immunohistochemical	O
investigations	O
(	O
HE	O
-	O
LFB	O
,	O
CD	O
-	O
68	O
,	O
Neurofilament	O
)	O
revealed	O
degeneration	B-Disease
of	I-Disease
myelin	I-Disease
and	I-Disease
axons	I-Disease
as	O
well	O
as	O
pseudocystic	B-Disease
transformation	I-Disease
in	O
areas	O
exposed	O
to	O
vincristine	B-Chemical
,	O
accompanied	O
by	O
secondary	O
changes	O
with	O
numerous	O
prominent	O
macrophages	O
.	O

A	O
better	O
controlled	O
regimen	O
for	O
administering	O
vincristine	B-Chemical
and	O
intrathecal	O
chemotherapy	O
is	O
recommended	O
.	O

Palpebral	O
twitching	O
in	O
a	O
depressed	B-Disease
adolescent	O
on	O
citalopram	B-Chemical
.	O

Current	O
estimates	O
suggest	O
that	O
between	O
0	O
.	O
4	O
%	O
and	O
8	O
.	O
3	O
%	O
of	O
children	O
and	O
adolescents	O
are	O
affected	O
by	O
major	B-Disease
depression	I-Disease
.	O

We	O
report	O
a	O
favorable	O
response	O
to	O
treatment	O
with	O
citalopram	B-Chemical
by	O
a	O
15	O
-	O
year	O
-	O
old	O
boy	O
with	O
major	B-Disease
depression	I-Disease
who	O
exhibited	O
palpebral	B-Disease
twitching	I-Disease
during	O
his	O
first	O
2	O
weeks	O
of	O
treatment	O
.	O

This	O
may	O
have	O
been	O
a	O
side	O
effect	O
of	O
citalopram	B-Chemical
as	O
it	O
remitted	O
with	O
redistribution	O
of	O
doses	O
.	O

The	O
3	O
-	O
week	O
sulphasalazine	B-Chemical
syndrome	O
strikes	O
again	O
.	O

A	O
34	O
-	O
year	O
-	O
old	O
lady	O
developed	O
a	O
constellation	O
of	O
dermatitis	B-Disease
,	O
fever	B-Disease
,	O
lymphadenopathy	B-Disease
and	O
hepatitis	O
,	O
beginning	O
on	O
the	O
17th	O
day	O
of	O
a	O
course	O
of	O
oral	O
sulphasalazine	B-Chemical
for	O
sero	O
-	O
negative	O
rheumatoid	B-Disease
arthritis	I-Disease
.	O

Cervical	O
and	O
inguinal	O
lymph	O
node	O
biopsies	O
showed	O
the	O
features	O
of	O
severe	O
necrotising	O
lymphadenitis	B-Disease
,	O
associated	O
with	O
erythrophagocytosis	O
and	O
prominent	O
eosinophilic	O
infiltrates	O
,	O
without	O
viral	O
inclusion	O
bodies	O
,	O
suggestive	O
of	O
an	O
adverse	B-Disease
drug	I-Disease
reaction	I-Disease
.	O
A	O
week	O
later	O
,	O
fulminant	O
drug	B-Disease
-	I-Disease
induced	I-Disease
hepatitis	I-Disease
,	O
associated	O
with	O
the	O
presence	O
of	O
anti	O
-	O
nuclear	O
autoantibodies	O
(	O
but	O
not	O
with	O
other	O
markers	O
of	O
autoimmunity	B-Disease
)	O
,	O
and	O
accompanied	O
by	O
multi	B-Disease
-	I-Disease
organ	I-Disease
failure	I-Disease
and	O
sepsis	B-Disease
,	O
supervened	O
.	O

She	O
subsequently	O
died	O
some	O
5	O
weeks	O
after	O
the	O
commencement	O
of	O
her	O
drug	O
therapy	O
.	O
Post	O
-	O
mortem	O
examination	O
showed	O
evidence	O
of	O
massive	B-Disease
hepatocellular	I-Disease
necrosis	I-Disease
,	O
acute	O
hypersensitivity	O
myocarditis	O
,	O
focal	O
acute	O
tubulo	O
-	O
interstitial	O
nephritis	B-Disease
and	O
extensive	O
bone	B-Disease
marrow	I-Disease
necrosis	I-Disease
,	O
with	O
no	O
evidence	O
of	O
malignancy	B-Disease
.	O

It	O
is	O
thought	O
that	O
the	O
clinico	O
-	O
pathological	O
features	O
and	O
chronology	O
of	O
this	O
case	O
bore	O
the	O
hallmarks	O
of	O
the	O
so	O
-	O
called	O
"	O
3	O
-	O
week	O
sulphasalazine	B-Chemical
syndrome	O
"	O
,	O
a	O
rare	O
,	O
but	O
often	O
fatal	O
,	O
immunoallergic	O
reaction	O
to	O
sulphasalazine	B-Chemical
.	O

Intravenous	O
administration	O
of	O
prochlorperazine	B-Chemical
by	O
15	O
-	O
minute	O
infusion	O
versus	O
2	O
-	O
minute	O
bolus	O
does	O
not	O
affect	O
the	O
incidence	O
of	O
akathisia	B-Disease
:	O
a	O
prospective	O
,	O
randomized	O
,	O
controlled	O
trial	O
.	O

STUDY	O
OBJECTIVE	O
:	O
We	O
sought	O
to	O
compare	O
the	O
rate	O
of	O
akathisia	B-Disease
after	O
administration	O
of	O
intravenous	O
prochlorperazine	B-Chemical
as	O
a	O
2	O
-	O
minute	O
bolus	O
or	O
15	O
-	O
minute	O
infusion	O
.	O

Patients	O
aged	O
18	O
years	O
or	O
older	O
treated	O
with	O
prochlorperazine	O
for	O
headache	B-Disease
,	O
nausea	B-Disease
,	O
or	O
vomiting	B-Disease
were	O
eligible	O
for	O
inclusion	O
.	O

Study	O
participants	O
were	O
randomized	O
to	O
receive	O
10	O
mg	O
of	O
prochlorperazine	B-Chemical
administered	O
intravenously	O
by	O
means	O
of	O
2	O
-	O
minute	O
push	O
(	O
bolus	O
group	O
)	O
or	O
10	O
mg	O
diluted	O
in	O
50	O
mL	O
of	O
normal	O
saline	O
solution	O
administered	O
by	O
means	O
of	O
intravenous	O
infusion	O
during	O
a	O
15	O
-	O
minute	O
period	O
(	O
infusion	O
group	O
)	O
.	O

The	O
main	O
outcome	O
was	O
the	O
number	O
of	O
study	O
participants	O
experiencing	O
akathisia	B-Disease
within	O
60	O
minutes	O
of	O
administration	O
.	O

Akathisia	O
was	O
defined	O
as	O
either	O
a	O
spontaneous	O
report	O
of	O
restlessness	O
or	O
agitation	B-Disease
or	O
a	O
change	O
of	O
2	O
or	O
more	O
in	O
the	O
patient	O
-	O
reported	O
akathisia	B-Disease
rating	O
scale	O
and	O
a	O
change	O
of	O
at	O
least	O
1	O
in	O
the	O
investigator	O
-	O
observed	O
akathisia	B-Disease
rating	O
scale	O
.	O

The	O
intensity	O
of	O
headache	B-Disease
and	O
nausea	B-Disease
was	O
measured	O
with	O
a	O
100	O
-	O
mm	O
visual	O
analog	O
scale	O
.	O

Seventy	O
-	O
three	O
percent	O
(	O
73	O
/	O
99	O
)	O
of	O
the	O
study	O
participants	O
were	O
treated	O
for	O
headache	B-Disease
and	O
70	O
%	O
(	O
70	O
/	O
99	O
)	O
for	O
nausea	B-Disease
.	O

In	O
the	O
bolus	O
group	O
,	O
26	O
.	O
0	O
%	O
(	O
13	O
/	O
50	O
)	O
had	O
akathisia	B-Disease
compared	O
with	O
32	O
.	O
7	O
%	O
(	O
16	O
/	O
49	O
)	O
in	O
the	O
infusion	O
group	O
(	O
Delta	O
=	O
-	O
6	O
.	O
7	O
%	O
;	O
95	O
%	O
confidence	O
interval	O
[	O
CI	O
]	O
-	O
24	O
.	O
6	O
%	O
to	O
11	O
.	O
2	O
%	O
)	O
.	O

The	O
difference	O
between	O
the	O
bolus	O
and	O
infusion	O
groups	O
in	O
the	O
percentage	O
of	O
participants	O
who	O
saw	O
a	O
50	O
%	O
reduction	O
in	O
their	O
headache	B-Disease
intensity	O
within	O
30	O
minutes	O
was	O
11	O
.	O
8	O
%	O
(	O
95	O
%	O
CI	O
-	O
9	O
.	O
6	O
%	O
to	O
33	O
.	O
3	O
%	O
)	O
.	O

The	O
difference	O
in	O
the	O
percentage	O
of	O
patients	O
with	O
a	O
50	O
%	O
reduction	O
in	O
their	O
nausea	B-Disease
was	O
12	O
.	O
6	O
%	O
(	O
95	O
%	O
CI	O
-	O
4	O
.	O
6	O
%	O
to	O
29	O
.	O
8	O
%	O
)	O
.	O

CONCLUSION	O
:	O
A	O
50	O
%	O
reduction	O
in	O
the	O
incidence	O
of	O
akathisia	B-Disease
when	O
prochlorperazine	B-Chemical
was	O
administered	O
by	O
means	O
of	O
15	O
-	O
minute	O
intravenous	O
infusion	O
versus	O
a	O
2	O
-	O
minute	O
intravenous	O
push	O
was	O
not	O
detected	O
.	O

The	O
efficacy	O
of	O
prochlorperazine	B-Chemical
in	O
the	O
treatment	O
of	O
headache	B-Disease
and	O
nausea	B-Disease
likewise	O
did	O
not	O
appear	O
to	O
be	O
affected	O
by	O
the	O
rate	O
of	O
administration	O
,	O
although	O
no	O
formal	O
statistical	O
comparisons	O
were	O
made	O
.	O

Combined	O
antiretroviral	O
therapy	O
causes	O
cardiomyopathy	B-Disease
and	O
elevates	O
plasma	O
lactate	B-Chemical
in	O
transgenic	O
AIDS	B-Disease
mice	O
.	O

Highly	O
active	O
antiretroviral	O
therapy	O
(	O
HAART	O
)	O
is	O
implicated	O
in	O
cardiomyopathy	B-Disease
(	O
CM	B-Disease
)	O
and	O
in	O
elevated	O
plasma	O
lactate	B-Chemical
(	O
LA	B-Chemical
)	O
in	O
AIDS	B-Disease
through	O
mechanisms	O
of	O
mitochondrial	B-Disease
dysfunction	I-Disease
.	O

To	O
determine	O
mitochondrial	O
events	O
from	O
HAART	O
in	O
vivo	O
,	O
8	O
-	O
week	O
-	O
old	O
hemizygous	O
transgenic	O
AIDS	B-Disease
mice	O
(	O
NL4	O
-	O
3Delta	O
gag	O
/	O
pol	O
;	O
TG	O
)	O
and	O
wild	O
-	O
type	O
FVB	O
/	O
n	O
littermates	O
were	O
treated	O
with	O
the	O
HAART	O
combination	O
of	O
zidovudine	B-Chemical
,	O
lamivudine	O
,	O
and	O
indinavir	B-Chemical
or	O
vehicle	O
control	O
for	O
10	O
days	O
or	O
35	O
days	O
.	O

At	O
termination	O
of	O
the	O
experiments	O
,	O
mice	O
underwent	O
echocardiography	O
,	O
quantitation	O
of	O
abundance	O
of	O
molecular	O
markers	O
of	O
CM	B-Disease
(	O
ventricular	O
mRNA	O
encoding	O
atrial	O
natriuretic	O
factor	O
[	O
ANF	O
]	O
and	O
sarcoplasmic	O
calcium	B-Chemical
ATPase	O
[	O
SERCA2	O
]	O
)	O
,	O
and	O
determination	O
of	O
plasma	O
LA	B-Chemical
.	O

Biochemically	O
,	O
LA	B-Chemical
was	O
elevated	O
(	O
8	O
.	O
5	O
+	O
/	O
-	O
2	O
.	O
0	O
mM	O
)	O
.	O

Results	O
show	O
that	O
cumulative	O
HAART	O
caused	O
mitochondrial	O
CM	B-Disease
with	O
elevated	O
LA	B-Chemical
in	O
AIDS	B-Disease
transgenic	O
mice	O
.	O

A	O
Phase	O
II	O
trial	O
of	O
cisplatin	B-Chemical
plus	O
WR	B-Chemical
-	I-Chemical
2721	I-Chemical
(	O
amifostine	B-Chemical
)	O
for	O
metastatic	O
breast	B-Disease
carcinoma	I-Disease
:	O
an	O
Eastern	O
Cooperative	O
Oncology	O
Group	O
Study	O
(	O
E8188	O
)	O
.	O

BACKGROUND	O
:	O
Cisplatin	B-Chemical
has	O
minimal	O
antitumor	O
activity	O
when	O
used	O
as	O
second	O
-	O
or	O
third	O
-	O
line	O
treatment	O
of	O
metastatic	O
breast	B-Disease
carcinoma	I-Disease
.	O

Older	O
reports	O
suggest	O
an	O
objective	O
response	O
rate	O
of	O
8	O
%	O
when	O
60	O
-	O
120	O
mg	O
/	O
m2	O
of	O
cisplatin	B-Chemical
is	O
administered	O
every	O
3	O
-	O
4	O
weeks	O
.	O

Although	O
a	O
dose	O
-	O
response	O
effect	O
has	O
been	O
observed	O
with	O
cisplatin	B-Chemical
,	O
the	O
dose	O
-	O
limiting	O
toxicities	B-Disease
associated	O
with	O
cisplatin	B-Chemical
(	O
e	O
.	O
g	O
.	O
,	O
nephrotoxicity	B-Disease
,	O
ototoxicity	B-Disease
,	O
and	O
neurotoxicity	B-Disease
)	O
have	O
limited	O
its	O
use	O
as	O
a	O
treatment	O
for	O
breast	B-Disease
carcinoma	I-Disease
.	O

WR	B-Chemical
-	I-Chemical
2721	I-Chemical
or	O
amifostine	B-Chemical
initially	O
was	O
developed	O
to	O
protect	O
military	O
personnel	O
in	O
the	O
event	O
of	O
nuclear	O
war	O
.	O

Amifostine	B-Chemical
subsequently	O
was	O
shown	O
to	O
protect	O
normal	O
tissues	O
from	O
the	O
toxic	O
effects	O
of	O
alkylating	B-Chemical
agents	I-Chemical
and	O
cisplatin	B-Chemical
without	O
decreasing	O
the	O
antitumor	O
effect	O
of	O
the	O
chemotherapy	O
.	O

Early	O
trials	O
of	O
cisplatin	B-Chemical
and	O
amifostine	B-Chemical
also	O
suggested	O
that	O
the	O
incidence	O
and	O
severity	O
of	O
cisplatin	B-Chemical
-	O
induced	O
nephrotoxicity	B-Disease
,	O
ototoxicity	B-Disease
,	O
and	O
neuropathy	B-Disease
were	O
reduced	O
.	O

METHODS	O
:	O
A	O
Phase	O
II	O
study	O
of	O
the	O
combination	O
of	O
cisplatin	B-Chemical
plus	O
amifostine	B-Chemical
was	O
conducted	O
in	O
patients	O
with	O
progressive	O
metastatic	O
breast	B-Disease
carcinoma	I-Disease
who	O
had	O
received	O
one	O
,	O
but	O
not	O
more	O
than	O
one	O
,	O
chemotherapy	O
regimen	O
for	O
metastatic	O
disease	O
.	O

Patients	O
received	O
amifostine	B-Chemical
,	O
910	O
mg	O
/	O
m2	O
intravenously	O
over	O
15	O
minutes	O
.	O

After	O
completion	O
of	O
the	O
amifostine	B-Chemical
infusion	O
,	O
cisplatin	B-Chemical
120	O
mg	O
/	O
m2	O
was	O
administered	O
over	O
30	O
minutes	O
.	O

Intravenous	O
hydration	O
and	O
mannitol	B-Chemical
was	O
administered	O
before	O
and	O
after	O
cisplatin	B-Chemical
.	O

Neurologic	B-Disease
toxicity	I-Disease
was	O
reported	O
in	O
52	O
%	O
of	O
patients	O
.	O

Seven	O
different	O
life	O
-	O
threatening	O
toxicities	B-Disease
were	O
observed	O
in	O
patients	O
while	O
receiving	O
treatment	O
.	O

CONCLUSIONS	O
:	O
The	O
combination	O
of	O
cisplatin	B-Chemical
and	O
amifostine	B-Chemical
in	O
this	O
study	O
resulted	O
in	O
an	O
overall	O
response	O
rate	O
of	O
16	O
%	O
.	O

Neither	O
a	O
tumor	B-Disease
-	O
protective	O
effect	O
nor	O
reduced	O
toxicity	B-Disease
to	O
normal	O
tissues	O
was	O
observed	O
with	O
the	O
addition	O
of	O
amifostine	B-Chemical
to	O
cisplatin	B-Chemical
in	O
this	O
trial	O
.	O

Oral	B-Chemical
contraceptives	I-Chemical
and	O
the	O
risk	O
of	O
myocardial	B-Disease
infarction	I-Disease
.	O

BACKGROUND	O
:	O
An	O
association	O
between	O
the	O
use	O
of	O
oral	B-Chemical
contraceptives	I-Chemical
and	O
the	O
risk	O
of	O
myocardial	O
infarction	O
has	O
been	O
found	O
in	O
some	O
,	O
but	O
not	O
all	O
,	O
studies	O
.	O

We	O
investigated	O
this	O
association	O
,	O
according	O
to	O
the	O
type	O
of	O
progestagen	B-Chemical
included	O
in	O
third	O
-	O
generation	O
(	O
i	O
.	O
e	O
.	O
,	O
desogestrel	O
or	O
gestodene	B-Chemical
)	O
and	O
second	O
-	O
generation	O
(	O
i	O
.	O
e	O
.	O
,	O
levonorgestrel	B-Chemical
)	O
oral	O
contraceptives	O
,	O
the	O
dose	O
of	O
estrogen	B-Chemical
,	O
and	O
the	O
presence	O
or	O
absence	O
of	O
prothrombotic	O
mutations	O
METHODS	O
:	O
In	O
a	O
nationwide	O
,	O
population	O
-	O
based	O
,	O
case	O
-	O
control	O
study	O
,	O
we	O
identified	O
and	O
enrolled	O
248	O
women	O
18	O
through	O
49	O
years	O
of	O
age	O
who	O
had	O
had	O
a	O
first	O
myocardial	B-Disease
infarction	I-Disease
between	O
1990	O
and	O
1995	O
and	O
925	O
control	O
women	O
who	O
had	O
not	O
had	O
a	O
myocardial	B-Disease
infarction	I-Disease
and	O
who	O
were	O
matched	O
for	O
age	O
,	O
calendar	O
year	O
of	O
the	O
index	O
event	O
,	O
and	O
area	O
of	O
residence	O
.	O

Subjects	O
supplied	O
information	O
on	O
oral	B-Chemical
-	I-Chemical
contraceptive	I-Chemical
use	O
and	O
major	O
cardiovascular	O
risk	O
factors	O
.	O

An	O
analysis	O
for	O
factor	O
V	O
Leiden	O
and	O
the	O
G20210A	O
mutation	O
in	O
the	O
prothrombin	O
gene	O
was	O
conducted	O
in	O
217	O
patients	O
and	O
763	O
controls	O
RESULTS	O
:	O
The	O
odds	O
ratio	O
for	O
myocardial	O
infarction	O
among	O
women	O
who	O
used	O
any	O
type	O
of	O
combined	O
oral	B-Chemical
contraceptive	I-Chemical
,	O
as	O
compared	O
with	O
nonusers	O
,	O
was	O
2	O
.	O
0	O
(	O
95	O
percent	O
confidence	O
interval	O
,	O
1	O
.	O
5	O
to	O
2	O
.	O
8	O
)	O
.	O

The	O
adjusted	O
odds	O
ratio	O
was	O
2	O
.	O
5	O
(	O
95	O
percent	O
confidence	O
interval	O
,	O
1	O
.	O
5	O
to	O
4	O
.	O
1	O
)	O
among	O
women	O
who	O
used	O
second	O
-	O
generation	O
oral	B-Chemical
contraceptives	I-Chemical
and	O
1	O
.	O
3	O
(	O
95	O
percent	O
confidence	O
interval	O
,	O
0	O
.	O
7	O
to	O
2	O
.	O
5	O
)	O
among	O
those	O
who	O
used	O
third	O
-	O
generation	O
oral	B-Chemical
contraceptives	I-Chemical
.	O

Among	O
women	O
who	O
used	O
oral	B-Chemical
contraceptives	I-Chemical
,	O
the	O
odds	O
ratio	O
was	O
2	O
.	O
1	O
(	O
95	O
percent	O
confidence	O
interval	O
,	O
1	O
.	O
5	O
to	O
3	O
.	O
0	O
)	O
for	O
those	O
without	O
a	O
prothrombotic	O
mutation	O
and	O
1	O
.	O
9	O
(	O
95	O
percent	O
confidence	O
interval	O
,	O
0	O
.	O
6	O
to	O
5	O
.	O
5	O
)	O
for	O
those	O
with	O
a	O
mutation	O
CONCLUSIONS	O
:	O
The	O
risk	O
of	O
myocardial	B-Disease
infarction	I-Disease
was	O
increased	O
among	O
women	O
who	O
used	O
second	O
-	O
generation	O
oral	B-Chemical
contraceptives	I-Chemical
.	O

The	O
results	O
with	O
respect	O
to	O
the	O
use	O
of	O
third	O
-	O
generation	O
oral	B-Chemical
contraceptives	I-Chemical
were	O
inconclusive	O
but	O
suggested	O
that	O
the	O
risk	O
was	O
lower	O
than	O
the	O
risk	O
associated	O
with	O
second	O
-	O
generation	O
oral	B-Chemical
contraceptives	I-Chemical
.	O

The	O
risk	O
of	O
myocardial	B-Disease
infarction	I-Disease
was	O
similar	O
among	O
women	O
who	O
used	O
oral	B-Chemical
contraceptives	I-Chemical
whether	O
or	O
not	O
they	O
had	O
a	O
prothrombotic	O
mutation	O
.	O

End	B-Disease
-	I-Disease
stage	I-Disease
renal	I-Disease
disease	I-Disease
(	O
ESRD	B-Disease
)	O
after	O
orthotopic	O
liver	O
transplantation	O
(	O
OLTX	O
)	O
using	O
calcineurin	O
-	O
based	O
immunotherapy	O
:	O
risk	O
of	O
development	O
and	O
treatment	O
.	O

BACKGROUND	O
:	O
The	O
calcineurin	O
inhibitors	O
cyclosporine	B-Chemical
and	O
tacrolimus	B-Chemical
are	O
both	O
known	O
to	O
be	O
nephrotoxic	B-Disease
.	O

Recently	O
,	O
however	O
,	O
we	O
have	O
had	O
an	O
increase	O
of	O
patients	O
who	O
are	O
presenting	O
after	O
OLTX	O
with	O
end	B-Disease
-	I-Disease
stage	I-Disease
renal	I-Disease
disease	I-Disease
(	O
ESRD	B-Disease
)	O
.	O

This	O
retrospective	O
study	O
examines	O
the	O
incidence	O
and	O
treatment	O
of	O
ESRD	B-Disease
and	O
chronic	B-Disease
renal	I-Disease
failure	I-Disease
(	O
CRF	B-Disease
)	O
in	O
OLTX	O
patients	O
.	O

Patients	O
were	O
divided	O
into	O
three	O
groups	O
:	O
Controls	O
,	O
no	O
CRF	B-Disease
or	O
ESRD	B-Disease
,	O
n	O
=	O
748	O
;	O
CRF	B-Disease
,	O
sustained	O
serum	O
creatinine	B-Chemical
>	O
2	O
.	O
5	O
mg	O
/	O
dl	O
,	O
n	O
=	O
41	O
;	O
and	O
ESRD	B-Disease
,	O
n	O
=	O
45	O
.	O

Groups	O
were	O
compared	O
for	O
preoperative	O
laboratory	O
variables	O
,	O
diagnosis	O
,	O
postoperative	O
variables	O
,	O
survival	O
,	O
type	O
of	O
ESRD	B-Disease
therapy	O
,	O
and	O
survival	O
from	O
onset	O
of	O
ESRD	B-Disease
.	O

RESULTS	O
:	O
At	O
13	O
years	O
after	O
OLTX	O
,	O
the	O
incidence	O
of	O
severe	O
renal	B-Disease
dysfunction	I-Disease
was	O
18	O
.	O
1	O
%	O
(	O
CRF	B-Disease
8	O
.	O
6	O
%	O
and	O
ESRD	B-Disease
9	O
.	O
5	O
%	O
)	O
.	O

Compared	O
with	O
control	O
patients	O
,	O
CRF	B-Disease
and	O
ESRD	B-Disease
patients	O
had	O
higher	O
preoperative	O
serum	O
creatinine	B-Chemical
levels	O
,	O
a	O
greater	O
percentage	O
of	O
patients	O
with	O
hepatorenal	B-Disease
syndrome	I-Disease
,	O
higher	O
percentage	O
requirement	O
for	O
dialysis	O
in	O
the	O
first	O
3	O
months	O
postoperatively	O
,	O
and	O
a	O
higher	O
1	O
-	O
year	O
serum	O
creatinine	B-Chemical
.	O

Multivariate	O
stepwise	O
logistic	O
regression	O
analysis	O
using	O
preoperative	O
and	O
postoperative	O
variables	O
identified	O
that	O
an	O
increase	O
of	O
serum	O
creatinine	B-Chemical
compared	O
with	O
average	O
at	O
1	O
year	O
,	O
3	O
months	O
,	O
and	O
4	O
weeks	O
postoperatively	O
were	O
independent	O
risk	O
factors	O
for	O
the	O
development	O
of	O
CRF	B-Disease
or	O
ESRD	B-Disease
with	O
odds	O
ratios	O
of	O
2	O
.	O
6	O
,	O
2	O
.	O
2	O
,	O
and	O
1	O
.	O
6	O
,	O
respectively	O
.	O

Overall	O
survival	O
from	O
the	O
time	O
of	O
OLTX	O
was	O
not	O
significantly	O
different	O
among	O
groups	O
,	O
but	O
by	O
year	O
13	O
,	O
the	O
survival	O
of	O
the	O
patients	O
who	O
had	O
ESRD	B-Disease
was	O
only	O
28	O
.	O
2	O
%	O
compared	O
with	O
54	O
.	O
6	O
%	O
in	O
the	O
control	O
group	O
.	O

Patients	O
developing	O
ESRD	B-Disease
had	O
a	O
6	O
-	O
year	O
survival	O
after	O
onset	O
of	O
ESRD	B-Disease
of	O
27	O
%	O
for	O
the	O
patients	O
receiving	O
hemodialysis	O
versus	O
71	O
.	O
4	O
%	O
for	O
the	O
patients	O
developing	O
ESRD	B-Disease
who	O
subsequently	O
received	O
kidney	O
transplants	O
.	O

CONCLUSIONS	O
:	O
Patients	O
who	O
are	O
more	O
than	O
10	O
years	O
post	O
-	O
OLTX	O
have	O
CRF	B-Disease
and	O
ESRD	B-Disease
at	O
a	O
high	O
rate	O
.	O

The	O
development	O
of	O
ESRD	B-Disease
decreases	O
survival	O
,	O
particularly	O
in	O
those	O
patients	O
treated	O
with	O
dialysis	O
only	O
.	O

Patients	O
who	O
develop	O
ESRD	B-Disease
have	O
a	O
higher	O
preoperative	O
and	O
1	O
-	O
year	O
serum	O
creatinine	B-Chemical
and	O
are	O
more	O
likely	O
to	O
have	O
hepatorenal	B-Disease
syndrome	I-Disease
.	O

However	O
,	O
an	O
increase	O
of	O
serum	O
creatinine	B-Chemical
at	O
various	O
times	O
postoperatively	O
is	O
more	O
predictive	O
of	O
the	O
development	O
of	O
CRF	B-Disease
or	O
ESRD	B-Disease
.	O

Epileptic	B-Disease
seizures	I-Disease
following	O
cortical	O
application	O
of	O
fibrin	O
sealants	O
containing	O
tranexamic	B-Chemical
acid	I-Chemical
in	O
rats	O
.	O

Recently	O
,	O
synthetic	O
fibrinolysis	O
inhibitors	O
such	O
as	O
tranexamic	B-Chemical
acid	I-Chemical
(	O
tAMCA	B-Chemical
)	O
have	O
been	O
considered	O
as	O
substitutes	O
for	O
aprotinin	O
.	O

However	O
,	O
tAMCA	B-Chemical
has	O
been	O
shown	O
to	O
cause	O
epileptic	B-Disease
seizures	I-Disease
.	O

We	O
wanted	O
to	O
study	O
whether	O
tAMCA	B-Chemical
retains	O
its	O
convulsive	B-Disease
action	O
if	O
incorporated	O
into	O
a	O
FS	O
.	O

METHOD	O
:	O
FS	O
containing	O
aprotinin	O
or	O
different	O
concentrations	O
of	O
tAMCA	B-Chemical
(	O
0	O
.	O
5	O
-	O
47	O
.	O
5	O
mg	O
/	O
ml	O
)	O
were	O
applied	O
to	O
the	O
pial	O
surface	O
of	O
the	O
cortex	O
of	O
anaesthetized	O
rats	O
.	O

FINDINGS	O
:	O
FS	O
containing	O
tAMCA	B-Chemical
caused	O
paroxysmal	O
brain	O
activity	O
which	O
was	O
associated	O
with	O
distinct	O
convulsive	B-Disease
behaviours	O
.	O

The	O
degree	O
of	O
these	O
seizures	B-Disease
increased	O
with	O
increasing	O
concentration	O
of	O
tAMCA	B-Chemical
.	O

Thus	O
,	O
FS	O
containing	O
47	O
.	O
5	O
mg	O
/	O
ml	O
tAMCA	B-Chemical
evoked	O
generalized	B-Disease
seizures	I-Disease
in	O
all	O
tested	O
rats	O
(	O
n	O
=	O
6	O
)	O
while	O
the	O
lowest	O
concentration	O
of	O
tAMCA	B-Chemical
(	O
0	O
.	O
5	O
mg	O
/	O
ml	O
)	O
only	O
evoked	O
brief	O
episodes	O
of	O
jerk	O
-	O
correlated	O
convulsive	B-Disease
potentials	O
in	O
1	O
of	O
6	O
rats	O
.	O

INTERPRETATION	O
:	O
Tranexamic	B-Chemical
acid	I-Chemical
retains	O
its	O
convulsive	B-Disease
action	O
within	O
FS	O
.	O

Thus	O
,	O
use	O
of	O
FS	O
containing	O
tAMCA	B-Chemical
for	O
surgery	O
within	O
or	O
close	O
to	O
the	O
CNS	O
may	O
pose	O
a	O
substantial	O
risk	O
to	O
the	O
patient	O
.	O

Sequential	O
observations	O
of	O
exencephaly	B-Disease
and	O
subsequent	O
morphological	O
changes	O
by	O
mouse	O
exo	O
utero	O
development	O
system	O
:	O
analysis	O
of	O
the	O
mechanism	O
of	O
transformation	O
from	O
exencephaly	B-Disease
to	O
anencephaly	B-Disease
.	O

Anencephaly	B-Disease
has	O
been	O
suggested	O
to	O
develop	O
from	O
exencephaly	B-Disease
;	O
however	O
,	O
there	O
is	O
little	O
direct	O
experimental	O
evidence	O
to	O
support	O
this	O
,	O
and	O
the	O
mechanism	O
of	O
transformation	O
remains	O
unclear	O
.	O

We	O
observed	O
the	O
exencephaly	B-Disease
induced	O
by	O
5	B-Chemical
-	I-Chemical
azacytidine	I-Chemical
at	O
embryonic	O
day	O
13	O
.	O
5	O
(	O
E13	O
.	O
5	O
)	O
,	O
let	O
the	O
embryos	O
develop	O
exo	O
utero	O
until	O
E18	O
.	O
5	O
,	O
and	O
re	O
-	O
observed	O
the	O
same	O
embryos	O
at	O
E18	O
.	O
5	O
.	O

We	O
confirmed	O
several	O
cases	O
of	O
transformation	O
from	O
exencephaly	B-Disease
to	O
anencephaly	B-Disease
.	O

However	O
,	O
in	O
many	O
cases	O
,	O
the	O
exencephalic	B-Disease
brain	O
tissue	O
was	O
preserved	O
with	O
more	O
or	O
less	O
reduction	O
during	O
this	O
period	O
.	O

To	O
analyze	O
the	O
transformation	O
patterns	O
,	O
we	O
classified	O
the	O
exencephaly	B-Disease
by	O
size	O
and	O
shape	O
of	O
the	O
exencephalic	B-Disease
tissue	O
into	O
several	O
types	O
at	O
E13	O
.	O
5	O
and	O
E18	O
.	O
5	O
.	O

It	O
was	O
found	O
that	O
the	O
transformation	O
of	O
exencephalic	B-Disease
tissue	O
was	O
not	O
simply	O
size	O
-	O
dependent	O
,	O
and	O
all	O
cases	O
of	O
anencephaly	B-Disease
at	O
E18	O
.	O
5	O
resulted	O
from	O
embryos	O
with	O
a	O
large	O
amount	O
of	O
exencephalic	B-Disease
tissue	O
at	O
E13	O
.	O
5	O
.	O

Microscopic	O
observation	O
showed	O
the	O
configuration	O
of	O
exencephaly	B-Disease
at	O
E13	O
.	O
5	O
,	O
frequent	O
hemorrhaging	B-Disease
and	O
detachment	O
of	O
the	O
neural	O
plate	O
from	O
surface	O
ectoderm	O
in	O
the	O
exencephalic	B-Disease
head	O
at	O
E15	O
.	O
5	O
,	O
and	O
multiple	O
modes	O
of	O
reduction	O
in	O
the	O
exencephalic	B-Disease
tissue	O
at	O
E18	O
.	O
5	O
.	O

From	O
observations	O
of	O
the	O
vasculature	O
,	O
altered	O
distribution	O
patterns	O
of	O
vessels	O
were	O
identified	O
in	O
the	O
exencephalic	B-Disease
head	O
.	O

These	O
findings	O
suggest	O
that	O
overgrowth	O
of	O
the	O
exencephalic	B-Disease
neural	O
tissue	O
causes	O
the	O
altered	O
distribution	O
patterns	O
of	O
vessels	O
,	O
subsequent	O
peripheral	O
circulatory	B-Disease
failure	I-Disease
and	O
/	O
or	O
hemorrhaging	B-Disease
in	O
various	O
parts	O
of	O
the	O
exencephalic	B-Disease
head	O
,	O
leading	O
to	O
the	O
multiple	O
modes	O
of	O
tissue	O
reduction	O
during	O
transformation	O
from	O
exencephaly	B-Disease
to	O
anencephaly	B-Disease
.	O

99mTc	B-Chemical
-	I-Chemical
glucarate	I-Chemical
for	O
detection	O
of	O
isoproterenol	B-Chemical
-	O
induced	O
myocardial	B-Disease
infarction	I-Disease
in	O
rats	O
.	O

Infarct	O
-	O
avid	O
radiopharmaceuticals	O
are	O
necessary	O
for	O
rapid	O
and	O
timely	O
diagnosis	O
of	O
acute	O
myocardial	B-Disease
infarction	I-Disease
.	O

The	O
animal	O
model	O
used	O
to	O
produce	O
infarction	B-Disease
implies	O
artery	O
ligation	O
but	O
chemical	O
induction	O
can	O
be	O
easily	O
obtained	O
with	O
isoproterenol	B-Chemical
.	O

A	O
new	O
infarct	B-Disease
-	O
avid	O
radiopharmaceutical	O
based	O
on	O
glucaric	B-Chemical
acid	I-Chemical
was	O
prepared	O
in	O
the	O
hospital	O
radiopharmacy	O
of	O
the	O
INCMNSZ	O
.	O

99mTc	B-Chemical
-	I-Chemical
glucarate	I-Chemical
was	O
easy	O
to	O
prepare	O
,	O
stable	O
for	O
96	O
h	O
and	O
was	O
used	O
to	O
study	O
its	O
biodistribution	O
in	O
rats	O
with	O
isoproterenol	B-Chemical
-	O
induced	O
acute	O
myocardial	B-Disease
infarction	I-Disease
.	O

Histological	O
studies	O
demonstrated	O
that	O
the	O
rats	O
developed	O
an	O
infarct	B-Disease
18	O
h	O
after	O
isoproterenol	B-Chemical
administration	O
.	O

Thirty	O
minutes	O
after	O
99mTc	B-Chemical
-	I-Chemical
glucarate	I-Chemical
administration	O
the	O
standardised	O
heart	O
uptake	O
value	O
S	O
(	O
h	O
)	O
UV	O
was	O
4	O
.	O
7	O
in	O
infarcted	O
rat	O
heart	O
which	O
is	O
six	O
times	O
more	O
than	O
in	O
normal	O
rats	O
.	O

The	O
high	O
image	O
quality	O
suggests	O
that	O
high	O
contrast	O
images	O
can	O
be	O
obtained	O
in	O
humans	O
and	O
the	O
96	O
h	O
stability	O
makes	O
it	O
an	O
ideal	O
agent	O
to	O
detect	O
,	O
in	O
patients	O
,	O
early	O
cardiac	B-Disease
infarction	I-Disease
.	O

Bupropion	B-Chemical
(	O
Zyban	B-Chemical
)	O
toxicity	B-Disease
.	O

Bupropion	B-Chemical
is	O
a	O
monocyclic	O
antidepressant	B-Chemical
structurally	O
related	O
to	O
amphetamine	B-Chemical
.	O

Zyban	B-Chemical
,	O
a	O
sustained	O
-	O
release	O
formulation	O
of	O
bupropion	B-Chemical
hydrochloride	I-Chemical
,	O
was	O
recently	O
released	O
in	O
Ireland	O
,	O
as	O
a	O
smoking	O
cessation	O
aid	O
.	O

In	O
the	O
initial	O
6	O
months	O
since	O
it	O
'	O
s	O
introduction	O
,	O
12	O
overdose	B-Disease
cases	O
have	O
been	O
reported	O
to	O
The	O
National	O
Poisons	O
Information	O
Centre	O
.	O

8	O
patients	O
developed	O
symptoms	O
of	O
toxicity	B-Disease
.	O

Common	O
features	O
included	O
tachycardia	B-Disease
,	O
drowsiness	O
,	O
hallucinations	B-Disease
and	O
convulsions	B-Disease
.	O

Two	O
patients	O
developed	O
severe	O
cardiac	B-Disease
arrhythmias	I-Disease
,	O
including	O
one	O
patient	O
who	O
was	O
resuscitated	O
following	O
a	O
cardiac	B-Disease
arrest	I-Disease
.	O

We	O
report	O
a	O
case	O
of	O
a	O
31	O
year	O
old	O
female	O
who	O
required	O
admission	O
to	O
the	O
Intensive	O
Care	O
Unit	O
for	O
ventilation	O
and	O
full	O
supportive	O
therapy	O
,	O
following	O
ingestion	O
of	O
13	O
.	O
5g	O
bupropion	B-Chemical
.	O

Recurrent	O
seizures	B-Disease
were	O
treated	O
with	O
diazepam	B-Chemical
and	O
broad	O
complex	O
tachycardia	B-Disease
was	O
successfully	O
treated	O
with	O
adenosine	B-Chemical
.	O

Zyban	B-Chemical
caused	O
significant	O
neurological	B-Disease
and	I-Disease
cardiovascular	I-Disease
toxicity	I-Disease
in	O
overdose	B-Disease
.	O

GLEPP1	O
receptor	O
tyrosine	B-Chemical
phosphatase	O
(	O
Ptpro	O
)	O
in	O
rat	O
PAN	B-Chemical
nephrosis	B-Disease
.	O

Glomerular	O
epithelial	O
protein	O
1	O
(	O
GLEPP1	O
)	O
is	O
a	O
podocyte	O
receptor	O
membrane	O
protein	O
tyrosine	B-Chemical
phosphatase	O
located	O
on	O
the	O
apical	O
cell	O
membrane	O
of	O
visceral	O
glomerular	O
epithelial	O
cell	O
and	O
foot	O
processes	O
.	O

To	O
better	O
understand	O
the	O
utility	O
of	O
GLEPP1	O
as	O
a	O
marker	O
of	O
glomerular	B-Disease
injury	I-Disease
,	O
the	O
amount	O
and	O
distribution	O
of	O
GLEPP1	O
protein	O
and	O
mRNA	O
were	O
examined	O
by	O
immunohistochemistry	O
,	O
Western	O
blot	O
and	O
RNase	O
protection	O
assay	O
in	O
a	O
model	O
of	O
podocyte	O
injury	O
in	O
the	O
rat	O
.	O

Puromycin	B-Chemical
aminonucleoside	I-Chemical
nephrosis	B-Disease
was	O
induced	O
by	O
single	O
intraperitoneal	O
injection	O
of	O
puromycin	B-Chemical
aminonucleoside	I-Chemical
(	O
PAN	B-Chemical
,	O
20	O
mg	O
/	O
100g	O
BW	O
)	O
.	O

Tissues	O
were	O
analyzed	O
at	O
0	O
,	O
5	O
,	O
7	O
,	O
11	O
,	O
21	O
,	O
45	O
,	O
80	O
and	O
126	O
days	O
after	O
PAN	B-Chemical
injection	O
so	O
as	O
to	O
include	O
both	O
the	O
acute	O
phase	O
of	O
proteinuria	B-Disease
associated	O
with	O
foot	O
process	O
effacement	O
(	O
days	O
5	O
-	O
11	O
)	O
and	O
the	O
chronic	O
phase	O
of	O
proteinuria	B-Disease
associated	O
with	O
glomerulosclerosis	B-Disease
(	O
days	O
45	O
-	O
126	O
)	O
.	O

We	O
conclude	O
that	O
GLEPP1	O
expression	O
,	O
unlike	O
podocalyxin	O
,	O
reflects	O
podocyte	O
injury	O
induced	O
by	O
PAN	B-Chemical
.	O

Antithymocyte	B-Chemical
globulin	I-Chemical
in	O
the	O
treatment	O
of	O
D	B-Chemical
-	I-Chemical
penicillamine	I-Chemical
-	O
induced	O
aplastic	B-Disease
anemia	I-Disease
.	O

A	O
patient	O
who	O
received	O
antithymocyte	B-Chemical
globulin	I-Chemical
therapy	O
for	O
aplastic	B-Disease
anemia	I-Disease
due	O
to	O
D	B-Chemical
-	I-Chemical
penicillamine	I-Chemical
therapy	O
is	O
described	O
.	O

Use	O
of	O
antithymocyte	B-Chemical
globulin	I-Chemical
may	O
be	O
the	O
optimal	O
treatment	O
of	O
D	B-Chemical
-	I-Chemical
penicillamine	I-Chemical
-	O
induced	O
aplastic	B-Disease
anemia	I-Disease
.	O

Metamizol	B-Chemical
potentiates	O
morphine	B-Chemical
antinociception	O
but	O
not	O
constipation	B-Disease
after	O
chronic	O
treatment	O
.	O

This	O
work	O
evaluates	O
the	O
antinociceptive	O
and	O
constipating	B-Disease
effects	O
of	O
the	O
combination	O
of	O
3	O
.	O
2	O
mg	O
/	O
kg	O
s	O
.	O
c	O
.	O
morphine	B-Chemical
with	O
177	O
.	O
8	O
mg	O
/	O
kg	O
s	O
.	O
c	O
.	O
metamizol	B-Chemical
in	O
acutely	O
and	O
chronically	O
treated	O
(	O
once	O
a	O
day	O
for	O
12	O
days	O
)	O
rats	O
.	O

On	O
the	O
13th	O
day	O
,	O
antinociceptive	O
effects	O
were	O
assessed	O
using	O
a	O
model	O
of	O
inflammatory	O
nociception	O
,	O
pain	B-Disease
-	O
induced	O
functional	O
impairment	O
model	O
,	O
and	O
the	O
charcoal	B-Chemical
meal	O
test	O
was	O
used	O
to	O
evaluate	O
the	O
intestinal	O
transit	O
.	O

Simultaneous	O
administration	O
of	O
morphine	B-Chemical
with	O
metamizol	B-Chemical
resulted	O
in	O
a	O
markedly	O
antinociceptive	O
potentiation	O
and	O
an	O
increasing	O
of	O
the	O
duration	O
of	O
action	O
after	O
a	O
single	O
(	O
298	O
+	O
/	O
-	O
7	O
vs	O
.	O
139	O
+	O
/	O
-	O
36	O
units	O
area	O
(	O
ua	O
)	O
;	O
P	O
<	O
0	O
.	O
001	O
)	O
and	O
repeated	O
administration	O
(	O
280	O
+	O
/	O
-	O
17	O
vs	O
.	O
131	O
+	O
/	O
-	O
22	O
ua	O
;	O
P	O
<	O
0	O
.	O
001	O
)	O
.	O

Antinociceptive	O
effect	O
of	O
morphine	B-Chemical
was	O
reduced	O
in	O
chronically	O
treated	O
rats	O
(	O
39	O
+	O
/	O
-	O
10	O
vs	O
.	O
18	O
+	O
/	O
-	O
5	O
au	O
)	O
while	O
the	O
combination	O
-	O
induced	O
antinociception	O
was	O
remained	O
similar	O
as	O
an	O
acute	O
treatment	O
(	O
298	O
+	O
/	O
-	O
7	O
vs	O
.	O
280	O
+	O
/	O
-	O
17	O
au	O
)	O
.	O

Acute	O
antinociceptive	O
effects	O
of	O
the	O
combination	O
were	O
partially	O
prevented	O
by	O
3	O
.	O
2	O
mg	O
/	O
kg	O
naloxone	B-Chemical
s	O
.	O
c	O
.	O

In	O
independent	O
groups	O
,	O
morphine	B-Chemical
inhibited	O
the	O
intestinal	O
transit	O
in	O
48	O
+	O
/	O
-	O
4	O
%	O
and	O
38	O
+	O
/	O
-	O
4	O
%	O
after	O
acute	O
and	O
chronic	O
treatment	O
,	O
respectively	O
,	O
suggesting	O
that	O
tolerance	O
did	O
not	O
develop	O
to	O
the	O
constipating	B-Disease
effects	O
.	O

The	O
combination	O
inhibited	O
intestinal	O
transit	O
similar	O
to	O
that	O
produced	O
by	O
morphine	B-Chemical
regardless	O
of	O
the	O
time	O
of	O
treatment	O
,	O
suggesting	O
that	O
metamizol	B-Chemical
did	O
not	O
potentiate	O
morphine	B-Chemical
-	O
induced	O
constipation	B-Disease
.	O

These	O
findings	O
show	O
a	O
significant	O
interaction	O
between	O
morphine	B-Chemical
and	O
metamizol	B-Chemical
in	O
chronically	O
treated	O
rats	O
,	O
suggesting	O
that	O
this	O
combination	O
could	O
be	O
useful	O
for	O
the	O
treatment	O
of	O
chronic	B-Disease
pain	I-Disease
.	O

Ifosfamide	B-Chemical
encephalopathy	B-Disease
presenting	O
with	O
asterixis	B-Disease
.	O

CNS	O
toxic	O
effects	O
of	O
the	O
antineoplastic	O
agent	O
ifosfamide	B-Chemical
(	O
IFX	B-Chemical
)	O
are	O
frequent	O
and	O
include	O
a	O
variety	O
of	O
neurological	O
symptoms	O
that	O
can	O
limit	O
drug	O
use	O
.	O

We	O
report	O
a	O
case	O
of	O
a	O
51	O
-	O
year	O
-	O
old	O
man	O
who	O
developed	O
severe	O
,	O
disabling	O
negative	O
myoclonus	B-Disease
of	O
the	O
upper	O
and	O
lower	O
extremities	O
after	O
the	O
infusion	O
of	O
ifosfamide	B-Chemical
for	O
plasmacytoma	B-Disease
.	O

Cranial	O
magnetic	O
resonance	O
imaging	O
and	O
extensive	O
laboratory	O
studies	O
failed	O
to	O
reveal	O
structural	B-Disease
lesions	I-Disease
of	I-Disease
the	I-Disease
brain	I-Disease
and	O
metabolic	B-Disease
abnormalities	I-Disease
.	O

An	O
electroencephalogram	O
showed	O
continuous	O
,	O
generalized	O
irregular	O
slowing	O
with	O
admixed	O
periodic	O
triphasic	O
waves	O
indicating	O
symptomatic	O
encephalopathy	B-Disease
.	O

The	O
administration	O
of	O
ifosfamide	B-Chemical
was	O
discontinued	O
and	O
within	O
12	O
h	O
the	O
asterixis	B-Disease
resolved	O
completely	O
.	O

In	O
the	O
patient	O
described	O
,	O
the	O
presence	O
of	O
asterixis	B-Disease
during	O
infusion	O
of	O
ifosfamide	B-Chemical
,	O
normal	O
laboratory	O
findings	O
and	O
imaging	O
studies	O
and	O
the	O
resolution	O
of	O
symptoms	O
following	O
the	O
discontinuation	O
of	O
the	O
drug	O
suggest	O
that	O
negative	O
myoclonus	B-Disease
is	O
associated	O
with	O
the	O
use	O
of	O
IFX	B-Chemical
.	O

Antagonism	O
between	O
interleukin	O
3	O
and	O
erythropoietin	O
in	O
mice	O
with	O
azidothymidine	B-Chemical
-	O
induced	O
anemia	B-Disease
and	O
in	O
bone	O
marrow	O
endothelial	O
cells	O
.	O

Azidothymidine	B-Chemical
(	O
AZT	B-Chemical
)	O
-	O
induced	O
anemia	B-Disease
in	O
mice	O
can	O
be	O
reversed	O
by	O
the	O
administration	O
of	O
IGF	O
-	O
IL	O
-	O
3	O
(	O
fusion	O
protein	O
of	O
insulin	O
-	O
like	O
growth	O
factor	O
II	O
(	O
IGF	O
II	O
)	O
and	O
interleukin	O
3	O
)	O
.	O

Although	O
interleukin	O
3	O
(	O
IL	O
-	O
3	O
)	O
and	O
erythropoietin	O
(	O
EPO	O
)	O
are	O
known	O
to	O
act	O
synergistically	O
on	O
hematopoietic	O
cell	O
proliferation	O
in	O
vitro	O
,	O
injection	O
of	O
IGF	O
-	O
IL	O
-	O
3	O
and	O
EPO	O
in	O
AZT	B-Chemical
-	O
treated	O
mice	O
resulted	O
in	O
a	O
reduction	O
of	O
red	O
cells	O
and	O
an	O
increase	O
of	O
plasma	O
EPO	O
levels	O
as	O
compared	O
to	O
animals	O
treated	O
with	O
IGF	O
-	O
IL	O
-	O
3	O
or	O
EPO	O
alone	O
.	O

There	O
was	O
a	O
significant	O
reduction	O
of	O
thymidine	B-Chemical
incorporation	O
into	O
both	O
erythroid	O
and	O
endothelial	O
cells	O
in	O
cultures	O
pre	O
-	O
treated	O
with	O
IGF	O
-	O
IL	O
-	O
3	O
and	O
EPO	O
.	O

Endothelial	O
cell	O
culture	O
supernatants	O
separated	O
by	O
ultrafiltration	O
and	O
ultracentrifugation	O
from	O
cells	O
treated	O
with	O
EPO	O
and	O
IL	O
-	O
3	O
significantly	O
reduced	O
thymidine	B-Chemical
incorporation	O
into	O
erythroid	O
cells	O
as	O
compared	O
to	O
identical	O
fractions	O
obtained	O
from	O
the	O
media	O
of	O
cells	O
cultured	O
with	O
EPO	O
alone	O
.	O

The	O
relationship	O
between	O
hippocampal	O
acetylcholine	O
release	O
and	O
cholinergic	O
convulsant	O
sensitivity	O
in	O
withdrawal	O
seizure	B-Disease
-	O
prone	O
and	O
withdrawal	O
seizure	B-Disease
-	O
resistant	O
selected	O
mouse	O
lines	O
.	O

BACKGROUND	O
:	O
The	O
septo	O
-	O
hippocampal	O
cholinergic	O
pathway	O
has	O
been	O
implicated	O
in	O
epileptogenesis	O
,	O
and	O
genetic	O
factors	O
influence	O
the	O
response	O
to	O
cholinergic	O
agents	O
,	O
but	O
limited	O
data	O
are	O
available	O
on	O
cholinergic	O
involvement	O
in	O
alcohol	B-Chemical
withdrawal	O
severity	O
.	O

Thus	O
,	O
the	O
relationship	O
between	O
cholinergic	O
activity	O
and	O
responsiveness	O
and	O
alcohol	B-Chemical
withdrawal	O
was	O
investigated	O
in	O
a	O
genetic	O
animal	O
model	O
of	O
ethanol	B-Chemical
withdrawal	O
severity	O
.	O

METHODS	O
:	O
Cholinergic	O
convulsant	O
sensitivity	O
was	O
examined	O
in	O
alcohol	B-Chemical
-	O
na	O
ve	O
Withdrawal	O
Seizure	B-Disease
-	O
Prone	O
(	O
WSP	O
)	O
and	O
-	O
Resistant	O
(	O
WSR	O
)	O
mice	O
.	O

Animals	O
were	O
administered	O
nicotine	B-Chemical
,	O
carbachol	B-Chemical
,	O
or	O
neostigmine	B-Chemical
via	O
timed	O
tail	O
vein	O
infusion	O
,	O
and	O
the	O
latencies	O
to	O
onset	O
of	O
tremor	B-Disease
and	O
clonus	O
were	O
recorded	O
and	O
converted	O
to	O
threshold	O
dose	O
.	O

We	O
also	O
used	O
microdialysis	O
to	O
measure	O
basal	O
and	O
potassium	B-Chemical
-	O
stimulated	O
acetylcholine	B-Chemical
(	O
ACh	B-Chemical
)	O
release	O
in	O
the	O
CA1	O
region	O
of	O
the	O
hippocampus	O
.	O

Potassium	B-Chemical
was	O
applied	O
by	O
reverse	O
dialysis	O
twice	O
,	O
separated	O
by	O
75	O
min	O
.	O

Hippocampal	O
ACh	B-Chemical
also	O
was	O
measured	O
during	O
testing	O
for	O
handling	O
-	O
induced	O
convulsions	B-Disease
.	O

RESULTS	O
:	O
Sensitivity	O
to	O
several	O
convulsion	B-Disease
endpoints	O
induced	O
by	O
nicotine	B-Chemical
,	O
carbachol	B-Chemical
,	O
and	O
neostigmine	B-Chemical
were	O
significantly	O
greater	O
in	O
WSR	O
versus	O
WSP	O
mice	O
.	O

In	O
microdialysis	O
experiments	O
,	O
the	O
lines	O
did	O
not	O
differ	O
in	O
basal	O
release	O
of	O
ACh	B-Chemical
,	O
and	O
50	O
mM	O
KCl	B-Chemical
increased	O
ACh	B-Chemical
output	O
in	O
both	O
lines	O
of	O
mice	O
.	O

However	O
,	O
the	O
increase	O
in	O
release	O
of	O
ACh	B-Chemical
produced	O
by	O
the	O
first	O
application	O
of	O
KCl	B-Chemical
was	O
2	O
-	O
fold	O
higher	O
in	O
WSP	O
versus	O
WSR	O
mice	O
.	O

When	O
hippocampal	O
ACh	B-Chemical
was	O
measured	O
during	O
testing	O
for	O
handling	O
-	O
induced	O
convulsions	B-Disease
,	O
extracellular	O
ACh	B-Chemical
was	O
significantly	O
elevated	O
(	O
192	O
%	O
)	O
in	O
WSP	O
mice	O
,	O
but	O
was	O
nonsignificantly	O
elevated	O
(	O
59	O
%	O
)	O
in	O
WSR	O
mice	O
.	O

CONCLUSIONS	O
:	O
These	O
results	O
suggest	O
that	O
differences	O
in	O
cholinergic	O
activity	O
and	O
postsynaptic	O
sensitivity	O
to	O
cholinergic	O
convulsants	B-Disease
may	O
be	O
associated	O
with	O
ethanol	B-Chemical
withdrawal	O
severity	O
and	O
implicate	O
cholinergic	O
mechanisms	O
in	O
alcohol	B-Chemical
withdrawal	O
.	O

Specifically	O
,	O
WSP	O
mice	O
may	O
have	O
lower	O
sensitivity	O
to	O
cholinergic	O
convulsants	B-Disease
compared	O
with	O
WSR	O
because	O
of	O
postsynaptic	O
receptor	O
desensitization	O
brought	O
on	O
by	O
higher	O
activity	O
of	O
cholinergic	O
neurons	O
.	O

Capsaicin	B-Chemical
-	O
induced	O
muscle	B-Disease
pain	I-Disease
alters	O
the	O
excitability	O
of	O
the	O
human	O
jaw	O
-	O
stretch	O
reflex	O
.	O

The	O
pathophysiology	O
of	O
painful	O
temporomandibular	B-Disease
disorders	I-Disease
is	O
not	O
fully	O
understood	O
,	O
but	O
evidence	O
suggests	O
that	O
muscle	B-Disease
pain	I-Disease
modulates	O
motor	O
function	O
in	O
characteristic	O
ways	O
.	O

Capsaicin	B-Chemical
(	O
10	O
micro	O
g	O
)	O
was	O
injected	O
into	O
the	O
masseter	O
muscle	O
to	O
induce	O
pain	B-Disease
in	O
11	O
healthy	O
volunteers	O
.	O

Short	O
-	O
latency	O
reflex	O
responses	O
were	O
evoked	O
in	O
the	O
masseter	O
and	O
temporalis	O
muscles	O
by	O
a	O
stretch	O
device	O
with	O
different	O
velocities	O
and	O
displacements	O
before	O
,	O
during	O
,	O
and	O
after	O
the	O
pain	B-Disease
.	O

The	O
normalized	O
reflex	O
amplitude	O
was	O
significantly	O
higher	O
during	O
pain	B-Disease
,	O
but	O
only	O
at	O
faster	O
stretches	O
in	O
the	O
painful	B-Disease
muscle	I-Disease
.	O

Increased	O
sensitivity	O
of	O
the	O
fusimotor	O
system	O
during	O
acute	O
muscle	B-Disease
pain	I-Disease
could	O
be	O
one	O
likely	O
mechanism	O
to	O
explain	O
the	O
findings	O
.	O

Effects	O
of	O
5	O
-	O
HT1B	O
receptor	O
ligands	O
microinjected	O
into	O
the	O
accumbal	O
shell	O
or	O
core	O
on	O
the	O
cocaine	B-Chemical
-	O
induced	O
locomotor	B-Disease
hyperactivity	I-Disease
in	O
rats	O
.	O

The	O
present	O
study	O
was	O
designed	O
to	O
examine	O
the	O
effect	O
of	O
5	O
-	O
HT1B	O
receptor	O
ligands	O
microinjected	O
into	O
the	O
subregions	O
of	O
the	O
nucleus	O
accumbens	O
(	O
the	O
shell	O
and	O
the	O
core	O
)	O
on	O
the	O
locomotor	B-Disease
hyperactivity	I-Disease
induced	O
by	O
cocaine	B-Chemical
in	O
rats	O
.	O

Male	O
Wistar	O
rats	O
were	O
implanted	O
bilaterally	O
with	O
cannulae	O
into	O
the	O
accumbens	O
shell	O
or	O
core	O
,	O
and	O
then	O
were	O
locally	O
injected	O
with	O
GR	B-Chemical
55562	I-Chemical
(	O
an	O
antagonist	O
of	O
5	O
-	O
HT1B	O
receptors	O
)	O
or	O
CP	B-Chemical
93129	I-Chemical
(	O
an	O
agonist	O
of	O
5	O
-	O
HT1B	O
receptors	O
)	O
.	O

Given	O
alone	O
to	O
any	O
accumbal	O
subregion	O
,	O
GR	B-Chemical
55562	I-Chemical
(	O
0	O
.	O
1	O
-	O
10	O
microg	O
/	O
side	O
)	O
or	O
CP	B-Chemical
93129	I-Chemical
(	O
0	O
.	O
1	O
-	O
10	O
microg	O
/	O
side	O
)	O
did	O
not	O
change	O
basal	O
locomotor	O
activity	O
.	O

Systemic	O
cocaine	B-Chemical
(	O
10	O
mg	O
/	O
kg	O
)	O
significantly	O
increased	O
the	O
locomotor	O
activity	O
of	O
rats	O
.	O

GR	B-Chemical
55562	I-Chemical
(	O
0	O
.	O
1	O
-	O
10	O
microg	O
/	O
side	O
)	O
,	O
administered	O
intra	O
-	O
accumbens	O
shell	O
prior	O
to	O
cocaine	B-Chemical
,	O
dose	O
-	O
dependently	O
attenuated	O
the	O
psychostimulant	O
-	O
induced	O
locomotor	B-Disease
hyperactivity	I-Disease
.	O

Such	O
attenuation	O
was	O
not	O
found	O
in	O
animals	O
which	O
had	O
been	O
injected	O
with	O
GR	B-Chemical
55562	I-Chemical
into	O
the	O
accumbens	O
core	O
.	O

When	O
injected	O
into	O
the	O
accumbens	O
shell	O
(	O
but	O
not	O
the	O
core	O
)	O
before	O
cocaine	B-Chemical
,	O
CP	B-Chemical
93129	I-Chemical
(	O
0	O
.	O
1	O
-	O
10	O
microg	O
/	O
side	O
)	O
enhanced	O
the	O
locomotor	O
response	O
to	O
cocaine	B-Chemical
;	O
the	O
maximum	O
effect	O
being	O
observed	O
after	O
10	O
microg	O
/	O
side	O
of	O
the	O
agonist	O
.	O

The	O
later	O
enhancement	O
was	O
attenuated	O
after	O
intra	O
-	O
accumbens	O
shell	O
treatment	O
with	O
GR	B-Chemical
55562	I-Chemical
(	O
1	O
microg	O
/	O
side	O
)	O
.	O

Our	O
findings	O
indicate	O
that	O
cocaine	B-Chemical
induced	O
hyperlocomotion	B-Disease
is	O
modified	O
by	O
5	O
-	O
HT1B	O
receptor	O
ligands	O
microinjected	O
into	O
the	O
accumbens	O
shell	O
,	O
but	O
not	O
core	O
,	O
this	O
modification	O
consisting	O
in	O
inhibitory	O
and	O
facilitatory	O
effects	O
of	O
the	O
5	O
-	O
HT1B	O
receptor	O
antagonist	O
(	O
GR	B-Chemical
55562	I-Chemical
)	O
and	O
agonist	O
(	O
CP	B-Chemical
93129	I-Chemical
)	O
,	O
respectively	O
.	O

Cocaine	B-Chemical
related	O
chest	B-Disease
pain	I-Disease
:	O
are	O
we	O
seeing	O
the	O
tip	O
of	O
an	O
iceberg	O
?	O

The	O
recreational	O
use	O
of	O
cocaine	B-Chemical
is	O
on	O
the	O
increase	O
.	O

The	O
emergency	O
nurse	O
ought	O
to	O
be	O
familiar	O
with	O
some	O
of	O
the	O
cardiovascular	O
consequences	O
of	O
cocaine	B-Chemical
use	O
.	O

In	O
particular	O
,	O
the	O
tendency	O
of	O
cocaine	B-Chemical
to	O
produce	O
chest	B-Disease
pain	I-Disease
ought	O
to	O
be	O
in	O
the	O
mind	O
of	O
the	O
emergency	O
nurse	O
when	O
faced	O
with	O
a	O
young	O
victim	O
of	O
chest	B-Disease
pain	I-Disease
who	O
is	O
otherwise	O
at	O
low	O
risk	O
.	O

The	O
mechanism	O
of	O
chest	B-Disease
pain	I-Disease
related	O
to	O
cocaine	B-Chemical
use	O
is	O
discussed	O
and	O
treatment	O
dilemmas	O
are	O
discussed	O
.	O

Finally	O
,	O
moral	O
issues	O
relating	O
to	O
the	O
testing	O
of	O
potential	O
cocaine	B-Chemical
users	O
will	O
be	O
addressed	O
.	O

Crossover	O
comparison	O
of	O
efficacy	O
and	O
preference	O
for	O
rizatriptan	B-Chemical
10	O
mg	O
versus	O
ergotamine	B-Chemical
/	O
caffeine	B-Chemical
in	O
migraine	B-Disease
.	O

Rizatriptan	B-Chemical
is	O
a	O
selective	O
5	B-Chemical
-	I-Chemical
HT	I-Chemical
(	O
1B	O
/	O
1D	O
)	O
receptor	O
agonist	O
with	O
rapid	O
oral	O
absorption	O
and	O
early	O
onset	O
of	O
action	O
in	O
the	O
acute	O
treatment	O
of	O
migraine	B-Disease
.	O

This	O
randomized	O
double	O
-	O
blind	O
crossover	O
outpatient	O
study	O
assessed	O
the	O
preference	O
for	O
1	O
rizatriptan	B-Chemical
10	O
mg	O
tablet	O
to	O
2	O
ergotamine	B-Chemical
1	O
mg	O
/	O
caffeine	B-Chemical
100	O
mg	O
tablets	O
in	O
439	O
patients	O
treating	O
a	O
single	O
migraine	B-Disease
attack	O
with	O
each	O
therapy	O
.	O

Of	O
patients	O
expressing	O
a	O
preference	O
(	O
89	O
.	O
1	O
%	O
)	O
,	O
more	O
than	O
twice	O
as	O
many	O
preferred	O
rizatriptan	B-Chemical
to	O
ergotamine	B-Chemical
/	O
caffeine	B-Chemical
(	O
69	O
.	O
9	O
vs	O
.	O
30	O
.	O
1	O
%	O
,	O
p	O
<	O
or	O
=	O
0	O
.	O
001	O
)	O
.	O

Faster	O
relief	O
of	O
headache	B-Disease
was	O
the	O
most	O
important	O
reason	O
for	O
preference	O
,	O
cited	O
by	O
67	O
.	O
3	O
%	O
of	O
patients	O
preferring	O
rizatriptan	O
and	O
54	O
.	O
2	O
%	O
of	O
patients	O
who	O
preferred	O
ergotamine	B-Chemical
/	O
caffeine	B-Chemical
.	O

The	O
co	O
-	O
primary	O
endpoint	O
of	O
being	O
pain	B-Disease
free	O
at	O
2	O
h	O
was	O
also	O
in	O
favor	O
of	O
rizatriptan	O
.	O

Forty	O
-	O
nine	O
percent	O
of	O
patients	O
were	O
pain	B-Disease
free	O
2	O
h	O
after	O
rizatriptan	B-Chemical
,	O
compared	O
with	O
24	O
.	O
3	O
%	O
treated	O
with	O
ergotamine	B-Chemical
/	O
caffeine	B-Chemical
(	O
p	O
<	O
or	O
=	O
0	O
.	O
001	O
)	O
,	O
rizatriptan	B-Chemical
being	O
superior	O
within	O
1	O
h	O
of	O
treatment	O
.	O

Headache	B-Disease
relief	O
at	O
2	O
h	O
was	O
75	O
.	O
9	O
%	O
for	O
rizatriptan	B-Chemical
and	O
47	O
.	O
3	O
%	O
for	O
ergotamine	B-Chemical
/	O
caffeine	B-Chemical
(	O
p	O
<	O
or	O
=	O
0	O
.	O
001	O
)	O
,	O
with	O
rizatriptan	B-Chemical
being	O
superior	O
to	O
ergotamine	B-Chemical
/	O
caffeine	B-Chemical
within	O
30	O
min	O
of	O
dosing	O
.	O

Almost	O
36	O
%	O
of	O
patients	O
taking	O
rizatriptan	B-Chemical
were	O
pain	B-Disease
free	O
at	O
2	O
h	O
and	O
had	O
no	O
recurrence	O
or	O
need	O
for	O
additional	O
medication	O
within	O
24	O
h	O
,	O
compared	O
to	O
20	O
%	O
of	O
patients	O
on	O
ergotamine	B-Chemical
/	O
caffeine	B-Chemical
(	O
p	O
<	O
or	O
=	O
0	O
.	O
001	O
)	O
.	O

Rizatriptan	B-Chemical
was	O
also	O
superior	O
to	O
ergotamine	B-Chemical
/	O
caffeine	B-Chemical
in	O
the	O
proportions	O
of	O
patients	O
with	O
no	O
nausea	B-Disease
,	O
vomiting	O
,	O
phonophobia	B-Disease
or	O
photophobia	B-Disease
and	O
for	O
patients	O
with	O
normal	O
function	O
2	O
h	O
after	O
drug	O
intake	O
(	O
p	O
<	O
or	O
=	O
0	O
.	O
001	O
)	O
.	O

More	O
patients	O
were	O
(	O
completely	O
,	O
very	O
or	O
somewhat	O
)	O
satisfied	O
2	O
h	O
after	O
treatment	O
with	O
rizatriptan	B-Chemical
(	O
69	O
.	O
8	O
%	O
)	O
than	O
at	O
2	O
h	O
after	O
treatment	O
with	O
ergotamine	B-Chemical
/	O
caffeine	B-Chemical
(	O
38	O
.	O
6	O
%	O
,	O
p	O
<	O
or	O
=	O
0	O
.	O
001	O
)	O
.	O

Recurrence	O
rates	O
were	O
31	O
.	O
4	O
%	O
with	O
rizatriptan	B-Chemical
and	O
15	O
.	O
3	O
%	O
with	O
ergotamine	B-Chemical
/	O
caffeine	B-Chemical
.	O

The	O
most	O
common	O
adverse	O
events	O
(	O
incidence	O
>	O
or	O
=	O
5	O
%	O
in	O
one	O
group	O
)	O
after	O
rizatriptan	B-Chemical
and	O
ergotamine	B-Chemical
/	O
caffeine	B-Chemical
,	O
respectively	O
,	O
were	O
dizziness	B-Disease
(	O
6	O
.	O
7	O
and	O
5	O
.	O
3	O
%	O
)	O
,	O
nausea	B-Disease
(	O
4	O
.	O
2	O
and	O
8	O
.	O
5	O
%	O
)	O
and	O
somnolence	B-Disease
(	O
5	O
.	O
5	O
and	O
2	O
.	O
3	O
%	O
)	O
.	O

Severe	O
ocular	B-Disease
and	I-Disease
orbital	I-Disease
toxicity	I-Disease
after	O
intracarotid	O
injection	O
of	O
carboplatin	B-Chemical
for	O
recurrent	O
glioblastomas	B-Disease
.	O

BACKGROUND	O
:	O
Glioblastoma	B-Disease
is	O
a	O
malignant	B-Disease
tumor	I-Disease
that	O
occurs	O
in	O
the	O
cerebrum	O
during	O
adulthood	O
.	O

Therefore	O
,	O
patients	O
with	O
glioblastoma	B-Disease
sometimes	O
have	O
intracarotid	O
injection	O
of	O
carcinostatics	O
added	O
to	O
the	O
treatment	O
regimen	O
.	O

Generally	O
,	O
carboplatin	B-Chemical
is	O
said	O
to	O
have	O
milder	O
side	O
effects	O
than	O
cisplatin	O
,	O
whose	O
ocular	B-Disease
and	I-Disease
orbital	I-Disease
toxicity	I-Disease
are	O
well	O
known	O
.	O

However	O
,	O
we	O
experienced	O
a	O
case	O
of	O
severe	O
ocular	B-Disease
and	I-Disease
orbital	I-Disease
toxicity	I-Disease
after	O
intracarotid	O
injection	O
of	O
carboplatin	B-Chemical
,	O
which	O
is	O
infrequently	O
reported	O
.	O

CASE	O
:	O
A	O
58	O
-	O
year	O
-	O
old	O
man	O
received	O
an	O
intracarotid	O
injection	O
of	O
carboplatin	B-Chemical
for	O
recurrent	O
glioblastomas	B-Disease
in	O
his	O
left	O
temporal	O
lobe	O
.	O

He	O
complained	O
of	O
pain	B-Disease
and	I-Disease
visual	I-Disease
disturbance	I-Disease
in	I-Disease
the	I-Disease
ipsilateral	I-Disease
eye	I-Disease
30	O
h	O
after	O
the	O
injection	O
.	O

Various	O
ocular	O
symptoms	O
and	O
findings	O
caused	O
by	O
carboplatin	B-Chemical
toxicity	B-Disease
were	O
seen	O
.	O

RESULTS	O
:	O
He	O
was	O
treated	O
with	O
intravenous	O
administration	O
of	O
corticosteroids	O
and	O
glycerin	B-Chemical
for	O
6	O
days	O
after	O
the	O
injection	O
.	O

Although	O
the	O
intraocular	O
pressure	O
elevation	O
caused	O
by	O
secondary	O
acute	O
angle	O
-	O
closure	O
glaucoma	B-Disease
decreased	O
and	O
ocular	B-Disease
pain	I-Disease
diminished	O
,	O
inexorable	O
papilledema	B-Disease
and	O
exudative	O
retinal	B-Disease
detachment	I-Disease
continued	O
for	O
3	O
weeks	O
.	O

Finally	O
,	O
6	O
weeks	O
later	O
,	O
diffuse	O
chorioretinal	B-Disease
atrophy	I-Disease
with	O
optic	B-Disease
atrophy	I-Disease
occurred	O
and	O
the	O
vision	O
in	O
his	O
left	O
eye	O
was	O
lost	O
.	O

CONCLUSION	O
:	O
When	O
performing	O
intracarotid	O
injection	O
of	O
carboplatin	B-Chemical
,	O
we	O
must	O
be	O
aware	O
of	O
its	O
potentially	O
blinding	O
ocular	B-Disease
toxicity	I-Disease
.	O

Visual	O
hallucinations	O
associated	O
with	O
zonisamide	B-Chemical
.	O

Zonisamide	B-Chemical
is	O
a	O
broad	O
-	O
spectrum	O
antiepileptic	O
drug	O
used	O
to	O
treat	O
various	O
types	O
of	O
seizures	B-Disease
.	O

Although	O
visual	B-Disease
hallucinations	I-Disease
have	O
not	O
been	O
reported	O
as	O
an	O
adverse	O
effect	O
of	O
this	O
agent	O
,	O
we	O
describe	O
three	O
patients	O
who	O
experienced	O
complex	O
visual	B-Disease
hallucinations	I-Disease
and	O
altered	O
mental	O
status	O
after	O
zonisamide	B-Chemical
treatment	O
was	O
begun	O
or	O
its	O
dosage	O
increased	O
.	O

All	O
three	O
had	O
been	O
diagnosed	O
earlier	O
with	O
epilepsy	B-Disease
,	O
and	O
their	O
electroencephalogram	O
(	O
EEG	O
)	O
findings	O
were	O
abnormal	O
.	O

During	O
monitoring	O
,	O
visual	B-Disease
hallucinations	I-Disease
did	O
not	O
correlate	O
with	O
EEG	O
readings	O
,	O
nor	O
did	O
video	O
recording	O
capture	O
any	O
of	O
the	O
described	O
events	O
.	O

None	O
of	O
the	O
patients	O
had	O
experienced	O
visual	B-Disease
hallucinations	I-Disease
before	O
this	O
event	O
.	O

The	O
only	O
recent	O
change	O
in	O
their	O
treatment	O
was	O
the	O
introduction	O
or	O
increased	O
dosage	O
of	O
zonisamide	B-Chemical
.	O

Until	O
then	O
,	O
clinicians	O
need	O
to	O
be	O
aware	O
of	O
this	O
possible	O
complication	O
associated	O
with	O
zonisamide	B-Chemical
.	O

Anti	O
-	O
epileptic	B-Disease
drugs	O
-	O
induced	O
de	O
novo	O
absence	B-Disease
seizures	I-Disease
.	O

The	O
authors	O
present	O
three	O
patients	O
with	O
de	O
novo	O
absence	B-Disease
epilepsy	I-Disease
after	O
administration	O
of	O
carbamazepine	B-Chemical
and	O
vigabatrin	B-Chemical
.	O

Despite	O
the	O
underlying	O
diseases	O
,	O
the	O
prognosis	O
for	O
drug	O
-	O
induced	O
de	O
novo	O
absence	B-Disease
seizure	I-Disease
is	O
good	O
because	O
it	O
subsides	O
rapidly	O
after	O
discontinuing	O
the	O
use	O
of	O
the	O
offending	O
drugs	O
.	O

The	O
gamma	B-Chemical
-	I-Chemical
aminobutyric	I-Chemical
acid	I-Chemical
-	O
transmitted	O
thalamocortical	O
circuitry	O
accounts	O
for	O
a	O
major	O
part	O
of	O
the	O
underlying	O
neurophysiology	O
of	O
the	O
absence	B-Disease
epilepsy	I-Disease
.	O

Because	O
drug	O
-	O
induced	O
de	O
novo	O
absence	B-Disease
seizure	I-Disease
is	O
rare	O
,	O
pro	O
-	O
absence	O
drugs	O
can	O
only	O
be	O
considered	O
a	O
promoting	O
factor	O
.	O

The	O
underlying	O
epileptogenecity	O
of	O
the	O
patients	O
or	O
the	O
synergistic	O
effects	O
of	O
the	O
accompanying	O
drugs	O
is	O
required	O
to	O
trigger	O
the	O
de	O
novo	O
absence	B-Disease
seizure	I-Disease
.	O

The	O
possibility	O
of	O
drug	O
-	O
induced	O
aggravation	O
should	O
be	O
considered	O
whenever	O
an	O
unexpected	O
increase	O
in	O
seizure	B-Disease
frequency	O
and	O
/	O
or	O
new	O
seizure	B-Disease
types	O
appear	O
following	O
a	O
change	O
in	O
drug	O
treatment	O
.	O

By	O
understanding	O
the	O
underlying	O
mechanism	O
of	O
absence	B-Disease
epilepsy	I-Disease
,	O
we	O
can	O
avoid	O
the	O
inappropriate	O
use	O
of	O
anticonvulsants	O
in	O
children	O
with	O
epilepsy	B-Disease
and	O
prevent	O
drug	O
-	O
induced	O
absence	B-Disease
seizures	I-Disease
.	O

Prenatal	O
dexamethasone	O
programs	O
hypertension	B-Disease
and	O
renal	B-Disease
injury	I-Disease
in	O
the	O
rat	O
.	O

The	O
purpose	O
of	O
the	O
present	O
study	O
was	O
to	O
determine	O
if	O
prenatal	O
dexamethasone	B-Chemical
programmed	O
a	O
progressive	O
increase	B-Disease
in	I-Disease
blood	I-Disease
pressure	I-Disease
and	O
renal	B-Disease
injury	I-Disease
in	O
rats	O
.	O

Pregnant	O
rats	O
were	O
given	O
either	O
vehicle	O
or	O
2	O
daily	O
intraperitoneal	O
injections	O
of	O
dexamethasone	B-Chemical
(	O
0	O
.	O
2	O
mg	O
/	O
kg	O
body	O
weight	O
)	O
on	O
gestational	O
days	O
11	O
and	O
12	O
,	O
13	O
and	O
14	O
,	O
15	O
and	O
16	O
,	O
17	O
and	O
18	O
,	O
or	O
19	O
and	O
20	O
.	O

Offspring	O
of	O
rats	O
administered	O
dexamethasone	B-Chemical
on	O
days	O
15	O
and	O
16	O
gestation	O
had	O
a	O
20	O
%	O
reduction	B-Disease
in	I-Disease
glomerular	I-Disease
number	I-Disease
compared	O
with	O
control	O
at	O
6	O
to	O
9	O
months	O
of	O
age	O
(	O
22	O
527	O
+	O
/	O
-	O
509	O
versus	O
28	O
050	O
+	O
/	O
-	O
561	O
,	O
P	O
<	O
0	O
.	O
05	O
)	O
,	O
which	O
was	O
comparable	O
to	O
the	O
percent	O
reduction	O
in	O
glomeruli	O
measured	O
at	O
3	O
weeks	O
of	O
age	O
.	O

Six	O
-	O
to	O
9	O
-	O
month	O
old	O
rats	O
receiving	O
prenatal	O
dexamethasone	B-Chemical
on	O
days	O
17	O
and	O
18	O
of	O
gestation	O
had	O
a	O
17	O
%	O
reduction	O
in	O
glomeruli	O
(	O
23	O
380	O
+	O
/	O
-	O
587	O
)	O
compared	O
with	O
control	O
rats	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
.	O

Male	O
rats	O
that	O
received	O
prenatal	O
dexamethasone	B-Chemical
on	O
days	O
15	O
and	O
16	O
,	O
17	O
and	O
18	O
,	O
and	O
13	O
and	O
14	O
of	O
gestation	O
had	O
elevated	O
blood	O
pressures	O
at	O
6	O
months	O
of	O
age	O
;	O
the	O
latter	O
group	O
did	O
not	O
have	O
a	O
reduction	B-Disease
in	I-Disease
glomerular	I-Disease
number	I-Disease
.	O

Adult	O
rats	O
given	O
dexamethasone	B-Chemical
on	O
days	O
15	O
and	O
16	O
of	O
gestation	O
had	O
more	O
glomeruli	O
with	O
glomerulosclerosis	B-Disease
than	O
control	O
rats	O
.	O

This	O
study	O
shows	O
that	O
prenatal	O
dexamethasone	B-Chemical
in	O
rats	O
results	O
in	O
a	O
reduction	B-Disease
in	I-Disease
glomerular	I-Disease
number	I-Disease
,	O
glomerulosclerosis	B-Disease
,	O
and	O
hypertension	B-Disease
when	O
administered	O
at	O
specific	O
points	O
during	O
gestation	O
.	O

Hypertension	B-Disease
was	O
observed	O
in	O
animals	O
that	O
had	O
a	O
reduction	O
in	O
glomeruli	O
as	O
well	O
as	O
in	O
a	O
group	O
that	O
did	O
not	O
have	O
a	O
reduction	B-Disease
in	I-Disease
glomerular	I-Disease
number	I-Disease
,	O
suggesting	O
that	O
a	O
reduction	B-Disease
in	I-Disease
glomerular	I-Disease
number	I-Disease
is	O
not	O
the	O
sole	O
cause	O
for	O
the	O
development	O
of	O
hypertension	B-Disease
.	O

Kidney	O
function	O
and	O
morphology	O
after	O
short	O
-	O
term	O
combination	O
therapy	O
with	O
cyclosporine	B-Chemical
A	I-Chemical
,	O
tacrolimus	B-Chemical
and	O
sirolimus	B-Chemical
in	O
the	O
rat	O
.	O

BACKGROUND	O
:	O
Sirolimus	B-Chemical
(	O
SRL	B-Chemical
)	O
may	O
supplement	O
calcineurin	O
inhibitors	O
in	O
clinical	O
organ	O
transplantation	O
.	O

These	O
are	O
nephrotoxic	B-Disease
,	O
but	O
SRL	B-Chemical
seems	O
to	O
act	O
differently	O
displaying	O
only	O
minor	O
nephrotoxic	B-Disease
effects	O
,	O
although	O
this	O
question	O
is	O
still	O
open	O
.	O

In	O
a	O
number	O
of	O
treatment	O
protocols	O
where	O
SRL	B-Chemical
was	O
combined	O
with	O
a	O
calcineurin	O
inhibitor	O
indications	O
of	O
a	O
synergistic	O
nephrotoxic	B-Disease
effect	O
were	O
described	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
examine	O
further	O
the	O
renal	O
function	O
,	O
including	O
morphological	O
analysis	O
of	O
the	O
kidneys	O
of	O
male	O
Sprague	O
-	O
Dawley	O
rats	O
treated	O
with	O
either	O
cyclosporine	B-Chemical
A	I-Chemical
(	O
CsA	B-Chemical
)	O
,	O
tacrolimus	B-Chemical
(	O
FK506	B-Chemical
)	O
or	O
SRL	O
as	O
monotherapies	O
or	O
in	O
different	O
combinations	O
.	O

METHODS	O
:	O
For	O
a	O
period	O
of	O
2	O
weeks	O
,	O
CsA	O
15	O
mg	O
/	O
kg	O
/	O
day	O
(	O
given	O
orally	O
)	O
,	O
FK506	B-Chemical
3	O
.	O
0	O
mg	O
/	O
kg	O
/	O
day	O
(	O
given	O
orally	O
)	O
or	O
SRL	B-Chemical
0	O
.	O
4	O
mg	O
/	O
kg	O
/	O
day	O
(	O
given	O
intraperitoneally	O
)	O
was	O
administered	O
once	O
a	O
day	O
as	O
these	O
doses	O
have	O
earlier	O
been	O
found	O
to	O
achieve	O
a	O
significant	O
immunosuppressive	O
effect	O
in	O
Sprague	O
-	O
Dawley	O
rats	O
.	O

The	O
morphological	O
analysis	O
of	O
the	O
kidneys	O
included	O
a	O
semi	O
-	O
quantitative	O
scoring	O
system	O
analysing	O
the	O
degree	O
of	O
striped	O
fibrosis	B-Disease
,	O
subcapsular	O
fibrosis	B-Disease
and	O
the	O
number	O
of	O
basophilic	O
tubules	O
,	O
plus	O
an	O
additional	O
stereological	O
analysis	O
of	O
the	O
total	O
grade	O
of	O
fibrosis	B-Disease
in	O
the	O
cortex	O
stained	O
with	O
Sirius	O
Red	O
.	O

RESULTS	O
:	O
CsA	B-Chemical
,	O
FK506	B-Chemical
and	O
SRL	B-Chemical
all	O
significantly	O
decreased	O
the	O
GFR	O
.	O

A	O
further	O
deterioration	O
was	O
seen	O
when	O
CsA	B-Chemical
was	O
combined	O
with	O
either	O
FK506	B-Chemical
or	O
SRL	B-Chemical
,	O
whereas	O
the	O
GFR	O
remained	O
unchanged	O
in	O
the	O
group	O
treated	O
with	O
FK506	B-Chemical
plus	O
SRL	B-Chemical
when	O
compared	O
with	O
treatment	O
with	O
any	O
of	O
the	O
single	O
substances	O
.	O

The	O
semi	O
-	O
quantitative	O
scoring	O
was	O
significantly	O
worst	O
in	O
the	O
group	O
treated	O
with	O
CsA	B-Chemical
plus	O
SRL	B-Chemical
(	O
P	O
<	O
0	O
.	O
001	O
compared	O
with	O
controls	O
)	O
and	O
the	O
analysis	O
of	O
the	O
total	O
grade	O
of	O
fibrosis	B-Disease
also	O
showed	O
the	O
highest	O
proportion	O
in	O
the	O
same	O
group	O
and	O
was	O
significantly	O
different	O
from	O
controls	O
(	O
P	O
<	O
0	O
.	O
02	O
)	O
.	O

The	O
FK506	B-Chemical
plus	O
SRL	B-Chemical
combination	O
showed	O
only	O
a	O
marginally	O
higher	O
degree	O
of	O
fibrosis	B-Disease
as	O
compared	O
with	O
controls	O
(	O
P	O
=	O
0	O
.	O
05	O
)	O
.	O

CONCLUSION	O
:	O
This	O
rat	O
study	O
demonstrated	O
a	O
synergistic	O
nephrotoxic	B-Disease
effect	O
of	O
CsA	B-Chemical
plus	O
SRL	B-Chemical
,	O
whereas	O
FK506	B-Chemical
plus	O
SRL	B-Chemical
was	O
better	O
tolerated	O
.	O

Evaluation	O
of	O
cardiac	O
troponin	O
I	O
and	O
T	O
levels	O
as	O
markers	O
of	O
myocardial	B-Disease
damage	I-Disease
in	O
doxorubicin	B-Chemical
-	O
induced	O
cardiomyopathy	B-Disease
rats	O
,	O
and	O
their	O
relationship	O
with	O
echocardiographic	O
and	O
histological	O
findings	O
.	O

BACKGROUND	O
:	O
Cardiac	O
troponins	O
I	O
(	O
cTnI	O
)	O
and	O
T	O
(	O
cTnT	O
)	O
have	O
been	O
shown	O
to	O
be	O
highly	O
sensitive	O
and	O
specific	O
markers	O
of	O
myocardial	B-Disease
cell	I-Disease
injury	I-Disease
.	O

We	O
investigated	O
the	O
diagnostic	O
value	O
of	O
cTnI	O
and	O
cTnT	O
for	O
the	O
diagnosis	O
of	O
myocardial	B-Disease
damage	I-Disease
in	O
a	O
rat	O
model	O
of	O
doxorubicin	B-Chemical
(	O
DOX	B-Chemical
)	O
-	O
induced	O
cardiomyopathy	B-Disease
,	O
and	O
we	O
examined	O
the	O
relationship	O
between	O
serial	O
cTnI	O
and	O
cTnT	O
with	O
the	O
development	O
of	O
cardiac	B-Disease
disorders	I-Disease
monitored	O
by	O
echocardiography	O
and	O
histological	O
examinations	O
in	O
this	O
model	O
.	O

METHODS	O
:	O
Thirty	O
-	O
five	O
Wistar	O
rats	O
were	O
given	O
1	O
.	O
5	O
mg	O
/	O
kg	O
DOX	B-Chemical
,	O
i	O
.	O
v	O
.	O
,	O
weekly	O
for	O
up	O
to	O
8	O
weeks	O
for	O
a	O
total	O
cumulative	O
dose	O
of	O
12	O
mg	O
/	O
kg	O
BW	O
.	O

By	O
using	O
transthoracic	O
echocardiography	O
,	O
anterior	O
and	O
posterior	O
wall	O
thickness	O
,	O
LV	O
diameters	O
and	O
LV	O
fractional	O
shortening	O
(	O
FS	O
)	O
were	O
measured	O
in	O
all	O
rats	O
before	O
DOX	B-Chemical
or	O
saline	O
,	O
and	O
at	O
weeks	O
6	O
and	O
9	O
after	O
treatment	O
in	O
all	O
surviving	O
rats	O
.	O

Histology	O
was	O
performed	O
in	O
DOX	O
-	O
rats	O
at	O
6	O
and	O
9	O
weeks	O
after	O
the	O
last	O
DOX	B-Chemical
dose	O
and	O
in	O
all	O
controls	O
.	O

RESULTS	O
:	O
Eighteen	O
of	O
the	O
DOX	B-Chemical
rats	O
died	O
prematurely	O
of	O
general	O
toxicity	B-Disease
during	O
the	O
9	O
-	O
week	O
period	O
.	O

End	O
-	O
diastolic	O
(	O
ED	O
)	O
and	O
end	O
-	O
systolic	O
(	O
ES	O
)	O
LV	O
diameters	O
/	O
BW	O
significantly	O
increased	O
,	O
whereas	O
LV	O
FS	O
was	O
decreased	O
after	O
9	O
weeks	O
in	O
the	O
DOX	B-Chemical
group	O
(	O
p	O
<	O
0	O
.	O
001	O
)	O
.	O

Histological	O
evaluation	O
of	O
hearts	O
from	O
all	O
rats	O
given	O
DOX	B-Chemical
revealed	O
significant	O
slight	O
degrees	O
of	O
perivascular	O
and	O
interstitial	O
fibrosis	B-Disease
.	O

Only	O
five	O
of	O
the	O
controls	O
exhibited	O
evidence	O
of	O
very	O
slight	O
perivascular	O
fibrosis	B-Disease
.	O

A	O
significant	O
rise	O
in	O
cTnT	O
was	O
found	O
in	O
DOX	B-Chemical
rats	O
after	O
cumulative	O
doses	O
of	O
7	O
.	O
5	O
and	O
12	O
mg	O
/	O
kg	O
in	O
comparison	O
with	O
baseline	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
.	O

cTnT	O
found	O
in	O
rats	O
after	O
12	O
mg	O
/	O
kg	O
were	O
significantly	O
greater	O
than	O
that	O
found	O
after	O
7	O
.	O
5	O
mg	O
/	O
kg	O
DOX	B-Chemical
.	O

Maximal	O
cTnI	O
(	O
pg	O
/	O
ml	O
)	O
and	O
cTnT	O
levels	O
were	O
significantly	O
increased	O
in	O
DOX	B-Chemical
rats	O
compared	O
with	O
controls	O
(	O
p	O
=	O
0	O
.	O
006	O
,	O
0	O
.	O
007	O
)	O
.	O

cTnI	O
(	O
ng	O
/	O
ml	O
)	O
,	O
CK	O
-	O
MB	O
mass	O
and	O
CK	O
remained	O
unchanged	O
in	O
DOX	B-Chemical
rats	O
compared	O
with	O
controls	O
.	O

CONCLUSIONS	O
:	O
Among	O
markers	O
of	O
ischemic	B-Disease
injury	I-Disease
after	O
DOX	B-Chemical
in	O
rats	O
,	O
cTnT	O
showed	O
the	O
greatest	O
ability	O
to	O
detect	O
myocardial	B-Disease
damage	I-Disease
assessed	O
by	O
echocardiographic	O
detection	O
and	O
histological	O
changes	O
.	O

Although	O
there	O
was	O
a	O
discrepancy	O
between	O
the	O
amount	O
of	O
cTnI	O
and	O
cTnT	O
after	O
DOX	B-Chemical
,	O
probably	O
due	O
to	O
heterogeneity	O
in	O
cross	O
-	O
reactivities	O
of	O
mAbs	O
to	O
various	O
cTnI	O
and	O
cTnT	O
forms	O
,	O
it	O
is	O
likely	O
that	O
cTnT	O
in	O
rats	O
after	O
DOX	B-Chemical
indicates	O
cell	O
damage	O
determined	O
by	O
the	O
magnitude	O
of	O
injury	O
induced	O
and	O
that	O
cTnT	O
should	O
be	O
a	O
useful	O
marker	O
for	O
the	O
prediction	O
of	O
experimentally	O
induced	O
cardiotoxicity	B-Disease
and	O
possibly	O
for	O
cardioprotective	O
experiments	O
.	O

Octreotide	B-Chemical
-	O
induced	O
hypoxemia	B-Disease
and	O
pulmonary	B-Disease
hypertension	I-Disease
in	O
premature	O
neonates	O
.	O

The	O
authors	O
report	O
2	O
cases	O
of	O
premature	O
neonates	O
who	O
had	O
enterocutaneous	O
fistula	B-Disease
complicating	O
necrotizing	B-Disease
enterocolitis	I-Disease
.	O

Pulmonary	B-Disease
hypertension	I-Disease
developed	O
after	O
administration	O
of	O
a	O
somatostatin	O
analogue	O
,	O
octreotide	B-Chemical
,	O
to	O
enhance	O
resolution	O
of	O
the	O
fistula	B-Disease
.	O

The	O
risk	O
of	O
venous	B-Disease
thromboembolism	I-Disease
in	O
women	O
prescribed	O
cyproterone	B-Chemical
acetate	I-Chemical
in	O
combination	O
with	O
ethinyl	B-Chemical
estradiol	I-Chemical
:	O
a	O
nested	O
cohort	O
analysis	O
and	O
case	O
-	O
control	O
study	O
.	O

BACKGROUND	O
:	O
Cyproterone	B-Chemical
acetate	I-Chemical
combined	O
with	O
ethinyl	B-Chemical
estradiol	I-Chemical
(	O
CPA	B-Chemical
/	O
EE	B-Chemical
)	O
is	O
licensed	O
in	O
the	O
UK	O
for	O
the	O
treatment	O
of	O
women	O
with	O
acne	B-Disease
and	O
hirsutism	B-Disease
and	O
is	O
also	O
a	O
treatment	O
option	O
for	O
polycystic	B-Disease
ovary	I-Disease
syndrome	I-Disease
(	O
PCOS	B-Disease
)	O
.	O

Previous	O
studies	O
have	O
demonstrated	O
an	O
increased	O
risk	O
of	O
venous	B-Disease
thromboembolism	I-Disease
(	O
VTE	B-Disease
)	O
associated	O
with	O
CPA	B-Chemical
/	O
EE	B-Chemical
compared	O
with	O
conventional	O
combined	O
oral	B-Chemical
contraceptives	I-Chemical
(	O
COCs	O
)	O
.	O

METHODS	O
:	O
Using	O
the	O
General	O
Practice	O
Research	O
Database	O
we	O
conducted	O
a	O
cohort	O
analysis	O
and	O
case	O
-	O
control	O
study	O
nested	O
within	O
a	O
population	O
of	O
women	O
aged	O
between	O
15	O
and	O
39	O
years	O
with	O
acne	B-Disease
,	O
hirsutism	B-Disease
or	O
PCOS	B-Disease
to	O
estimate	O
the	O
risk	O
of	O
VTE	B-Disease
associated	O
with	O
CPA	B-Chemical
/	O
EE	B-Chemical
.	O

RESULTS	O
:	O
The	O
age	O
-	O
adjusted	O
incidence	O
rate	O
ratio	O
for	O
CPA	B-Chemical
/	O
EE	B-Chemical
versus	O
conventional	O
COCs	O
was	O
2	O
.	O
20	O
[	O
95	O
%	O
confidence	O
interval	O
(	O
CI	O
)	O
1	O
.	O
35	O
-	O
3	O
.	O
58	O
]	O
.	O

Using	O
as	O
the	O
reference	O
group	O
women	O
who	O
were	O
not	O
using	O
oral	O
contraception	O
,	O
had	O
no	O
recent	O
pregnancy	O
or	O
menopausal	O
symptoms	O
,	O
the	O
case	O
-	O
control	O
analysis	O
gave	O
an	O
adjusted	O
odds	O
ratio	O
(	O
OR	O
(	O
adj	O
)	O
)	O
of	O
7	O
.	O
44	O
(	O
95	O
%	O
CI	O
3	O
.	O
67	O
-	O
15	O
.	O
08	O
)	O
for	O
CPA	B-Chemical
/	O
EE	B-Chemical
use	O
compared	O
with	O
an	O
OR	O
(	O
adj	O
)	O
of	O
2	O
.	O
58	O
(	O
95	O
%	O
CI	O
1	O
.	O
60	O
-	O
4	O
.	O
18	O
)	O
for	O
use	O
of	O
conventional	O
COCs	O
.	O

CONCLUSIONS	O
:	O
We	O
have	O
demonstrated	O
an	O
increased	O
risk	O
of	O
VTE	B-Disease
associated	O
with	O
the	O
use	O
of	O
CPA	B-Chemical
/	O
EE	B-Chemical
in	O
women	O
with	O
acne	B-Disease
,	O
hirsutism	B-Disease
or	O
PCOS	B-Disease
although	O
residual	O
confounding	O
by	O
indication	O
cannot	O
be	O
excluded	O
.	O

The	O
effect	O
of	O
treatment	O
with	O
gum	B-Chemical
Arabic	I-Chemical
on	O
gentamicin	B-Chemical
nephrotoxicity	B-Disease
in	O
rats	O
:	O
a	O
preliminary	O
study	O
.	O

In	O
the	O
present	O
work	O
we	O
assessed	O
the	O
effect	O
of	O
treatment	O
of	O
rats	O
with	O
gum	B-Chemical
Arabic	I-Chemical
on	O
acute	B-Disease
renal	I-Disease
failure	I-Disease
induced	O
by	O
gentamicin	B-Chemical
(	O
GM	B-Chemical
)	O
nephrotoxicity	B-Disease
.	O

Rats	O
were	O
treated	O
with	O
the	O
vehicle	O
(	O
2	O
mL	O
/	O
kg	O
of	O
distilled	O
water	O
and	O
5	O
%	O
w	O
/	O
v	O
cellulose	O
,	O
10	O
days	O
)	O
,	O
gum	B-Chemical
Arabic	I-Chemical
(	O
2	O
mL	O
/	O
kg	O
of	O
a	O
10	O
%	O
w	O
/	O
v	O
aqueous	O
suspension	O
of	O
gum	B-Chemical
Arabic	I-Chemical
powder	O
,	O
orally	O
for	O
10	O
days	O
)	O
,	O
or	O
gum	B-Chemical
Arabic	I-Chemical
concomitantly	O
with	O
GM	B-Chemical
(	O
80mg	O
/	O
kg	O
/	O
day	O
intramuscularly	O
,	O
during	O
the	O
last	O
six	O
days	O
of	O
the	O
treatment	O
period	O
)	O
.	O

Nephrotoxicity	B-Disease
was	O
assessed	O
by	O
measuring	O
the	O
concentrations	O
of	O
creatinine	B-Chemical
and	O
urea	B-Chemical
in	O
the	O
plasma	O
and	O
reduced	O
glutathione	B-Chemical
(	O
GSH	B-Chemical
)	O
in	O
the	O
kidney	O
cortex	O
,	O
and	O
by	O
light	O
microscopic	O
examination	O
of	O
kidney	O
sections	O
.	O

The	O
results	O
indicated	O
that	O
concomitant	O
treatment	O
with	O
gum	B-Chemical
Arabic	I-Chemical
and	O
GM	B-Chemical
significantly	O
increased	O
creatinine	O
and	O
urea	B-Chemical
by	O
about	O
183	O
and	O
239	O
%	O
,	O
respectively	O
(	O
compared	O
to	O
432	O
and	O
346	O
%	O
,	O
respectively	O
,	O
in	O
rats	O
treated	O
with	O
cellulose	O
and	O
GM	B-Chemical
)	O
,	O
and	O
decreased	O
that	O
of	O
cortical	O
GSH	B-Chemical
by	O
21	O
%	O
(	O
compared	O
to	O
27	O
%	O
in	O
the	O
cellulose	O
plus	O
GM	B-Chemical
group	O
)	O
The	O
GM	B-Chemical
-	O
induced	O
proximal	O
tubular	B-Disease
necrosis	I-Disease
appeared	O
to	O
be	O
slightly	O
less	O
severe	O
in	O
rats	O
given	O
GM	B-Chemical
together	O
with	O
gum	B-Chemical
Arabic	I-Chemical
than	O
in	O
those	O
given	O
GM	B-Chemical
and	O
cellulose	O
.	O

It	O
could	O
be	O
inferred	O
that	O
gum	O
Arabic	O
treatment	O
has	O
induced	O
a	O
modest	O
amelioration	O
of	O
some	O
of	O
the	O
histological	O
and	O
biochemical	O
indices	O
of	O
GM	B-Chemical
nephrotoxicity	B-Disease
.	O

Further	O
work	O
is	O
warranted	O
on	O
the	O
effect	O
of	O
the	O
treatments	O
on	O
renal	O
functional	O
aspects	O
in	O
models	O
of	O
chronic	B-Disease
renal	I-Disease
failure	I-Disease
,	O
and	O
on	O
the	O
mechanism	O
(	O
s	O
)	O
involved	O
.	O

Increased	O
frequency	O
of	O
venous	B-Disease
thromboembolism	I-Disease
with	O
the	O
combination	O
of	O
docetaxel	B-Chemical
and	O
thalidomide	B-Chemical
in	O
patients	O
with	O
metastatic	O
androgen	O
-	O
independent	O
prostate	B-Disease
cancer	I-Disease
.	O

STUDY	O
OBJECTIVE	O
:	O
To	O
evaluate	O
the	O
frequency	O
of	O
venous	B-Disease
thromboembolism	I-Disease
(	O
VTE	B-Disease
)	O
in	O
patients	O
with	O
advanced	O
androgen	O
-	O
independent	O
prostate	B-Disease
cancer	I-Disease
who	O
were	O
treated	O
with	O
docetaxel	B-Chemical
alone	O
or	O
in	O
combination	O
with	O
thalidomide	B-Chemical
.	O

PATIENTS	O
:	O
Seventy	O
men	O
,	O
aged	O
50	O
-	O
80	O
years	O
,	O
with	O
advanced	O
androgen	O
-	O
independent	O
prostate	B-Disease
cancer	I-Disease
.	O

INTERVENTION	O
:	O
Each	O
patient	O
received	O
either	O
intravenous	O
docetaxel	B-Chemical
30	O
mg	O
/	O
m2	O
/	O
week	O
for	O
3	O
consecutive	O
weeks	O
,	O
followed	O
by	O
1	O
week	O
off	O
,	O
or	O
the	O
combination	O
of	O
continuous	O
oral	O
thalidomide	B-Chemical
200	O
mg	O
every	O
evening	O
plus	O
the	O
same	O
docetaxel	B-Chemical
regimen	O
.	O

This	O
4	O
-	O
week	O
cycle	O
was	O
repeated	O
until	O
there	O
was	O
evidence	O
of	O
excessive	O
toxicity	B-Disease
or	O
disease	O
progression	O
.	O

MEASUREMENTS	O
AND	O
MAIN	O
RESULTS	O
:	O
None	O
of	O
23	O
patients	O
who	O
received	O
docetaxel	B-Chemical
alone	O
developed	O
VTE	B-Disease
,	O
whereas	O
9	O
of	O
47	O
patients	O
(	O
19	O
%	O
)	O
who	O
received	O
docetaxel	B-Chemical
plus	O
thalidomide	B-Chemical
developed	O
VTE	B-Disease
(	O
p	O
=	O
0	O
.	O
025	O
)	O
.	O

CONCLUSION	O
:	O
The	O
addition	O
of	O
thalidomide	B-Chemical
to	O
docetaxel	B-Chemical
in	O
the	O
treatment	O
of	O
prostate	B-Disease
cancer	I-Disease
significantly	O
increases	O
the	O
frequency	O
of	O
VTE	B-Disease
.	O

Clinicians	O
should	O
be	O
aware	O
of	O
this	O
potential	O
complication	O
when	O
adding	O
thalidomide	B-Chemical
to	O
chemotherapeutic	O
regimens	O
.	O

Ticlopidine	B-Chemical
-	O
induced	O
cholestatic	B-Disease
hepatitis	I-Disease
.	O

OBJECTIVE	O
:	O
To	O
report	O
2	O
cases	O
of	O
ticlopidine	B-Chemical
-	O
induced	O
cholestatic	B-Disease
hepatitis	I-Disease
,	O
investigate	O
its	O
mechanism	O
,	O
and	O
compare	O
the	O
observed	O
main	O
characteristics	O
with	O
those	O
of	O
the	O
published	O
cases	O
.	O

CASE	O
SUMMARIES	O
:	O
Two	O
patients	O
developed	O
prolonged	O
cholestatic	B-Disease
hepatitis	I-Disease
after	O
receiving	O
ticlopidine	B-Chemical
following	O
percutaneous	O
coronary	O
angioplasty	O
,	O
with	O
complete	O
remission	O
during	O
the	O
follow	O
-	O
up	O
period	O
.	O

T	O
-	O
cell	O
stimulation	O
by	O
therapeutic	O
concentration	O
of	O
ticlopidine	B-Chemical
was	O
demonstrated	O
in	O
vitro	O
in	O
the	O
patients	O
,	O
but	O
not	O
in	O
healthy	O
controls	O
.	O

DISCUSSION	O
:	O
Cholestatic	B-Disease
hepatitis	I-Disease
is	O
a	O
rare	O
complication	O
of	O
the	O
antiplatelet	O
agent	O
ticlopidine	B-Chemical
;	O
several	O
cases	O
have	O
been	O
reported	O
but	O
few	O
in	O
the	O
English	O
literature	O
.	O

Our	O
patients	O
developed	O
jaundice	B-Disease
following	O
treatment	O
with	O
ticlopidine	B-Chemical
and	O
showed	O
the	O
clinical	O
and	O
laboratory	O
characteristics	O
of	O
cholestatic	B-Disease
hepatitis	I-Disease
,	O
which	O
resolved	O
after	O
discontinuation	O
of	O
the	O
drug	O
.	O

An	O
objective	O
causality	O
assessment	O
revealed	O
that	O
the	O
adverse	O
drug	O
event	O
was	O
probably	O
related	O
to	O
the	O
use	O
of	O
ticlopidine	B-Chemical
.	O

The	O
mechanisms	O
of	O
this	O
ticlopidine	B-Chemical
-	O
induced	O
cholestasis	B-Disease
are	O
unclear	O
.	O

Immune	O
mechanisms	O
may	O
be	O
involved	O
in	O
the	O
drug	O
'	O
s	O
hepatotoxicity	B-Disease
,	O
as	O
suggested	O
by	O
the	O
T	O
-	O
cell	O
stimulation	O
study	O
reported	O
here	O
.	O

CONCLUSIONS	O
:	O
Cholestatic	B-Disease
hepatitis	I-Disease
is	O
a	O
rare	O
adverse	O
effect	O
of	O
ticlopidine	B-Chemical
that	O
may	O
be	O
immune	O
mediated	O
.	O

This	O
complication	O
will	O
be	O
observed	O
even	O
less	O
often	O
in	O
the	O
future	O
as	O
ticlopidine	B-Chemical
is	O
being	O
replaced	O
by	O
the	O
newer	O
antiplatelet	O
agent	O
clopidogrel	B-Chemical
.	O

Epithelial	O
sodium	B-Chemical
channel	O
(	O
ENaC	O
)	O
subunit	O
mRNA	O
and	O
protein	O
expression	O
in	O
rats	O
with	O
puromycin	B-Chemical
aminonucleoside	I-Chemical
-	O
induced	O
nephrotic	B-Disease
syndrome	I-Disease
.	O

In	O
experimental	O
nephrotic	B-Disease
syndrome	I-Disease
,	O
urinary	O
sodium	O
excretion	O
is	O
decreased	O
during	O
the	O
early	O
phase	O
of	O
the	O
disease	O
.	O

The	O
rate	O
-	O
limiting	O
constituent	O
of	O
collecting	O
duct	O
sodium	B-Chemical
transport	O
is	O
the	O
epithelial	O
sodium	B-Chemical
channel	O
(	O
ENaC	O
)	O
.	O

We	O
examined	O
the	O
abundance	O
of	O
ENaC	O
subunit	O
mRNAs	O
and	O
proteins	O
in	O
puromycin	B-Chemical
aminonucleoside	I-Chemical
(	O
PAN	B-Chemical
)	O
-	O
induced	O
nephrotic	B-Disease
syndrome	I-Disease
.	O

The	O
time	O
courses	O
of	O
urinary	O
sodium	B-Chemical
excretion	O
,	O
plasma	O
aldosterone	B-Chemical
concentration	O
and	O
proteinuria	B-Disease
were	O
studied	O
in	O
male	O
Sprague	O
-	O
Dawley	O
rats	O
treated	O
with	O
a	O
single	O
dose	O
of	O
either	O
PAN	B-Chemical
or	O
vehicle	O
.	O

The	O
kinetics	O
of	O
urinary	O
sodium	B-Chemical
excretion	O
and	O
the	O
appearance	O
of	O
proteinuria	B-Disease
were	O
comparable	O
with	O
those	O
reported	O
previously	O
.	O

Sodium	B-Chemical
retention	O
occurred	O
on	O
days	O
2	O
,	O
3	O
and	O
6	O
after	O
PAN	B-Chemical
injection	O
.	O

A	O
significant	O
up	O
-	O
regulation	O
of	O
alphaENaC	O
and	O
betaENaC	O
mRNA	O
abundance	O
on	O
days	O
1	O
and	O
2	O
preceded	O
sodium	B-Chemical
retention	O
on	O
days	O
2	O
and	O
3	O
.	O

Conversely	O
,	O
down	O
-	O
regulation	O
of	O
alphaENaC	O
,	O
betaENaC	O
and	O
gammaENaC	O
mRNA	O
expression	O
on	O
day	O
3	O
occurred	O
in	O
the	O
presence	O
of	O
high	O
aldosterone	B-Chemical
concentrations	O
,	O
and	O
was	O
followed	O
by	O
a	O
return	O
of	O
sodium	B-Chemical
excretion	O
to	O
control	O
values	O
.	O

The	O
amounts	O
of	O
alphaENaC	O
,	O
betaENaC	O
and	O
gammaENaC	O
proteins	O
were	O
not	O
increased	O
during	O
PAN	B-Chemical
-	O
induced	O
sodium	B-Chemical
retention	O
.	O

In	O
conclusion	O
,	O
ENaC	O
mRNA	O
expression	O
,	O
especially	O
alphaENaC	O
,	O
is	O
increased	O
in	O
the	O
very	O
early	O
phase	O
of	O
the	O
experimental	O
model	O
of	O
PAN	B-Chemical
-	O
induced	O
nephrotic	O
syndrome	O
in	O
rats	O
,	O
but	O
appears	O
to	O
escape	O
from	O
the	O
regulation	O
by	O
aldosterone	B-Chemical
after	O
day	O
3	O
.	O

Sub	O
-	O
chronic	O
low	O
dose	O
gamma	B-Chemical
-	I-Chemical
vinyl	I-Chemical
GABA	I-Chemical
(	O
vigabatrin	B-Chemical
)	O
inhibits	O
cocaine	B-Chemical
-	O
induced	O
increases	O
in	O
nucleus	O
accumbens	O
dopamine	B-Chemical
.	O

RATIONALE	O
:	O
gamma	B-Chemical
-	I-Chemical
Vinyl	I-Chemical
GABA	I-Chemical
(	O
GVG	B-Chemical
)	O
irreversibly	O
inhibits	O
GABA	B-Chemical
-	O
transaminase	O
.	O

This	O
non	O
-	O
receptor	O
mediated	O
inhibition	O
requires	O
de	O
novo	O
synthesis	O
for	O
restoration	O
of	O
functional	O
GABA	B-Chemical
catabolism	O
.	O

OBJECTIVES	O
:	O
Given	O
its	O
preclinical	O
success	O
for	O
treating	O
substance	B-Disease
abuse	I-Disease
and	O
the	O
increased	O
risk	O
of	O
visual	B-Disease
field	I-Disease
defects	I-Disease
(	O
VFD	B-Disease
)	O
associated	O
with	O
cumulative	O
lifetime	O
exposure	O
,	O
we	O
explored	O
the	O
effects	O
of	O
sub	O
-	O
chronic	O
low	O
dose	O
GVG	B-Chemical
on	O
cocaine	B-Chemical
-	O
induced	O
increases	O
in	O
nucleus	O
accumbens	O
(	O
NAcc	O
)	O
dopamine	B-Chemical
(	O
DA	B-Chemical
)	O
.	O

RESULTS	O
:	O
Sub	O
-	O
chronic	O
GVG	B-Chemical
exposure	O
inhibited	O
the	O
effect	O
of	O
cocaine	B-Chemical
for	O
3	O
days	O
,	O
which	O
exceeded	O
in	O
magnitude	O
and	O
duration	O
the	O
identical	O
acute	O
dose	O
.	O

CONCLUSIONS	O
:	O
Sub	O
-	O
chronic	O
low	O
dose	O
GVG	B-Chemical
potentiates	O
and	O
extends	O
the	O
inhibition	O
of	O
cocaine	B-Chemical
-	O
induced	O
increases	O
in	O
dopamine	B-Chemical
,	O
effectively	O
reducing	O
cumulative	O
exposures	O
and	O
the	O
risk	O
for	O
VFDS	O
.	O

MR	O
imaging	O
with	O
quantitative	O
diffusion	O
mapping	O
of	O
tacrolimus	B-Chemical
-	O
induced	O
neurotoxicity	B-Disease
in	O
organ	O
transplant	O
patients	O
.	O

Our	O
objective	O
was	O
to	O
investigate	O
brain	O
MR	O
imaging	O
findings	O
and	O
the	O
utility	O
of	O
diffusion	O
-	O
weighted	O
(	O
DW	O
)	O
imaging	O
in	O
organ	O
transplant	O
patients	O
who	O
developed	O
neurologic	O
symptoms	O
during	O
tacrolimus	B-Chemical
therapy	O
.	O

Brain	O
MR	O
studies	O
,	O
including	O
DW	O
imaging	O
,	O
were	O
prospectively	O
performed	O
in	O
14	O
organ	O
transplant	O
patients	O
receiving	O
tacrolimus	B-Chemical
who	O
developed	O
neurologic	B-Disease
complications	I-Disease
.	O

Of	O
the	O
14	O
patients	O
,	O
5	O
(	O
35	O
.	O
7	O
%	O
)	O
had	O
white	B-Disease
matter	I-Disease
abnormalities	I-Disease
,	O
1	O
(	O
7	O
.	O
1	O
%	O
)	O
had	O
putaminal	B-Disease
hemorrhage	I-Disease
,	O
and	O
8	O
(	O
57	O
.	O
1	O
%	O
)	O
had	O
normal	O
findings	O
on	O
initial	O
MR	O
images	O
.	O

Among	O
the	O
5	O
patients	O
with	O
white	B-Disease
matter	I-Disease
abnormalities	I-Disease
,	O
4	O
patients	O
(	O
80	O
.	O
0	O
%	O
)	O
showed	O
higher	O
than	O
normal	O
ADC	O
values	O
on	O
initial	O
MR	O
images	O
,	O
and	O
all	O
showed	O
complete	O
resolution	O
on	O
follow	O
-	O
up	O
images	O
.	O

The	O
remaining	O
1	O
patient	O
(	O
20	O
.	O
0	O
%	O
)	O
showed	O
lower	O
than	O
normal	O
ADC	O
value	O
and	O
showed	O
incomplete	O
resolution	O
with	O
cortical	B-Disease
laminar	I-Disease
necrosis	I-Disease
.	O

Diffusion	O
-	O
weighted	O
imaging	O
may	O
be	O
useful	O
in	O
predicting	O
the	O
outcomes	O
of	O
the	O
lesions	O
of	O
tacrolimus	B-Chemical
-	O
induced	O
neurotoxicity	B-Disease
.	O

L	B-Chemical
-	I-Chemical
arginine	I-Chemical
transport	O
in	O
humans	O
with	O
cortisol	B-Chemical
-	O
induced	O
hypertension	B-Disease
.	O

A	O
deficient	O
L	B-Chemical
-	I-Chemical
arginine	I-Chemical
-	O
nitric	B-Chemical
oxide	I-Chemical
system	O
is	O
implicated	O
in	O
cortisol	B-Chemical
-	O
induced	O
hypertension	B-Disease
.	O

We	O
investigate	O
whether	O
abnormalities	O
in	O
L	B-Chemical
-	I-Chemical
arginine	I-Chemical
uptake	O
contribute	O
to	O
this	O
deficiency	O
.	O

Hydrocortisone	B-Chemical
acetate	I-Chemical
(	O
50	O
mg	O
)	O
was	O
given	O
orally	O
every	O
6	O
hours	O
for	O
24	O
hours	O
after	O
a	O
5	O
-	O
day	O
fixed	O
-	O
salt	O
diet	O
(	O
150	O
mmol	O
/	O
d	O
)	O
.	O

L	B-Chemical
-	I-Chemical
arginine	I-Chemical
uptake	O
was	O
assessed	O
in	O
mononuclear	O
cells	O
incubated	O
with	O
L	B-Chemical
-	I-Chemical
arginine	I-Chemical
(	O
1	O
to	O
300	O
micromol	O
/	O
L	O
)	O
,	O
incorporating	O
100	O
nmol	O
/	O
L	O
[	B-Chemical
3H	I-Chemical
]	I-Chemical
-	I-Chemical
l	I-Chemical
-	I-Chemical
arginine	I-Chemical
for	O
a	O
period	O
of	O
5	O
minutes	O
at	O
37	O
degrees	O
C	O
.	O

Forearm	O
[	B-Chemical
3H	I-Chemical
]	I-Chemical
-	I-Chemical
L	I-Chemical
-	I-Chemical
arginine	I-Chemical
extraction	O
was	O
calculated	O
after	O
infusion	O
of	O
[	B-Chemical
3H	I-Chemical
]	I-Chemical
-	I-Chemical
L	I-Chemical
-	I-Chemical
arginine	I-Chemical
into	O
the	O
brachial	O
artery	O
at	O
a	O
rate	O
of	O
100	O
nCi	O
/	O
min	O
for	O
80	O
minutes	O
.	O

Deep	O
forearm	O
venous	O
samples	O
were	O
collected	O
for	O
determination	O
of	O
L	B-Chemical
-	I-Chemical
arginine	I-Chemical
extraction	O
.	O

Plasma	O
cortisol	B-Chemical
concentrations	O
were	O
significantly	O
raised	O
during	O
the	O
active	O
phase	O
(	O
323	O
+	O
/	O
-	O
43	O
to	O
1082	O
+	O
/	O
-	O
245	O
mmol	O
/	O
L	O
,	O
P	O
<	O
0	O
.	O
05	O
)	O
.	O

Neither	O
L	B-Chemical
-	I-Chemical
arginine	I-Chemical
transport	O
into	O
mononuclear	O
cells	O
(	O
placebo	O
vs	O
active	O
,	O
26	O
.	O
3	O
+	O
/	O
-	O
3	O
.	O
6	O
vs	O
29	O
.	O
0	O
+	O
/	O
-	O
2	O
.	O
1	O
pmol	O
/	O
10	O
000	O
cells	O
per	O
5	O
minutes	O
,	O
respectively	O
,	O
at	O
an	O
l	B-Chemical
-	I-Chemical
arginine	I-Chemical
concentration	O
of	O
300	O
micromol	O
/	O
L	O
)	O
nor	O
L	B-Chemical
-	I-Chemical
arginine	I-Chemical
extraction	O
in	O
the	O
forearm	O
(	O
at	O
80	O
minutes	O
,	O
placebo	O
vs	O
active	O
,	O
1	O
868	O
904	O
+	O
/	O
-	O
434	O
962	O
vs	O
2	O
013	O
910	O
+	O
/	O
-	O
770	O
619	O
disintegrations	O
per	O
minute	O
)	O
was	O
affected	O
by	O
cortisol	B-Chemical
treatment	O
;	O
ie	O
,	O
that	O
L	B-Chemical
-	I-Chemical
arginine	I-Chemical
uptake	O
is	O
not	O
affected	O
by	O
short	O
-	O
term	O
cortisol	B-Chemical
treatment	O
.	O

We	O
conclude	O
that	O
cortisol	B-Chemical
-	O
induced	O
increases	B-Disease
in	I-Disease
blood	I-Disease
pressure	I-Disease
are	O
not	O
associated	O
with	O
abnormalities	O
in	O
the	O
l	B-Chemical
-	I-Chemical
arginine	I-Chemical
transport	O
system	O
.	O

Amount	O
of	O
bleeding	B-Disease
and	O
hematoma	B-Disease
size	O
in	O
the	O
collagenase	O
-	O
induced	O
intracerebral	B-Disease
hemorrhage	I-Disease
rat	O
model	O
.	O

The	O
aggravated	O
risk	O
on	O
intracerebral	B-Disease
hemorrhage	I-Disease
(	O
ICH	B-Disease
)	O
with	O
drugs	O
used	O
for	O
stroke	B-Disease
patients	O
should	O
be	O
estimated	O
carefully	O
.	O

We	O
therefore	O
established	O
sensitive	O
quantification	O
methods	O
and	O
provided	O
a	O
rat	O
ICH	B-Disease
model	O
for	O
detection	O
of	O
ICH	B-Disease
deterioration	O
.	O

In	O
ICH	B-Disease
intrastriatally	O
induced	O
by	O
0	O
.	O
014	O
-	O
unit	O
,	O
0	O
.	O
070	O
-	O
unit	O
,	O
and	O
0	O
.	O
350	O
-	O
unit	O
collagenase	O
,	O
the	O
amount	O
of	O
bleeding	B-Disease
was	O
measured	O
using	O
a	O
hemoglobin	O
assay	O
developed	O
in	O
the	O
present	O
study	O
and	O
was	O
compared	O
with	O
the	O
morphologically	O
determined	O
hematoma	B-Disease
volume	O
.	O

The	O
blood	O
amounts	O
and	O
hematoma	B-Disease
volumes	O
were	O
significantly	O
correlated	O
,	O
and	O
the	O
hematoma	B-Disease
induced	O
by	O
0	O
.	O
014	O
-	O
unit	O
collagenase	O
was	O
adequate	O
to	O
detect	O
ICH	B-Disease
deterioration	O
.	O

In	O
ICH	B-Disease
induction	O
using	O
0	O
.	O
014	O
-	O
unit	O
collagenase	O
,	O
heparin	B-Chemical
enhanced	O
the	O
hematoma	B-Disease
volume	O
3	O
.	O
4	O
-	O
fold	O
over	O
that	O
seen	O
in	O
control	O
ICH	B-Disease
animals	O
and	O
the	O
bleeding	B-Disease
7	O
.	O
6	O
-	O
fold	O
.	O

Data	O
suggest	O
that	O
this	O
sensitive	O
hemoglobin	O
assay	O
is	O
useful	O
for	O
ICH	B-Disease
detection	O
,	O
and	O
that	O
a	O
model	O
with	O
a	O
small	O
ICH	B-Disease
induced	O
with	O
a	O
low	O
-	O
dose	O
collagenase	O
should	O
be	O
used	O
for	O
evaluation	O
of	O
drugs	O
that	O
may	O
affect	O
ICH	B-Disease
.	O

Estradiol	B-Chemical
reduces	O
seizure	B-Disease
-	O
induced	O
hippocampal	B-Disease
injury	I-Disease
in	O
ovariectomized	O
female	O
but	O
not	O
in	O
male	O
rats	O
.	O

Estrogens	O
protect	O
ovariectomized	O
rats	O
from	O
hippocampal	B-Disease
injury	I-Disease
induced	O
by	O
kainic	B-Chemical
acid	I-Chemical
-	O
induced	O
status	B-Disease
epilepticus	I-Disease
(	O
SE	B-Disease
)	O
.	O

We	O
compared	O
the	O
effects	O
of	O
17beta	B-Chemical
-	I-Chemical
estradiol	I-Chemical
in	O
adult	O
male	O
and	O
ovariectomized	O
female	O
rats	O
subjected	O
to	O
lithium	B-Chemical
-	O
pilocarpine	B-Chemical
-	O
induced	O
SE	B-Disease
.	O

Rats	O
received	O
subcutaneous	O
injections	O
of	O
17beta	B-Chemical
-	I-Chemical
estradiol	I-Chemical
(	O
2	O
microg	O
/	O
rat	O
)	O
or	O
oil	O
once	O
daily	O
for	O
four	O
consecutive	O
days	O
.	O

SE	B-Disease
was	O
induced	O
20	O
h	O
following	O
the	O
second	O
injection	O
and	O
terminated	O
3	O
h	O
later	O
.	O

The	O
extent	O
of	O
silver	B-Chemical
-	O
stained	O
CA3	O
and	O
CA1	O
hippocampal	O
neurons	O
was	O
evaluated	O
2	O
days	O
after	O
SE	B-Disease
.	O

17beta	B-Chemical
-	I-Chemical
Estradiol	I-Chemical
did	O
not	O
alter	O
the	O
onset	O
of	O
first	O
clonus	O
in	O
ovariectomized	O
rats	O
but	O
accelerated	O
it	O
in	O
males	O
.	O

17beta	B-Chemical
-	I-Chemical
Estradiol	I-Chemical
reduced	O
the	O
argyrophilic	O
neurons	O
in	O
the	O
CA1	O
and	O
CA3	O
-	O
C	O
sectors	O
of	O
ovariectomized	O
rats	O
.	O

In	O
males	O
,	O
estradiol	B-Chemical
increased	O
the	O
total	O
damage	O
score	O
.	O

These	O
findings	O
suggest	O
that	O
the	O
effects	O
of	O
estradiol	B-Chemical
on	O
seizure	B-Disease
threshold	O
and	O
damage	O
may	O
be	O
altered	O
by	O
sex	O
-	O
related	O
differences	O
in	O
the	O
hormonal	O
environment	O
.	O

Pseudoacromegaly	B-Disease
induced	O
by	O
the	O
long	O
-	O
term	O
use	O
of	O
minoxidil	B-Chemical
.	O

Acromegaly	B-Disease
is	O
an	O
endocrine	B-Disease
disorder	I-Disease
caused	O
by	O
chronic	O
excessive	O
growth	O
hormone	O
secretion	O
from	O
the	O
anterior	O
pituitary	O
gland	O
.	O

Significant	O
disfiguring	O
changes	O
occur	O
as	O
a	O
result	O
of	O
bone	O
,	O
cartilage	O
,	O
and	O
soft	O
tissue	O
hypertrophy	O
,	O
including	O
the	O
thickening	O
of	O
the	O
skin	O
,	O
coarsening	O
of	O
facial	O
features	O
,	O
and	O
cutis	B-Disease
verticis	I-Disease
gyrata	I-Disease
.	O

Pseudoacromegaly	B-Disease
,	O
on	O
the	O
other	O
hand	O
,	O
is	O
the	O
presence	O
of	O
similar	O
acromegaloid	O
features	O
in	O
the	O
absence	O
of	O
elevated	O
growth	O
hormone	O
or	O
insulin	O
-	O
like	O
growth	O
factor	O
levels	O
.	O

We	O
present	O
a	O
patient	O
with	O
pseudoacromegaly	B-Disease
that	O
resulted	O
from	O
the	O
long	O
-	O
term	O
use	O
of	O
minoxidil	B-Chemical
at	O
an	O
unusually	O
high	O
dose	O
.	O

This	O
is	O
the	O
first	O
case	O
report	O
of	O
pseudoacromegaly	B-Disease
as	O
a	O
side	O
effect	O
of	O
minoxidil	B-Chemical
use	O
.	O

Combined	O
androgen	O
blockade	O
-	O
induced	O
anemia	B-Disease
in	O
prostate	B-Disease
cancer	I-Disease
patients	O
without	O
bone	O
involvement	O
.	O

BACKGROUND	O
:	O
To	O
determine	O
the	O
onset	O
and	O
extent	O
of	O
combined	O
androgen	O
blockade	O
(	O
CAB	O
)	O
-	O
induced	O
anemia	B-Disease
in	O
prostate	B-Disease
cancer	I-Disease
patients	O
without	O
bone	O
involvement	O
.	O

PATIENTS	O
AND	O
METHODS	O
:	O
Forty	O
-	O
two	O
patients	O
with	O
biopsy	O
-	O
proven	O
prostatic	B-Disease
adenocarcinoma	I-Disease
[	O
26	O
with	O
stage	O
C	O
(	O
T3N0M0	O
)	O
and	O
16	O
with	O
stage	O
D1	O
(	O
T3N1M0	O
)	O
]	O
were	O
included	O
in	O
this	O
study	O
.	O

All	O
patients	O
received	O
CAB	O
[	O
leuprolide	B-Chemical
acetate	I-Chemical
(	O
LHRH	B-Chemical
-	I-Chemical
A	I-Chemical
)	O
3	O
.	O
75	O
mg	O
,	O
intramuscularly	O
,	O
every	O
28	O
days	O
plus	O
250	O
mg	O
flutamide	B-Chemical
,	O
tid	O
,	O
per	O
Os	O
]	O
and	O
were	O
evaluated	O
for	O
anemia	B-Disease
by	O
physical	O
examination	O
and	O
laboratory	O
tests	O
at	O
baseline	O
and	O
4	O
subsequent	O
intervals	O
(	O
1	O
,	O
2	O
,	O
3	O
and	O
6	O
months	O
post	O
-	O
CAB	O
)	O
.	O

Hb	O
,	O
PSA	O
and	O
Testosterone	B-Chemical
measurements	O
were	O
recorded	O
.	O

Severe	O
and	O
clinically	O
evident	O
anemia	B-Disease
of	O
Hb	O
<	O
11	O
g	O
/	O
dl	O
with	O
clinical	O
symptoms	O
was	O
detected	O
in	O
6	O
patients	O
(	O
14	O
.	O
3	O
%	O
)	O
.	O

This	O
CAB	O
-	O
induced	O
anemia	B-Disease
was	O
normochromic	O
and	O
normocytic	O
.	O

At	O
six	O
months	O
post	O
-	O
CAB	O
,	O
patients	O
with	O
severe	O
anemia	B-Disease
had	O
a	O
Hb	O
mean	O
value	O
of	O
10	O
.	O
2	O
+	O
/	O
-	O
0	O
.	O
1	O
g	O
/	O
dl	O
(	O
X	O
+	O
/	O
-	O
SE	O
)	O
,	O
whereas	O
the	O
other	O
patients	O
had	O
mild	O
anemia	B-Disease
with	O
Hb	O
mean	O
value	O
of	O
13	O
.	O
2	O
+	O
/	O
-	O
0	O
.	O
17	O
(	O
X	O
+	O
/	O
-	O
SE	O
)	O
.	O

The	O
development	O
of	O
severe	O
anemia	B-Disease
at	O
6	O
months	O
post	O
-	O
CAB	O
was	O
predictable	O
by	O
the	O
reduction	O
of	O
Hb	O
baseline	O
value	O
of	O
more	O
than	O
2	O
.	O
5	O
g	O
/	O
dl	O
after	O
3	O
months	O
of	O
CAB	O
(	O
p	O
=	O
0	O
.	O
01	O
)	O
.	O

The	O
development	O
of	O
severe	O
CAB	O
-	O
induced	O
anemia	B-Disease
in	O
prostate	B-Disease
cancer	I-Disease
patients	O
did	O
not	O
correlate	O
with	O
T	O
baseline	O
values	O
(	O
T	O
<	O
3	O
ng	O
/	O
ml	O
versus	O
T	O
>	O
or	O
=	O
3	O
ng	O
/	O
ml	O
)	O
,	O
with	O
age	O
(	O
<	O
76	O
yrs	O
versus	O
>	O
or	O
=	O
76	O
yrs	O
)	O
,	O
and	O
clinical	O
stage	O
(	O
stage	O
C	O
versus	O
stage	O
D1	O
)	O
.	O

Severe	O
and	O
clinically	O
evident	O
anemia	B-Disease
was	O
easily	O
corrected	O
by	O
subcutaneous	O
injections	O
(	O
3	O
times	O
/	O
week	O
for	O
1	O
month	O
)	O
of	O
recombinant	O
erythropoietin	O
(	O
rHuEPO	O
-	O
beta	O
)	O
.	O

CONCLUSION	O
:	O
Our	O
data	O
suggest	O
that	O
rHuEPO	O
-	O
beta	O
correctable	O
CAB	O
-	O
induced	O
anemia	B-Disease
occurs	O
in	O
14	O
.	O
3	O
%	O
of	O
prostate	B-Disease
cancer	I-Disease
patients	O
after	O
6	O
months	O
of	O
therapy	O
.	O

Delirium	B-Disease
during	O
clozapine	B-Chemical
treatment	O
:	O
incidence	O
and	O
associated	O
risk	O
factors	O
.	O

BACKGROUND	O
:	O
Incidence	O
and	O
risk	O
factors	O
for	O
delirium	B-Disease
during	O
clozapine	B-Chemical
treatment	O
require	O
further	O
clarification	O
.	O

METHODS	O
:	O
We	O
used	O
computerized	O
pharmacy	O
records	O
to	O
identify	O
all	O
adult	O
psychiatric	B-Disease
inpatients	O
treated	O
with	O
clozapine	B-Chemical
(	O
1995	O
-	O
96	O
)	O
,	O
reviewed	O
their	O
medical	O
records	O
to	O
score	O
incidence	O
and	O
severity	O
of	O
delirium	B-Disease
,	O
and	O
tested	O
associations	O
with	O
potential	O
risk	O
factors	O
.	O

RESULTS	O
:	O
Subjects	O
(	O
n	O
=	O
139	O
)	O
were	O
72	O
women	O
and	O
67	O
men	O
,	O
aged	O
40	O
.	O
8	O
+	O
/	O
-	O
12	O
.	O
1	O
years	O
,	O
hospitalized	O
for	O
24	O
.	O
9	O
+	O
/	O
-	O
23	O
.	O
3	O
days	O
,	O
and	O
given	O
clozapine	B-Chemical
,	O
gradually	O
increased	O
to	O
an	O
average	O
daily	O
dose	O
of	O
282	O
+	O
/	O
-	O
203	O
mg	O
(	O
3	O
.	O
45	O
+	O
/	O
-	O
2	O
.	O
45	O
mg	O
/	O
kg	O
)	O
for	O
18	O
.	O
9	O
+	O
/	O
-	O
16	O
.	O
4	O
days	O
.	O

Delirium	B-Disease
was	O
diagnosed	O
in	O
14	O
(	O
10	O
.	O
1	O
%	O
incidence	O
,	O
or	O
1	O
.	O
48	O
cases	O
/	O
person	O
-	O
years	O
of	O
exposure	O
)	O
;	O
71	O
.	O
4	O
%	O
of	O
cases	O
were	O
moderate	O
or	O
severe	O
.	O

Associated	O
factors	O
were	O
co	O
-	O
treatment	O
with	O
other	O
centrally	O
antimuscarinic	O
agents	O
,	O
poor	O
clinical	O
outcome	O
,	O
older	O
age	O
,	O
and	O
longer	O
hospitalization	O
(	O
by	O
17	O
.	O
5	O
days	O
,	O
increasing	O
cost	O
)	O
;	O
sex	O
,	O
diagnosis	O
or	O
medical	O
co	O
-	O
morbidity	O
,	O
and	O
daily	O
clozapine	B-Chemical
dose	O
,	O
which	O
fell	O
with	O
age	O
,	O
were	O
unrelated	O
.	O

CONCLUSIONS	O
:	O
Delirium	B-Disease
was	O
found	O
in	O
10	O
%	O
of	O
clozapine	B-Chemical
-	O
treated	O
inpatients	O
,	O
particularly	O
in	O
older	O
patients	O
exposed	O
to	O
other	O
central	O
anticholinergics	O
.	O

Delirium	B-Disease
was	O
inconsistently	O
recognized	O
clinically	O
in	O
milder	O
cases	O
and	O
was	O
associated	O
with	O
increased	O
length	O
-	O
of	O
-	O
stay	O
and	O
higher	O
costs	O
,	O
and	O
inferior	O
clinical	O
outcome	O
.	O

Neuroprotective	O
action	O
of	O
MPEP	B-Chemical
,	O
a	O
selective	O
mGluR5	O
antagonist	O
,	O
in	O
methamphetamine	B-Chemical
-	O
induced	O
dopaminergic	O
neurotoxicity	B-Disease
is	O
associated	O
with	O
a	O
decrease	O
in	O
dopamine	B-Chemical
outflow	O
and	O
inhibition	O
of	O
hyperthermia	B-Disease
in	O
rats	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
examine	O
the	O
role	O
of	O
metabotropic	O
glutamate	B-Chemical
receptor	O
5	O
(	O
mGluR5	O
)	O
in	O
the	O
toxic	O
action	O
of	O
methamphetamine	B-Chemical
on	O
dopaminergic	O
neurones	O
in	O
rats	O
.	O

Methamphetamine	B-Chemical
(	O
10	O
mg	O
/	O
kg	O
sc	O
)	O
,	O
administered	O
five	O
times	O
,	O
reduced	O
the	O
levels	O
of	O
dopamine	B-Chemical
and	O
its	O
metabolites	O
in	O
striatal	O
tissue	O
when	O
measured	O
72	O
h	O
after	O
the	O
last	O
injection	O
.	O

A	O
selective	O
antagonist	O
of	O
mGluR5	O
,	O
2	B-Chemical
-	I-Chemical
methyl	I-Chemical
-	I-Chemical
6	I-Chemical
-	I-Chemical
(	I-Chemical
phenylethynyl	I-Chemical
)	I-Chemical
pyridine	I-Chemical
(	O
MPEP	B-Chemical
;	O
5	O
mg	O
/	O
kg	O
ip	O
)	O
,	O
when	O
administered	O
five	O
times	O
immediately	O
before	O
each	O
methamphetamine	B-Chemical
injection	O
reversed	O
the	O
above	O
-	O
mentioned	O
methamphetamine	B-Chemical
effects	O
.	O

A	O
single	O
MPEP	B-Chemical
(	O
5	O
mg	O
/	O
kg	O
ip	O
)	O
injection	O
reduced	O
the	O
basal	O
extracellular	O
dopamine	B-Chemical
level	O
in	O
the	O
striatum	O
,	O
as	O
well	O
as	O
dopamine	B-Chemical
release	O
stimulated	O
either	O
by	O
methamphetamine	B-Chemical
(	O
10	O
mg	O
/	O
kg	O
sc	O
)	O
or	O
by	O
intrastriatally	O
administered	O
veratridine	B-Chemical
(	O
100	O
microM	O
)	O
.	O

Moreover	O
,	O
it	O
transiently	O
diminished	O
the	O
methamphetamine	B-Chemical
(	O
10	O
mg	O
/	O
kg	O
sc	O
)	O
-	O
induced	O
hyperthermia	B-Disease
and	O
reduced	O
basal	O
body	O
temperature	O
.	O

MPEP	B-Chemical
administered	O
into	O
the	O
striatum	O
at	O
high	O
concentrations	O
(	O
500	O
microM	O
)	O
increased	O
extracellular	O
dopamine	B-Chemical
levels	O
,	O
while	O
lower	O
concentrations	O
(	O
50	O
-	O
100	O
microM	O
)	O
were	O
devoid	O
of	O
any	O
effect	O
.	O

The	O
results	O
of	O
this	O
study	O
suggest	O
that	O
the	O
blockade	O
of	O
mGluR5	O
by	O
MPEP	B-Chemical
may	O
protect	O
dopaminergic	O
neurones	O
against	O
methamphetamine	B-Chemical
-	O
induced	O
toxicity	B-Disease
.	O

Neuroprotection	O
rendered	O
by	O
MPEP	B-Chemical
may	O
be	O
associated	O
with	O
the	O
reduction	O
of	O
the	O
methamphetamine	B-Chemical
-	O
induced	O
dopamine	B-Chemical
efflux	O
in	O
the	O
striatum	O
due	O
to	O
the	O
blockade	O
of	O
extrastriatal	O
mGluR5	O
,	O
and	O
with	O
a	O
decrease	O
in	O
hyperthermia	B-Disease
.	O

Protective	O
efficacy	O
of	O
neuroactive	O
steroids	B-Chemical
against	O
cocaine	B-Chemical
kindled	O
-	O
seizures	B-Disease
in	O
mice	O
.	O

Neuroactive	O
steroids	B-Chemical
demonstrate	O
pharmacological	O
actions	O
that	O
have	O
relevance	O
for	O
a	O
host	O
of	O
neurological	B-Disease
and	I-Disease
psychiatric	I-Disease
disorders	I-Disease
.	O

They	O
offer	O
protection	O
against	O
seizures	B-Disease
in	O
a	O
range	O
of	O
models	O
and	O
seem	O
to	O
inhibit	O
certain	O
stages	O
of	O
drug	B-Disease
dependence	I-Disease
in	O
preclinical	O
assessments	O
.	O

The	O
present	O
study	O
was	O
designed	O
to	O
evaluate	O
two	O
endogenous	O
and	O
one	O
synthetic	O
neuroactive	O
steroid	B-Chemical
that	O
positively	O
modulate	O
the	O
gamma	B-Chemical
-	I-Chemical
aminobutyric	I-Chemical
acid	I-Chemical
(	O
GABA	B-Chemical
(	O
A	O
)	O
)	O
receptor	O
against	O
the	O
increase	O
in	O
sensitivity	O
to	O
the	O
convulsant	O
effects	O
of	O
cocaine	B-Chemical
engendered	O
by	O
repeated	O
cocaine	B-Chemical
administration	O
(	O
seizure	B-Disease
kindling	O
)	O
.	O

Allopregnanolone	B-Chemical
(	O
3alpha	B-Chemical
-	I-Chemical
hydroxy	I-Chemical
-	I-Chemical
5alpha	I-Chemical
-	I-Chemical
pregnan	I-Chemical
-	I-Chemical
20	I-Chemical
-	I-Chemical
one	I-Chemical
)	O
,	O
pregnanolone	B-Chemical
(	O
3alpha	B-Chemical
-	I-Chemical
hydroxy	I-Chemical
-	I-Chemical
5beta	I-Chemical
-	I-Chemical
pregnan	I-Chemical
-	I-Chemical
20	I-Chemical
-	I-Chemical
one	I-Chemical
)	O
and	O
ganaxolone	B-Chemical
(	O
a	O
synthetic	O
derivative	O
of	O
allopregnanolone	B-Chemical
3alpha	B-Chemical
-	I-Chemical
hydroxy	I-Chemical
-	I-Chemical
3beta	I-Chemical
-	I-Chemical
methyl	I-Chemical
-	I-Chemical
5alpha	I-Chemical
-	I-Chemical
pregnan	I-Chemical
-	I-Chemical
20	I-Chemical
-	I-Chemical
one	I-Chemical
)	O
were	O
tested	O
for	O
their	O
ability	O
to	O
suppress	O
the	O
expression	O
(	O
anticonvulsant	O
effect	O
)	O
and	O
development	O
(	O
antiepileptogenic	O
effect	O
)	O
of	O
cocaine	B-Chemical
-	O
kindled	O
seizures	B-Disease
in	O
male	O
,	O
Swiss	O
-	O
Webster	O
mice	O
.	O

Kindled	O
seizures	B-Disease
were	O
induced	O
by	O
daily	O
administration	O
of	O
60	O
mg	O
/	O
kg	O
cocaine	B-Chemical
for	O
5	O
days	O
.	O

All	O
of	O
these	O
positive	O
GABA	B-Chemical
(	O
A	O
)	O
modulators	O
suppressed	O
the	O
expression	O
of	O
kindled	O
seizures	B-Disease
,	O
whereas	O
only	O
allopregnanolone	B-Chemical
and	O
ganaxolone	B-Chemical
inhibited	O
the	O
development	O
of	O
kindling	O
.	O

Allopregnanolone	B-Chemical
and	O
pregnanolone	B-Chemical
,	O
but	O
not	O
ganaxolone	B-Chemical
,	O
also	O
reduced	O
cumulative	O
lethality	O
associated	O
with	O
kindling	O
.	O

These	O
findings	O
demonstrate	O
that	O
some	O
neuroactive	O
steroids	B-Chemical
attenuate	O
convulsant	O
and	O
sensitizing	O
properties	O
of	O
cocaine	B-Chemical
and	O
add	O
to	O
a	O
growing	O
literature	O
on	O
their	O
potential	O
use	O
in	O
the	O
modulation	O
of	O
effects	O
of	O
drugs	O
of	O
abuse	O
.	O

Effect	O
of	O
humoral	O
modulators	O
of	O
morphine	B-Chemical
-	O
induced	O
increase	B-Disease
in	I-Disease
locomotor	I-Disease
activity	I-Disease
of	O
mice	O
.	O

The	O
effect	O
of	O
humoral	O
modulators	O
on	O
the	O
morphine	B-Chemical
-	O
induced	O
increase	B-Disease
in	I-Disease
locomotor	I-Disease
activity	I-Disease
of	O
mice	O
was	O
studied	O
.	O

The	O
subcutaneous	O
administration	O
of	O
10	O
mg	O
/	O
kg	O
of	O
morphine	B-Chemical
-	O
HC1	O
produced	O
a	O
marked	O
increase	B-Disease
in	I-Disease
locomotor	I-Disease
activity	I-Disease
in	O
mice	O
.	O

The	O
morphine	B-Chemical
-	O
induced	O
hyperactivity	B-Disease
was	O
potentiated	O
by	O
scopolamine	B-Chemical
and	O
attenuated	O
by	O
physostigmine	B-Chemical
.	O

In	O
contrast	O
,	O
both	O
methscopolamine	B-Chemical
and	O
neostigmine	B-Chemical
,	O
which	O
do	O
not	O
penetrate	O
the	O
blood	O
-	O
brain	O
barrier	O
,	O
had	O
no	O
effect	O
on	O
the	O
hyperactivity	B-Disease
produced	O
by	O
morphine	B-Chemical
.	O

Pretreatment	O
of	O
mice	O
with	O
alpha	B-Chemical
-	I-Chemical
methyltyrosine	I-Chemical
(	O
20	O
mg	O
/	O
kg	O
i	O
.	O
p	O
.	O
,	O
one	O
hour	O
)	O
,	O
an	O
inhibitor	O
of	O
tyrosine	B-Chemical
hydroxylase	O
,	O
significantly	O
decreased	O
the	O
activity	O
-	O
increasing	O
effects	O
of	O
morphine	B-Chemical
.	O

On	O
the	O
other	O
hand	O
,	O
pretreatment	O
with	O
p	B-Chemical
-	I-Chemical
chlorophenylalamine	I-Chemical
(	O
3	O
X	O
320	O
mg	O
/	O
kg	O
i	O
.	O
p	O
.	O
,	O
24	O
hr	O
)	O
,	O
a	O
serotonin	B-Chemical
depletor	O
,	O
caused	O
no	O
significant	O
change	O
in	O
the	O
hyperactivity	B-Disease
.	O

